Fabrication and characterization of Bioactive/Biodegradable materials for tissue engineering by ORRU', ROBERTO
   
 
 
 
 
Università degli Studi di Cagliari  
 
 
 
PHD DEGREE 
IN INNOVATION SCIENCE AND TECHNOLOGIES 
Cycle XXXII 
 
 
TITLE OF THE PHD THESIS 
 
FABRICATION AND CHARACTERISATION OF 
BIOACTIVE/BIODEGRADABLE MATERIALS FOR TISSUE 
ENGINEERING 
 
Scientific Disciplinary Sector(s) 
ING-IND/22  
 
 
PhD Student:                         Ing. Marina Luginina 
 
Coordinator of the PhD Programme      Prof. Ing. Roberto Orrù 
 
Supervisor                         Prof. Ing. Roberto Orrù 
 
 
 Final exam. Academic Year 2018 – 2019 
Thesis defence: January-February 2020 Session 
  
 
 
 
 
 
 
 
 
 
To my family and the beloved person who supported me on this journey
Acknowledgments 
 
Throughout my PhD I have had the chance to work with amazing people, to whom I 
would like to thank and dedicate the following words.  
First of all, I would like to express my sincere gratitude for my advisor Prof. Roberto 
Orrù. During these three years he guided and continuously supported me through my 
PhD work, encouraged my research and provided insightful comments. I would like 
to thank him for patience and immense knowledge, as well as for the possibility to 
practice and collaborate with other projects, and ultimately to grow as a research 
scientist.  
Besides my advisor, I would like to thank Prof. Giacomo Cao, for his 
encouragements, great discussions and for the hard questions which incented me to 
widen my research from various perspectives. 
Without the precious support of Prof. Orrù and Prof. Cao it would not be possible to 
conduct this PhD study. It was a great pleasure for me working with them. 
I am grateful for the possibility to perform my research activity in the framework of 
the International PhD in Innovation Sciences and Technologies at the University of 
Cagliari. 
During this three year program I also had chance to collaborate and work at the 
advanced research centers in France and Germany.  
In this regard, I would like to warmly thank Prof. Valeria Cannillo and Dr. Devis 
Bellucci (Università di Modena e Reggio Emilia, Italy) for the interesting and fruitful 
collaboration. 
I would like also to express my sincere gratitude for my supervisors during my 
internship at CIRIMAT laboratory (Université de Toulouse, CNRS, France) Dr. 
Christophe Drouet, Dr. David Grossin and Dr. Fabien Brouillet. This experience 
opened new horizons in a field of biomaterial’s research for me. To all of them goes 
my appreciation for their competence and priceless advices. 
Furthermore, I would like to express my special gratitude for Dr. Liliana Liverani and 
Prof. Dr.-Ing. habil. Aldo R. Boccaccini for their valuable guidance and the 
possibility to conduct the research project at the Institute of Biomaterials (Friedrich–
Alexander University Erlangen–Nürnberg, Germany). Their knowledge and 
professionalism were priceless. This internship has allowed me to gain a broad 
spectrum of knowledge in the field of hard and soft tissue engineering.  
Moreover, I would like to warmly thank my colleagues who have also became my 
friends, in particular, Francesco, Giovanna, Selena, Barbara, Roberta, Alessandro, 
Blessing, Gabriele and Fabio. Thank you for always willing to help and support me. I 
would like to extend my appreciation to the people that I have met during my 
internships at CIRIMAT and Institute of Biomaterials. Even if it was for a short 
period of time, I am extremely grateful for their kindness and assistance that make 
my stay and work in new countries so pleasant.  
There are not enough words to describe all my gratitude for my family. Mom, 
Antonio, Gaia and Gianfranco, most important people in my life, thank you for your 
love and support during this long journey. Even if you were far, you encouraged and 
helped me to go even through the toughest moments.  
And finally, beyond words, my immense gratitude to Artem. Thank you for always 
being there for me and for your positive attitude no matter what, for your patience 
and for your love. You always know how uplift me and how to put a smile upon my 
face.  
Abstract  
 
One of the main concerns in public healthcare in both developed and developing 
countries which cause handicap, physical disability and patient chronic pain is 
currently related to musculoskeletal problems and, in particular, to osteoarticular 
diseases. Since these diseases and induced defects affect millions of people 
worldwide, treatment of bone tumors, traumatology, osteoporosis and others 
pathologies, especially for aging populations, gained prime importance.  
In the past decades, great effort from scientific/medical society has been addressed to 
the development of safe reliable synthetic bone graft materials as alternative to allo- 
and autografts. The use of latter ones is usually associated with transmission 
complications as well as with immunological rejection and morbidity.  
Calcium phosphates, in general, and in particular, hydroxyapatite, nanocrystalline 
biomimetic apatites and amorphous calcium phosphates, as well as bioactive glasses, 
recently gained much attention as promising materials for the treatment of non-self-
healing bone defects. However, despite undeniable advantages such as 
biocompatibility, non-toxicity, and good bioactivity, clinical applications of these 
materials are still limited.   
In the present thesis, beyond the state of art, it was attempted to tackle various 
problems related to the development and essential systematic characterization of 
innovative materials for hard and soft tissue engineering. 
In the first part of the study, bioactivity of novel low alkaline glass using simulated 
body fluid (SBF) was assessed. Specifically, the eﬀects produced by devitriﬁcation 
phenomena which take place during the consolidation of amorphous glass powder on 
the biological behavior of the resulting material was considered. 
The second part of the study was dedicated to the evaluation of biological 
compatibility of different calcium phosphate/bioactive glass composites. To this 
purpose, different composites obtained by combining of hydroxyapatite with a low 
alkaline bioactive glass were first sintered into bulk discs via innovative spark plasma 
sintering technique and then exposed to the cell tests using murine long bone 
osteocyte-like immortalized cell line. The results were compared with the findings 
deriving from the SBF tests performed previously. 
The third part of the thesis was focused of the development of novel functionally 
graded materials in the calcium phosphate/bioactive glass system.  
In the fourth part of the thesis, the synthesis, sintering and physico-chemical 
characterization of highly carbonated magnesium-doped amorphous calcium 
phosphates, a novel family of bone substitute materials, was reported and discussed.  
Fifth part of this thesis deals with the fabrication and characterization of fibrous 
polymer/bioactive glass composite scaffolds for soft tissue engineering. Recently, it 
has been shown that bioactive glasses are able not only directly bond with the bone, 
but they also possess angiogenesis potential (bioactive glass ion dissolution products 
can induce new blood vessels regeneration). The latter property is crucial for the 
treatment of soft tissue wounds. The extension of bioactive glass application to areas 
such as peripheral nerve repair, healing of burn injures and chronic wound healing 
attracted much attention lately. In the present study, fibrous scaffolds from different 
biodegradable polymers coupled with bioactive glasses were fabricated using 
electrospinning technique. Biological performances in a presence of bone murine 
stromal cells as well as mechanical properties of prepared scaffold were investigated. 
 
Keywords: bone repair, calcium phosphates, bioactive glasses, spark plasma 
sintering, bioactivity, amorphous calcium phosphates, electrospinning.  
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Chapter 1. Introduction  
 
1.1 Aim and Objectives 
During this PhD program I had chance to work and contribute to different research 
projects. Beyond the state of art, the general aim of this thesis is to provide new 
insights related to the development and systematic characterization of biomaterials 
for tissue engineering, their fundamental properties along with possible applications. 
The present thesis is divided into independent chapters according to the arguments 
studied. The specific problematics and research objectives of each considered subject 
are reported in chapter’s introduction part.  
1.2 Thesis structure 
The layout of thesis is described as follows: 
Chapter 1 introduces the general aim and structure of the thesis. 
Chapter 2 provides an overview about bone nature, in particular, bone functions, 
structure, composition and mechanical properties. It concludes with a description of 
the bone remodeling process and gives a brief overview about bone capacity to self-
regenerate. Better understanding of bone biology is essential for the development of 
novel biomaterials that can closer mimic the native tissue at the site of restoration. 
Chapter 3 represents a current state of art in the field of bone tissue repair. It begins 
by illustrating the existing clinical need of materials for bone tissue repair and 
regeneration; then naturally-derived bone substitutes are discussed. Furthermore, the 
necessity of the development of synthetic biomaterials and their ideal properties are 
discussed. Subsequently, a brief classification of biomaterials, depending on the host 
tissue response, is given. The variety of currently investigated and applied 
biomaterials is discussed as well. Specific focus is given to bioceramics, in particular 
to hydroxyapatite, biomimetic apatites, amorphous calcium phosphates and bioactive 
2 
 
glasses. An overview on how it is possible to evaluate by means of in vitro test the 
bioactivity of bioceramics is also given. 
In Chapter 4 first a general overview on sintering techniques which can be applied to 
process biomaterials into final bulk products is provided.  Additionally, fabrication of 
functionally graded materials, promising candidates for hard tissue repair, is also 
discussed. 
The following chapters specifically deal with the results of the different research 
projects carried out during this PhD program.  
Chapter 5 is dedicated to the assessment of crystallization effect on in vitro 
bioactivity of novel CaO-rich bioglass-derived glass-ceramic. 
In Chapter 6, the results obtained during a cell biological study involving a novel 
CaO-rich bioactive glass and hydroxyapatite/CaO-rich bioactive glass composites are 
described and discussed.  
Chapter 7 is dedicated to the development of advanced functionally graded materials 
in the calcium phosphate/bioactive glass system. Some preliminary results are 
reported. 
Chapter 8 is based on the achievements from the experimental work obtained during 
my internship at CIRIMAT laboratory (France). In particular, the synthesis routes 
which allow to produce highly carbonated/magnesium doped amorphous calcium 
phosphates are described and discussed. 
In Chapter 9, the results relative to the research project carried out at the Institute of 
Biomaterials (Germany) are presented.  Fabrication of polymer/bioactive glass 
composite electrospun scaffolds along with cell biological test and assessment of 
mechanical properties is reported.  
And finally, the concluding Chapter 10 gives a general overview on the main results, 
achieved in the framework of my PhD research program.   
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Chapter 2. Human bone tissue  
 
Human bone is a complex biological tissue where minerals are integrated into soft 
matrices. It represents one of the types of mineralized or calcified tissues. Within 
human body, mineralized tissues can be also found in forms of enamel, dentin and 
cementum. They possess unique hierarchical structure and chemical composition [1]. 
However, the differences occur on a level of crystal size and shape, in percentage of 
minerals and proteins, as well as in allocation of trace mineral ions [2].   
2.1 Functions and structure of human bones 
The human skeleton system, consisting of 206 bones and connective tissues called 
ligaments, tendons, and cartilage, is generally aimed to internal structural support 
(Fig. 2.1) [3,4]. Moreover, it displays other important functions [5,6]: 
 Mechanical: bones possess specific mechanical properties which allow 
human body to withstand the effect of gravity and mechanical stresses; 
additionally,  skeleton system facilitates mobility by serving as points of 
attachment for muscles; 
 Protective: it fences vital organs and soft tissues;  
 Hematopoietic: bone provides a milieu for hematopoiesis (bone marrow 
situated in cancellous bone produces red and white blood cells for 
oxygenation of other tissues);  
 Metabolic: bones are responsible for the maintaining of mineral homeostasis.   
More precisely, bone mineral act as storage for inorganic minerals such as 
calcium, phosphorus and magnesium which are crucial for normal body 
functioning. These mineral ions, being released into the bloodstream,  support 
physiological processes and help to avoid muscles and nerves disorders [7,8]. 
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Based on the anatomy, structure and functions, different classifications of bones are 
available.  
Anatomical classification 
Axial skeleton consisting of about 80 bones, including the cranium, facial bones, rib 
cage, vertebral column, and others, mainly performs protective functions, as well as 
allows supporting of the central weight, and maintaining the posture.  
Appendicular skeleton, in turn, ensures balance and stability, and also provides 
locomotion and manipulation function. Appendicular bones are located 
symmetrically within human body, and mainly consist of the long bones.  
  
 
Figure 2.1: Human Skeletal System (axial and appendicular bones) [4]. 
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According to the morphological features, i.e. shapes, the following types of bones can 
be distinguished: 
 Long bones: clavicle, humerus, radius, femur, tibia, fibula et al.  
This kind of bones provides strength, structure and mobility. They have shaft 
(diaphysis) and two ends (epiphysis). Bone marrow which produces blood cells 
is located inside long bones.   
 Short bones: carpus, patella, tarsus.  
Their primary function is to ensure stability and some movement.   
 Flat bones: hip, parietal, frontal, nasal bone et al.  
The main function of flat bones is a protection of internal organs such as brain, 
heart, and pelvic organs.  
 Irregular bones: ethimoid, palatine, maxilla, vertebrae et al. 
This kind of bones possesses a fairly complex shape, which helps to protect 
inner organs and nerves. 
 Sesamoid bones: patella, pisiform.  
This type of bones can be defined as subtype of short bones embedded within a 
tendon of the hands, knees and feet.  
 
Structural classification 
From the microscopic viewpoint, human bones are classified into two different types: 
woven and lamellar bones (Fig. 2.2) [6]. Woven bone, which is considered as primary 
and immature, is a major bone type during the development of fetus, however, it also 
occurs during the bone remodelling process in adults. Woven bone is characterized 
by haphazard collagen fibres arrangements and possesses low mechanical resistance. 
In turn, lamellar bone is characterized by regular parallel alignment of collagen fibres 
(lamellae). This is a typical mature form of adult bones with relatively strong 
mechanical properties [9].  
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Figure 2.2: Schematic image of woven (immature) and lamellar (mature) bones. 
Woven bone shows a disorganized lamellar structure due to the interlacing 
arrangement of collagen ﬁbers [10]. 
According to the macroscopic classification, bones can be divided into trabecular 
(also known as spongy or cancellous) and cortical (compact or cortex) types [10,11]. 
Although, the elemental composition is identical for those two types [12], they differ 
with respect to microarchitecture and porosity, and, consequently, mechanical  
properties are also diverse (Table 2.1).  
Bone type 
Tensile 
strength 
(MPa) 
Young’s 
Modulus 
(GPa) 
Compressive 
strength 
(MPa) 
Fracture 
toughness 
Porosity Density, 
g/cm3 
Cortical 
bone 50-151 3-30 130-180 2-12 <30% 1.7-2.0 
Cancellous 
bone 10-20 0.02-0.5 2-12 0.1-0.8 50-90% 0.15-1 
Table 2.1: Mechanical properties of human cortical and cancellous bone [13–17]. 
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Cortical bone 
Cortical bone contributes for approximately 80% to the human skeleton weight. It 
consists of closely packed multiple columns, also known as osteons or Haversian 
systems (Fig. 2.3). Osteon is built of concentric layers (lamellae) that surround 
haversian canals which contain bone’s vascular supplies. Periosteum (fibrous layer) 
and endosteum are external and internal layers of cortical bone, respectively. Osteons 
are connected via Volkmann’s or perforating canals.  
Cancellous bone 
Due to its high porosity, cancellous bone is less dense and stiff than cortical bone and 
its specific surface area is larger. It ﬁlls the interior and ends of long bones, as well as 
the interior of vertebrae. Trabeculae are primary atomical and functional units of 
cancellous bone that form a network (Fig. 2.3). Trabeculae network is covered by 
thin layer of endosteum (connective tissue) and creates a room for blood vessels and 
marrow.  
 
Figure 2.3: Schematic structure of compact and cancellous bone (cross-section) [18].  
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2.2 Bone composition   
General composition of bones can be defined by the subsequent parts [6,10,12,19]: 
i) cells (osteoblast, bone lining cells, ostecytes, osteoclasts) (Fig. 2.4);  
ii) extracellular matrix (consisting of organic and inorganic parts). 
2.2.1 Bone cells  
Bone is a dynamic complex system which is exposed to growth, modelling and 
remodelling during life through the coordinated activities of osteoblasts, osteocytes, 
osteoclasts, and bone lining cells [20,21]. Bone growth, modelling and remodeling 
processes are discussed in more detail in Paragraph 2.3.  
Each type of bone cells plays a specific role, for instance osteoblasts (4-6% of all 
bone cells), being located mainly on bone surface, are responsible for bone formation 
[22].  
Bone lining cells are thought to be involved in a joining process between bone 
resorption and formation [23]. The presence of bone lining cells was detected on the 
bone surface, covering area where neither resorption nor bone formation occur [24].  
Osteocytes, the most numerous family of cells (up to 95%), are involved in bone 
development [25,26]. In particular, at the final part of newly bone formation, a subset 
of osteoblasts turns into octeocytes and integrates into the internal part of bone 
matrix. 
Osteoclasts, in turn, operate as mediators responsible for the dissolution and 
adsorption of bone tissue. Osteoporosis and other bone disorders could be launched 
by anomalous growth in osteoclast formation and activity, causing disproportion 
between resorption and formation. This process leads to decreasing of bone density 
and favours bone fractures [27]. However, it was found that octeoclasts produce 
cytokines, a broad class of proteins which is crucial in cell signalling [28]. Cell 
signalling is a complex process which governs cells activity and ensures the correct 
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response to the environmental changes taking place during the development, tissue 
repair and normal mineral homeostasis.  
Osteoblasts, bone lining cells and osteocytes, also known as osteoprogenotor cells, 
originate from mesenchymal stem cells (MSCs), whereas osteoclasts derive from 
hemopoietic stem cells (Table 2.2).  
 
Figure 2.4: Schematic representation of the evolution of osteoblasts and osteoclasts in 
bone formation [29]. 
Cell type Location Origin Morphology 
Osteoblast bone surface mesenchymal stem cells cuboidal cells 
Bone lining cells bone surface mesenchymal stem cells thin cells 
Ostecytes inner part of the bone 
mesenchymal stem 
cells star-shaped cells 
Osteoclasts bone surface hemopoietic stem cells 
giant, multi-nucleated 
cells 
Table 2.2: Summary on bone cells types, sites and morphology [10,29–31]. 
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2.2.2 Extracellular bone matrix 
Bone is a heterogeneous composite material composed of 50 to 70% of inorganic 
substances (bone mineral or apatite), 20 to 40% of organic matrix, 5 to 10% of water 
and approximately 3% of lipids [6,32]. The organic component is the main 
responsible for bone resistance to tensile stress whereas the inorganic portion for the 
one to compression. 
2.2.2.1 Organic matrix  
Organic extracellular matrix serves as a scaffold upon which inorganic bone mineral 
deposits. In general, organic matrix provides elasticity and structural flexibility to 
bone, which otherwise would be unduly rigid.  
Organic bone matrix is mainly composed by collagenous proteins, primarily type I 
collagens (85-90%) and non-collagenous proteins including osteocalcin, osteonectin, 
osteopontin, fibronectin and bone sialoprotein II, bone morphogenetic proteins 
(BMPs), and growth factors [33–36]. Extracellular matrix proteins and their functions 
are reported in Table 2.3.  
Type I collagen, representing the most abundant protein in bone tissue, is involved in 
the process of inorganic bone apatite mineralization [37–39]. It was also found that 
type I collagen, without the presence of any other agents, can intrinsically initiate and 
manage the in vitro growth of apatite minerals (inorganic part of extracellular matrix) 
[40].   
In turn, osteocalcin generated by the osteoblast cells represents the most abundant 
non-collagenous protein in extracellular bone matrix, and its role is to inhibit bone 
formation [41,42]. Osteopontin, another non-collagenous protein, plays an essential 
part in regulation of osteoclast activity, and it directs the inhibition or nucleation of 
bone apatite [43,44].   
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Additionally, small leucine-rich proteoglycans including decorin, biglycan, lumican, 
osteoaderin, and seric proteins affect bone cell activity and help to regulate matrix 
mineralisation.  
Protein (Chromosome Location) Function 
Collagen-related proteins  
type I (17q21.23, 7q22.1) Most abundant bone matrix protein 
type X (6q21) Found in hypertrophic cartilage 
type III (2q31) Trace amounts in bone; may regulate collagen fibril 
diameter 
type V (9q34.2-34.3; 2q24.3-31; 
19q13.2) 
Trace amounts in bone; may regulate collagen fibril 
diameter 
Serum proteins in bone matrix  
albumin (4q11-13) Decreases apatite crystal growth 
α2-HS glycoprotein (3q27) Bovine analog is fetuin 
Glycoaminoglycan-containing proteins 
and leucine-rich repeat proteins 
 
aggrecan (15q26.1) Matrix organization, retention of 
calcium/phosphorus 
versican (5q14.3) Defines space destined to become bone 
decorin (12q21.3) Regulates collagen fibril diameter; binds TGF-β 
biglycan (Xq28) Binds collagen; binds TGF-β; genetic determinant 
of peak bone mass 
hyaluronan (multigene complex) May work with versican to define space destined to 
become bone 
Glycoproteins  
alkaline phosphatase (1p36.1-p34) Hydrolyzes mineral deposition inhibitors 
osteonectin (5q31.3-32) Regulates collagen fibril diameter 
SIBLING proteins  
osteopontin (4q21) Regulates osteoclasts; inhibits mineralization and 
remodeling 
bone sialoprotein (4q21) Initiates mineralization 
MEPE (4q21.1) Regulator of phosphate metabolism 
RGD-containing glycoproteins  
thrombospondins (15q15, 6q27, 
1q21, 5q13, 19p13.1) 
Cell attachment 
fibronectin (2q34) Binds to cells 
vitronectin (17q11) Cell attachment 
fibrillin 1 and 2 (15q21.1, 5q23-31) Regulates elastic fiber formation 
γ-Carboxy glutamic acid–containing 
proteins 
 
matrix Gla protein (12p13.1-p12.3) Inhibits mineralization 
osteocalcin (1q25-q31) Regulates osteoclasts; inhibits mineralization 
protein S (3p11.2) Liver product, may be made by osteoblasts 
Table 2. 3:  Extracellular matrix proteins (adapted from [6]). 
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2.2.2.2 Bone mineral  
The inorganic part, also known as bone mineral or biological apatite, represents the 
main forming component of the bone. 
Bone mineral, firstly exposed to structural identification by XRD in 1926, was 
recognized as calcium phosphate similar to geological hydroxyapatite [45]. However, 
following studies on chemical composition and crystal structure of geological, 
synthetic and biological apatites revealed significant differences between them. From 
the structural viewpoint, bone mineral crystals, unlike synthetic and geological 
apatites, exhibit extremely small particle size. First studies, based on the 
measurements of X-ray diffraction peaks broadening, revealed that bone crystal sizes 
vary from 31Å to 290Å. In the fifties, more detailed studies carried out by using 
electron microscopy and diffraction [46] showed that bone crystals possess plate form 
approximately 500Å long, 250Å wide, and 100Å thick. For a long period of time, the 
main issue to overcome in order to precisely evaluate the bone crystal shape and size 
was the necessity to remove the entire organic matrix without altering the bone 
crystals. This step is essential to provide accurate measurements by high resolution 
transmition electron microscopy (HRTEM) and electron diffraction. Subsequently, it 
was established and confirmed by atomic force microscopy, that bone apatite crystals 
are thin crystals in nanometer range, which display a plate-like habit, i.e. 1-4 nm 
thick, 8-15 nm wide, and 20-35nm long [47,48]. 
From the compositional viewpoint, it was soon evidenced that stoichiometric 
hydroxyapatite (HA), previously used as a model for biological apatite, does not 
correspond to the bone mineral composition. Indeed, anionic/cationic substitutions 
and the existence of different types of ion vacancies within the structure of bone 
apatite were detected. Bone mineral was found to be calcium-deficient and hydroxyl-
deficient carbonated apatite [49,50]. Regarding the presence of (OH-) hydroxyl 
groups, typical for stoichiometric hydroxyapatite, different analysis techniques, 
comprising solid state Nuclear Magnetic Resonance (NMR) [51] and Raman 
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spectroscopy [52], revealed a very small percentage of hydroxyl groups. In contrast, a 
significant amount of carbonate ions (CO32-) [53,54] was detected. According to 
various studies, such content can vary in a range between 3 to 9 wt.% [49,55,56]. 
Further detailed investigations evidenced that carbonate ions can occupy two anionic 
sites in the apatite structure: OH- sites (type A carbonated apatite) and PO43- sites 
(type B carbonated apatite) [57,58]. The presence of A-type or B-type depends on the 
origin of mineralized tissue. For instance, bone mineral is mainly composed of B-
type whereas enamel corresponds to both A and B carbonate substitute types. 
Another feature that was observed within the structure of biological apatites is that 
PO43- sites can be also occupied by hydrogen phosphate ions (HPO42-) [49].  
However, it is worth mentioning that, due to numerous difficulties including the 
interactions between crystals and surrounding environments, as well as instability of 
newly formed crystals and their phase transformations, it is hard to describe a single 
chemical composition and structure for nanosized bone mineral crystal. Therefore, 
only general formulations can be provided. In this light, huge efforts were dedicated 
not only to study biological apatites but also to evaluate the properties of biomimetic 
synthetic apatites. The final aim was to extrapolate the obtained results to better 
understand the chemical composition of biological apatites. 
For instance, the phenomena of internal hydrolysis (eq. 1) between PO43- ions and 
water was firstly observed for the synthetic apatites and further confirmed for the 
biological ones [59,60].  
ܲ ସܱ
ଷି + ܪଶܱ → ܪܲ ସܱଶି + ܱܪି (eq. 1) 
In addition, besides the carbonate (CO32-), which is the main substituent ionic group 
in bone mineral [61], other trace elements like Mg2+, Na+, Cl-, F-, K+, Sr2+ have also 
been detected [19,62] in various amounts. Typical compositions of the mineral part of 
calcified tissues in the human body are summarized in Table 2.4. 
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Composition (wt%) Enamel Dentine Cementum Bone HA 
Calcium (Ca) 36.5 35.1 ~35 34.8 39.6 
Phosphorus ( P) 17.7 16.9 ~16 15.2 18.5 
Ca/P (molar ratio) 1.63 1.61 ~1.65 <1.67 1.67 
Sodium (Na) 0.5 0.6 - 0.9 – 
Magnesium (Mg) 0.44 1.23 0.5–0.9 0.72 – 
Potassium (K) 0.08 0.05 - 0.03 – 
Carbonate (CO32−) 3.5 5.6 - 7.4 – 
Fluoride 0.01 0.06 Up to 0.9 0.03 – 
Chloride 0.30 0.01 - 0.13 – 
Pyrophosphate (P2O7 4−) 0.022 0.10 - 0.07 – 
Total inorganic 97 70 60 65 100 
Total organic 1.5 20 25 25 – 
Water 1.5 10 15 10 – 
Table 2.4: Inorganic phases composition of adult human calcified tissues (adapted 
from [62]). 
The most representative chemical formula of the bone mineral, suggesting a 
relatively homogeneous composition and taking into account different substitutions 
within the structure of biological apatite, was proposed by Legros based on the 
generalization of different cortical bone analyses [49]: 
Ca8.3(PO4)4.3(CO3, HPO4)1.7(CO3,OH)0.3 
Although the use of carbonated apatite as a model for biological mineralized tissues 
of vertebrates is currently accepted, the issue of the bone mineral crystal surface 
remains highly debated.  
Some particularities on the surface of bone mineral crystals were firstly highlighted 
in the early fifties during ionic exchange experiments [63]. Further investigations 
showed the presence of a significant amount of water, and an increased concentration 
of Ca and Mg ions on the bone crystal surface [63–65]. It is worth to mention that 
about 66% of all Mg in the human body is located on this surface hydrated layer. 
Therefore, Mg ions can be easily involved into the ion exchange processes, enter in 
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extracellular fluids and be rapidly delivered to the various organs, tissues and nerves 
[66,67].  
In turn, different spectroscopic studies revealed the presence of specific lines which 
cannot be attributed to crystalline apatite [68–70]. FTIR analysis clearly evidenced 
the appearance of specific “non-apatitic” environments in  ν4PO4 and ν2CO3 domains. 
A significant content of labile HPO42- groups situated on the surface of apatite 
crystals was detected by NMR [71]. Further ion exchange experiments proved that 
these “non-apatitic” environments are located in the same domain as a surface 
hydrated layer [72,73]. NMR analysis performed on the synthetic biomimetic apatites 
suggested that the nature of this mineral disordered hydrated surface layer can be 
related to octacalcium phosphate phase (OCP) [74]. Recently, a study based on 
advanced solid-state nuclear magnetic resonance (ssNMR) carried out on the freshly 
extracted bone ‘kept in its native hydration state’ confirmed a model where apatite 
nanocrystals are covered by a highly hydrophilic disordered mineral layer that 
consists of Ca2+, HPO42-, CO32- ions, and water (Fig. 2.5) [75]. Authors identified this 
layer as amorphous calcium phosphate (ACP)-related phase rather than OCP related 
phase [74]. Additionally, the core/shell model was confirmed for apatite particles in 
dentine [76–78].  
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Figure 2.5: Schematic representation of the stacking of apatite platelets. The platelets 
are composed of a crystalline apatitic core and an amorphous layer composed of 
(PO43−, Ca2+, OH−, CO32−) and (HPO42−, Ca2+, CO32−, H2O), respectively. Water 
molecules that form a structuring network with the hydrated ACP-like layer induce 
the orientation of the HA platelets [75]. 
2.3 Remodeling and bone capacity to regenerate  
As mentioned previously, bone is a dynamic tissue that adapts its structure over a 
lifetime. It is initially formed during development through either an intramembranous 
or endochondral ossification process [79]. Once formed, the bone grows and changes 
its shape by modeling. The latter one is the process through which bone changes its 
shape as a response to physiologic or mechanical stimuli. During this process, bone 
resorption and formation are two uncoupled pathways, happening on distinct surfaces 
[6]. In normal conditions, bone remodeling occurs due to the coupled activity of 
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osteoclasts, which break down bone, and osteoblasts, that form a new bone matrix 
[80,81]. Resorption followed by the tissue formation take place in the same 
anatomical site, to maintain bone mass (Fig. 2.6). Remodeling is a complex 
coordinated process which is regulated by hormones, large number of growth-factors 
and cytokines [82,83]. It allows to guarantee bone tissue turnover in adult skeleton 
while preserving bone strength and integrity. It also plays an important role in 
maintaining the normal mineral homeostasis [84]. Bone renewing is an essential 
process in order to repair microdamages caused by daily physical load. Interestingly,  
during the human life time, the total mass of bone substance in the skeletal system is 
synthesized and resorbed, in normal conditions, every five to six years [85].  
 
Figure 2.6: Schematic diagram representing the process of bone remodeling [86].  
The remodeling cycle consists of five sequential phases, namely, activation, 
resorption, reversal, formation, and mineralization. The activation phase starts by 
initiating a remodeling signal triggered by osteocytes. In the resorption step, 
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osteoblasts respond to signals generated by osteocytes, or direct endocrine activation 
signals, by recruiting osteoclast precursors to the remodeling site. The subsequent 
reversal phase is characterized by disappearance of almost all osteoclasts. The 
formation stage is characterized by the complete replacement of osteoclastic cells 
with osteoblastic ones. The mineralization step includes the terminal differentiation 
of the osteoblasts. The resting bone surface environment is maintained until the next 
wave of remodeling is initiated. 
Since bone is a highly active metabolic tissue, it possesses the capacity to regenerate 
even in case of severe fractures (Fig. 2.7) [87].  
 
 Figure 2.7: Schematic process of bone self-healing [88].  
Generally, bone defects can heal spontaneously without fibrous scar formation, at 
least under suitable physiological conditions. In particular, the fracture bone 
undergoes four stages of healing: 
 Formation of a hematoma (blood-filled swelling);   
 Formation of a fibrocartilage callus;  
 Bony callus replaces fibrocartilage callus;  
 Bone remodeling occurs as response to mechanical stresses. 
Each of these steps is characterized by a specific set of cellular and molecular events.  
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However, when the bone loss exceeds a critical size, self-repair is hindered, which 
means that cells cannot migrate from one bone side to the other. In the literature, this 
kind of defects is known as critical-sized defects (CSD). Due to the specific factors 
that affect healing process, there is no consensus regarding the exact dimension of the 
CSD [89]. In general, “critical-sized bone defects are technically defined as those that 
will not heal spontaneously during the patient’s lifetime” [90]. They should cause the 
damage in both cancellous and cortical bone and be stable [91]. Currently, the animal 
model that describes critical bone defects is considered as the most suitable for 
studying bone healing mechanisms [92].  
Among the causes of large bone defects, the most common ones are fractures, 
infection, inflammatory arthritis, osteoporosis, osteonecrosis, metabolic bone disease, 
tumors, and musculoskeletal disorders such as rheumatoid arthritis [93,94]. 
Additionally, the risk of fractures increases with age due to the reduced release of 
specific agents and hormones involved in bone regeneration process. Indeed, 
osteoblasts become gradually less effective in repairing of microfactures, which, in 
general, leads to the decrease of bone density.  
It should be noted that, the process of bone formation, healing and remodeling has to 
be considered in the due attention when addressing the challenge of designing 
biomaterials for bone regeneration. 
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Chapter 3. State of Art in Bone Repair 
  
3.1 Clinical need of materials for bone repair  
Every year more than two million of people undergo different bone grafting 
procedure, including knee and hip replacement, spinal fusion, reconstructive, 
maxillofacial and others operations [95,96]. Indeed, bone one of the most 
transplanted tissues all over the world, the second only after blood [97]. Bone grafts 
made from different biomaterials are utilised in order to fill voids and to provide solid 
support on which cells can anchor and build new bone.  
Currently there are different accepted definitions of biomaterials (materials used for 
grafting). The first one was given by the American National Institute of Health in 
1984 and described biomaterial as ‘‘any substance or combination of substances, 
other than drugs, synthetic or natural in origin, which can be used for any period of 
time, which augments or replaces partially or totally any tissue, organ or function of 
the body, in order to maintain or improve the quality of life of the individual’’. 
Additionally, on the Consensus Conference of the European Society for Biomaterials 
(1986) it was stated that biomaterial is “a nonviable material used in a 
medical device, intended to interact with biological systems”. In this regard, another 
important term that needs to be specified is “tissue engineering” (TE). According to 
the currently accepted definition, TE is “an interdisciplinary field that applies the 
principles of engineering and life sciences toward the development of biological 
substitutes that restore, maintain, or improve tissue function or a whole organ” 
[98]. 
Generally, the ideal bone tissue substitute for critical-sized bone defects has to 
provide an environment that mimics bone’s natural healing process. More accurately, 
it should possess both osteogenesis and angiogenesis properties, be sufficiently 
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resistant from the mechanical viewpoint and provide integration with host tissues, as 
well as facilitate load transfer under weight-bearing conditions. 
Traditionally, due to their biological origin, the applied materials for the treatment of 
large bone defect are the following: 
- autologous bone (from the same patient),  
- allogeneic bone (from another patient), 
- xenogeneic bone substitutes (from an animal or coral). 
Autologous (or Autogenous) grafts 
Nowadays, the procedure involving the use of autologous bone, is accepted as a 
‘gold-standard’ in bone grafting [99,100]. In this case, bone tissue is transplanted 
from one site to another within the same individual [101].  
The advantage of autogenous bone lies in the possession of all essential elements for 
successful bone repair. For instance, autogenous bone is osteoconductive and 
osteoinductive, as well as it houses growth factors and osteogenic cells with no 
associated immune-related risks. During the healing process, autologous bone is 
gradually replaced by the newly forming bone. However, there are various issues and 
risks associated with the use of autologous bone, namely: high percentage of donor 
site morbidity [102,103]; difficulties related to the shaping of the bone graft, limited 
quantity of the material, infections, and neurovascular injury [104]. Additionally, in 
case of pediatric and elderly patients, autogenous bone availability is significantly 
limited.  
Allogeneic bone 
Allogeneic bone can either be derived from cadavers or living donors. It represents 
alternative approach to the autologous bone. In order to avoid host-versus-graft 
immune response, allografts have to be processed, prior implantation, to remove all 
living cellular components. This procedure alters the biological properties of 
allograft. In particular, the final bone graft contains the osteoconductive mineral basis 
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for bone healing, but lacks the osteogenic properties of autologous bone.  The main 
drawbacks associated with the use of allogeneic bone are the inherent risk of 
infection transmission and induced unfavourable host immune response, which leads 
to the rejection and additional operations [105,106]. 
Xenogenic bone 
Xenogeneic bone, another heterologous grafting material, is derived from animal 
species other than humams. For instance, coral (natural source of hydroxyapatite), 
cattle, horses, and pigs. Generally, this type of materials is relatively inert and slowly 
resorbable in physiological conditions. Skeleton of corals that consists of calcium 
carbonate (CaCO3) are used to obtain natural hydroxyapatite (HA). Bovine bone is 
also utilized in bone grafting. Similarly to allogeneic bone, bovine bone has to 
undergo a specific treatment, namely, deproteinization, meaning that all organic 
components should be chemically removed.  
Despite its high biocompatibility, main disadvantages of this type of materials 
include brittleness and difficulty to handling [107]. The availability of xenogeneic 
formulations is also limited and, similarly to their allogeneic counterparts, the use of 
xenografts is associated with risks of infection transmission.  
3.2 Properties required to design materials for bone tissue repair 
An alternative approach, developed in order to overcome limitations of autologous, 
allogeneic and xenogeneic bones, consists of using synthetic materials with tuneable 
properties to restore areas of bone loss. The ability to control the chemical 
composition and structure of such material is crucial in order to obtain a correct 
biological interaction between the artificial graft and host living tissue. It is worth to 
mention also that, depending on the application, specific characteristics of 
biomaterials are required. Ideally, the synthetic biomaterial should as possible mimic 
the tissue at the site of restoration. However, since this is a difficult task to achieve, 
the following characteristics are generally required:  
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Biocompatibility 
This property implies no toxicity, no inflammatory reaction, no hemolysis, and no 
coagulation reaction, meaning that a material can be safely used in the human body. 
Definition of biocompatibility was provided by various authors depending on the 
context [108,109]. In general terms, “Biocompatibility is defined as the ability of a 
biomaterial to perform its desired function with respect to a medical therapy, without 
eliciting any undesirable or systemic effects in the recipient or beneficiary of that 
therapy, but generating the most appropriate beneficial cellular or tissue response in 
that specific situation, and optimizing the clinically relevant performance of the 
therapy” [110].  
Osteoinductivity 
Osteoinductivity can be defined as the ability of a material to trigger osteogenesis 
(the process of new bone formation) [111,112]. It “means that primitive, 
undifferentiated and pluripotent cells are somehow stimulated to develop into the 
bone-forming cell lineage” [113]. 
Osteoconductivity 
An osteoconductive material should allow cell attachment, proliferation, 
multiplication, migration, in order to form extracellular matrix on its surface and into 
its pores [113]. 
Mechanical properties 
The material for bone graft should possess suitable mechanical properties to match 
those of natural bone at the site of implantation, i.e. bending, compressive and tensile 
strengths as well as fatigue resistance, to sustain loads applied during bone growth 
and remodelling [114,115]. 
Biodegradability 
The material resorption rate should match the one of bone regeneration growth [115]. 
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Porosity and pore size 
There is no consensus on the optimal porosity and pore size. Porosity and 
interconnectivity between the pores are important for the distribution of nutrients, 
especially in a microenvironment that lacks neovascularisation. Additionally, the size 
of the pores determines the types of molecules that can navigate through or that can 
be entrapped for subsequent release [115–118]. 
Surface properties 
In order to provide effective cell attachment, differentiation and proliferation, a 
suitable surface chemistry and topological features are required [119–121]. 
Processing 
The fabrication process of a final graft should not affect the original material 
properties and subsequent clinical use. Additionally, grafts should be readily 
produced into irregular shapes that match the defects in the bone of individual 
patients [122]. 
Commercialisation 
Materials for bone grafting should be fabricated at an acceptable cost for 
commercialization [122]. 
3.3 Classification of biomaterials depending on a type of host tissue response 
As mentioned above, when a synthetic material is placed within the human body, 
tissue reacts towards it. This specific reaction depends on the characteristics of the 
implant material. According to these types of the reactions, the following 
classification of biomaterials can be defined (Table 3.1, adapted from [123]). It worth 
to mention that, the classification reported below is very simplified and does not 
strictly provide the real biomaterial behaviour.    
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Graft/tissue 
interaction Tissue reaction  Materials examples 
Biotoxic 
Atrophy, pathological change or 
rejection of living tissue near the 
material as a result of chemical, 
galvanic or other processes 
Alloys containing cadmium, 
vanadium, and other toxic 
elements, carbon steels, 
carbides, methylmethacrylate 
 Bioinert 
Coexistence with the material without 
noticeable change, separation from 
material by a layer of fibrous tissue 
Tantalum, titanium, alumina and 
zirconia ceramics 
Bioactive 
Formation of direct biochemical bonds 
with the surface of the implanted 
material, new bone free growth 
Bone autografts, hydro-
xyapatite and tricacium 
phosphate, bioglasses 
Bioresorbable 
Gradual dissolution of the material by 
the biosystems of the organism, 
replacement without toxicity and 
rejection 
Porous tricalcium phosphate,  
calcium phosphate salts, some 
bioglasses, polyurethan 
Table 3.1: Biomaterials classification according to the surrounding tissue reaction.  
Indeed, as pointed out very recently when considering the typically called bioinert 
ceramics the term “bioinert” should be used carefully, since any material placed 
within living body provokes a response [124]. However, for sake of simplicity, such 
classification will be still considered hereto after in the present study.  
3.4 Biomaterials for bone tissue repair 
In general, materials that can be used for bone grafting can be classified into the four 
main groups: metals, polymers (natural and synthetic), ceramics (as well as glasses) 
and composites. Metals, polymers and ceramics possess different properties that, in 
turn, determine their applications. However, on their own, these materials are able to 
mimic biological tissues only to a certain extent, especially in case of bones. The use 
of composites, which combine the properties of two or more biomaterials, represents 
a promising approach to overcome the current limitations of single-phase materials. 
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3.4.1 Metals 
Traditionally, metals are used in order to replace load-bearing bones [125], for 
instance, in case of total hip joint replacement. Other important applications of 
metallic biomaterials are in the field of dentistry and orthodontics. Metals and alloys 
which are currently applied for implant manufacturing include Fe, Cr, Co, Ni, Ti, Ta, 
Mo and W. They possess a combination of favourable mechanical properties, such as 
tensile strength, fracture toughness and fatigue strength, which are required for load-
bearing or strain applications. In addition, they are relatively non-cytotoxic, at least in 
limited quantities. However, one of the main drawbacks of the metallic biomaterials 
is the fact that metal cannot mechanically replicate bone due to the dramatically 
different Young’s moduli (Table 3.2, adapted from [100]). Therefore, after 
implantation, surrounding bone tends to undergo undesirable change in the mechanics 
(stress shielding) and, as a long term outcome, bone gradually become weaker and 
prone to fracture. Another crucial issue related to the use of metals for grafts is 
corrosion caused by the chemical reaction with the physiological environments 
(enzymes and acids). As a result, loss of the structural integrity of the implant, 
accompanied by the release of toxic elements in high amount, can occur in some 
cases [126,127]. 
Material Young’s modulus (GPa) 
 
Ultimate tensile strength 
(MPa) 
 
Cortical bone 7-25 50-150 
Cancellous bone 0.1-1 <1 
Stainless steel 316L 200 207-1160 
CoCrMo alloy 230 430-1028 
Ti-6Al-4V 105 780-1050 
Table 3.2: Comparative mechanical properties of bone and metals used for 
biomedical purposes (adapted from [100]). 
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3.4.2 Natural and synthetic polymers 
Natural and synthetic polymers typically exhibit excellent biocompatibility and 
customizable properties, i.e. their chemistry and biodegradation rate can be tailored 
according to the application [125,128]. Therefore, they are widely applied in field of 
tissue engineering and regenerative medicine.  
Collagen, heparin, chitosan, gelatine, hyaluronan, alginate, and cellulose represent 
biopolymers that can be derived from natural sources in abundant amount. Natural 
polymers mimic components which are present in extracellular matrices, while 
synthetic ones are relatively versatile, for instance Poly(Epsilon-Caprolactone) 
(PCL), Poly-vinyl chloride (PVC), Poly(Lactic-co-Glycolic acid) (PLGA) and others. 
The particular advantage of polymers is that they can promote cell attachment, 
proliferation, and differentiation through the use of bio-functional molecules 
[129,130]. However, the application of polymers, especially natural ones, is limited 
nowadays because of their poor stability during processing (instability at high 
temperatures), propensity to swell when in contact with organic fluids, and, mostly, 
due to the strength limitations.  
3.4.3 Bioceramics  
Bioceramics represent a broad class of advanced materials to be employed in bone 
grafting and dentistry. According to the definition given by Hench “bioceramics are 
those ceramics used for the repair and reconstruction of diseased or damaged parts of 
the musculoskeletal system” [13]. 
Bioceramics constitute a subset of biomaterials that can display either amorphous or 
crystalline structure. This class of the materials includes bioactive glasses, such as 
Bioglass®, glass-ceramics, and Calcium Phosphates (CaP) based ceramics 
[56,131,132]. 
Within the human body, bioceramics can be applied in different forms, i.e. as solid 
pieces (parts of joint prosthesis or in the reconstruction of middle ear ossicles), or as 
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powders and granules, to be used for bone filling. Other forms of bioceramics 
currently applied in the field of tissue engineering include coatings and porous 
scaffolds. The broad range of bioceramic’s clinical applications is shown in Figure 
3.1 [133].  
It is worth mentioning that, according to the general classification (Table 3.1), 
bioceramics can also be divided into the following subtypes, based on the associated 
in vivo reaction: 
(i) Bioinert: ceramics that have a modest interaction with the body (e.g., 
alumina, and zirconia);  
(ii) Bioactive: ceramics that bond directly with bones, without having fibrillar 
connective tissue between them (e. g. hydroxyapatite, bioactive glasses); 
(iii) Resorbable: ceramics that degrade gradually over time allowing bone in-
growth and eventual replacement of the artificial material with the natural 
tissue (Tricalcium phosphate (TCP)-based ceramics). 
Bioinert ceramics, such as Al2O3 and ZrO2 have a high chemical stability in vivo as 
well as high mechanical strength; they induce a minimal adverse response in the 
surrounding physiological environment [134–136].  
As indicated above, HA and glass-based ceramics belong to the class of bioactive 
ceramics that differ from bioinert one through the ability to bond directly with the 
living tissue [137]. According to the definition of bioactivity: “A bioactive material is 
one that elicits a specific biological response at the interface of the material which 
results in the formation of a bond between the tissues and the material” [138]. The 
concept of “bioactivity” will be discussed in more detail in Paragraph 3.5. 
On the other hand, bioresorbable ceramics completely dissolve over time and are 
intended to be replaced by the natural host tissue [73, 74]. In this regard it is worth to 
mention that, the ceramic dissolution rate should match the kinetic of the newly bone 
formation, as well as ceramic graft should exhibit appropriate mechanical properties 
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during the healing process. On the other hand, generally, bone formation is slower, 
with respect to ceramic resorption, so that particular attention should be paid when 
designing bioresorbable ceramics.  
 
Figure 3.1: Clinical use of bioceramics and composites [133]. 
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3.4.3.1 Calcium Phosphate-based Ceramics (CaP) 
Among bone substitute materials, calcium phosphate (CaP)-based ceramics have 
drawn great interest due to the similarity with the mineral component of human bone 
[139]. Indeed, they have been extensively applied for hard tissue repair and 
regeneration, both in orthopedics and dentistry, due to their good biocompatibility, 
osseointegration and osteoconduction for the last 40 years [140]. 
There are numerous compounds in the CaP-based system (Table 3.3 adapted from 
[139]); the most commonly investigated ones are the following:  HA, β-tricalcium 
phosphate (β-TCP) and biphasic calcium phosphate (BCP) [134,139,141].  
Compound Abbreviation Chemical formula Ca/P ratio 
Monocalcium phosphate 
monohydred MCPM Ca(H2PO4)
.H20 0.5 
Dicalcium phosphate 
dihydred DCPD CaHPO4
.2H20 1.0 
Octacalcium phosphate OCP Ca8H2(PO4)6.5H2O 1.33 
α-Tricalcium phosphate α-TCP α-Ca3(PO4)2 1.5 
β-Tricalcium phosphate β-TCP β-Ca3(PO4)2 1.5 
Amorphous Calcium 
Phosphate ACP Ca9(PO4)6 1.2-2.2 
Hydroxyapatite HA Ca10(PO4)6(OH)2 1.67 
Fluorapatite FA Ca5(PO4)3F 1.67 
Table 3.3:  Selected CaP-compounds with corresponding chemical formula, 
abbreviations and ratio Ca/P (adapted from[139]). 
3.4.3.1.1 Hydroxyapatite (HA) 
HA is a complex phosphate of calcium with a Ca/P ratio equal to 1.67 and chemical 
formula Ca5(PO4)3OH or, more often, Ca10(PO4)6(OH)2, to indicate that the crystal 
cell unit consists of two molecules. Among the family of CaP-based compounds, HA 
represents the most investigated one. Morphological features, physicochemical and 
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biological properties of HA have been extensively explored for biomedical 
applications [142–146].  
Structurally and compositionally, HA shares similarities to inorganic component of 
bone tissue; therefore, for a long period of time, HA was exploited as a model 
compound to mimic the biomineralization process [147,148].  
The main advantages of HA-based ceramics comprise [149]: 
- excellent biocompatibility; 
- bioactivity (indeed, HA supports nucleating sites for the precipitation of apatite 
crystals in culture medium [150]);  
- non-inflammatory behavior, non-immunogenicity;  
- high osteoconductive, osteoinductive properties.  
In order to describe the interaction between HA-based ceramic and bone tissue, the 
model schematically shown in Figure 3.2 was suggested [151]. The mechanism 
consists of the following 8 subsequent steps:  
1-2) solubilization of the hydroxyapatite surface; 3) achievement of the equilibrium 
condition between physiological fluids and the modified surface of hydroxyapatite; 4) 
adsorption of proteins and organic material; 5-6) cell adhesion and proliferation; 7) 
beginning of new bone formation; 8) new bone formed.  
Despite undeniable advantages offered by HA-based ceramics, there are also different 
drawbacks currently limiting their applications, such as resorption rate in vivo and 
mechanical properties.  
Indeed, from the thermodynamical point of view, HA is the most stable CaP 
compound under the physiological conditions (body temperature, pH and body fluids 
composition) [152]. 
32 
 
 
Figure 3.2: Schematic representation of the phenomena that occur on the surface of 
HA after implantation [151]. 
Thus, HA resorbs slowly and undergoes little conversion to a bone-like material after 
implantation. The native dissolution rate of crystalline HA in vivo, approximately 10 
wt.% per year, is significantly lower than the growth rate of newly formed bone 
tissue [153]. Therefore, the application of crystalline HA-based bioceramics is 
hindered in bone grafting, where an adequate degradability level is required. 
Another major limitation of HA-based ceramics concerns their mechanical properties. 
Depending on the porosity, density, sinterability, and crystal size, mechanical 
properties of HA may vary significantly [154]. In general, HA-based ceramics are 
brittle with a poor fatigue resistance, so that they are not generally suitable for 
load-bearing applications [155].  
However, despite such limitations, HA is used in a number of different applications, 
namely, in craniomaxillofacial reconstruction, spinal surgery, as well as coating in 
orthopedic (e.g., hip joint prosthesis) and dental implants [155–158]. Due to the 
similarity to biological apatite, HA is also employed in diverse non-medical 
applications including chromatography of nucleic acids, proteins, and other biological 
compounds and for drug delivery purposes [140]. Additionally, HA is added to some 
brands of toothpaste [159]. 
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Since pure HA cannot be found in biological systems, different techniques have been 
developed so far in order to synthesize it. In general, they can be divided into solid-
state reactions and wet methods [160], including precipitation, hydrolysis, 
and hydrothermal synthesis [161]. It should be stressed that physicochemical 
properties and morphology of HA significantly depend on the origin/preparation 
method. 
 
3.4.3.1.2 Biomimetic nanocrystalline apatites (BNAs) 
As discussed in Chapter 2 (Paragraph 2.2.2.2), the main inorganic part of animal and 
human normal bone tissue can be reliably represented as an ion-substituted 
nanocrystalline apatite [162]. The better understanding of the structure and 
composition of biological apatites allowed recently to synthesize their biomimetic 
analogous, which are also referred in the literature as calcium-deficient 
hydroxyapatites (CDHAs). For instance, it is known that biological apatites appear to 
be poorly crystalline compounds; their chemical composition depart from the 
stoichiometric crystalline phase, namely hydroxyapatite (HA, Ca10(PO4)6(OH)2),  by 
calcium and hydroxide ions deficiency [163]. In this light, BNAs attracted much 
attention so far, since they can closer approach the natural biological apatite. Indeed, 
the deficiency in the amount of Ca, the imperfections, and vacancies, are taken into 
account in the BNA structure [164]. Disorders and vacancies, in turn, determine the 
fact that BNAs are more soluble, and possess higher resorption rate in vivo [165]. 
Moreover, the vacancies present in nanocrystalline apatites can be occupied by 
divalent anions, such as hydrogen phosphate (HPO42-) or carbonate (CO32-). 
Magnesium or strontium can also substitute calcium ions in BNAs. 
Regarding the preparation of synthetic biomimetic apatites, several routes have been 
proposed, such as, precipitation by double decomposition, hydrolysis, sol-gel, and 
hydrothermal methods. It is worth to mention that, the method selected to prepare 
BNA determines the amount and kind of substitutions [166].  
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In case of precipitation by double-decomposition, the temperature and pH are strictly 
related to the degree of crystallinity and calcium deficiency in the obtained apatite. 
An effect produced in these materials by their maturation or aging in solution was 
also observed. Specifically, freshly-precipitated poorly crystallized, non-
stoichiometric apatites exhibit a tendency to evolve in solution toward stoichiometry 
and greater crystallinity [72,167]. The systematic studies of the physico-chemical 
properties and the impact of synthesis and post-synthesis parameters on BNA 
formation are available in the literature [163,166,168,169].   
BNA is considered as a very promising material for artificial bone substitutes [170]; 
for instance, it can be used to prepare cements, coatings and composites biomaterials 
[166].  
 
3.4.3.1.3 Amorphous Calcium Phosphates (ACPs) 
ACPs represent a special class of CaP and can be found in various biological systems, 
especially in primitive organisms [171]. ACP possesses short range order in the form 
of roughly spherical Ca9(PO4)6 units, with an average diameter of 0.95 nm, known in 
the literature as “Posner’s clusters” (Fig. 3.3) [172]. 
It is worth to mention that, ACP is an intermediate phase formed during the 
preparation by precipitation of the several CaPs reported in a Table 3.3, and it is 
currently considered as a precursor phase of bone mineral in vertebrates. Indeed, 
several authors have recently provided evidence that ACP appear as a transitory 
phase during the mineralization of calcified tissue. More precisely, ACP was detected 
in newly formed (outer) murine tooth enamel, newly formed fin bones of zebrafish 
and in the early intramembranous mineralisation of murine calvaria tissue [173–175]. 
However, due to the various crucial aspects related to the accurate sample preparation 
and/or analysis without altering of initial material state, even nowadays the issue of 
the occurrence of an ACP phase in such newly mineralised tissues of vertebrates 
remains highly debated. 
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Figure 3.3: Structure of ACP. Representation of Posner’s cluster with a S6 symmetry. 
Three calcium ions are superimposed (red), forming a column on the C3 axis of the 
figure located at z = 0, 1/2 and 1. Two other groups of three calcium ions are at the 
periphery of the cluster at z = 3/4 and z = 1/4 positions. Phosphorus atoms (green) of 
phosphate groups are at z = 1/2 position, with two of the oxygen atoms (blue) of the 
phosphate tetrahedrons. The global chemical composition corresponds to Ca9(PO4)6 
[176].  
The various methods adopted so far to prepare and stabilize the ACP phase were 
summarized in a comprehensive review by Combes and co-workers [176]. For 
instance, ACPs can be synthesized at low-temperature by wet precipitation technique 
[177] or using high energy processing method. The latter one, a dry route, appears to 
be less common, since it does not allow to obtain large amounts of pure ACP. On the 
other hand, the wet technique based on the double decomposition of calcium and 
phosphate salts in aqueous or water–alcohol solutions are more widely applied. 
However, the chemical composition of ACPs prepared by precipitation strongly 
depends on the pH, temperature and concentration of solutions [164]. Indeed, due to 
36 
 
instability of ACP and its reactivity in solution, it could easily convert into 
nanocrystalline apatite (analogous to bone mineral, see 3.4.3.1.2). This feature is 
particularly interesting for the preparation of novel biomaterials which can better 
mimic the composition of a bone mineral. Among the current applications of ACPs, 
there are injectable cements for orthopaedic applications, dental fillers and coatings 
on metal prosthesis [176].  
3.4.3.2 Bioactive Glass and Glass Ceramics 
Glasses are non-crystalline amorphous solids without long-range order that are 
commonly composed of silica-based materials with other constituents. Those ones 
which are used in biomedical properties (“bioglasses”) differ from soda-lime glass 
(commonly used in windows or bottles) compositionally; in particular, less silica and 
higher amounts of calcium and phosphorus are present in bioglasses. The original 
bioactive glass, also known as Bioglass®  45S5, was developed in 1969 by Professor 
Larry Hench.  
Herein a short historical overview on “how bioglass was invented?” [178]: 
… Bioglass is important to biomaterials as one of the first completely synthetic 
materials that seamlessly bonds to bone. It was developed by Professor Larry Hench 
and colleagues. In 1967 Hench was Assistant Professor at the University of Florida. 
At that time his work focused on glass materials and their interaction with nuclear 
radiation. In August of that year, he shared a bus ride to an Army Materials 
Conference in Sagamore, New York with a US Army Colonel who had just returned 
from Vietnam where he was in charge of supplies to 15 MASH units. This colonel 
was not particularly interested in the radiation resistance of glass. Rather, he 
challenged Hench with the following: hundreds of limbs a week in Vietnam were 
being amputated because the body was found to reject the metals and polymer 
materials used to repair the body. “If you can make a material that will resist gamma 
rays why not make a material the body won’t resist?” 
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Hench returned from the conference and wrote a proposal to the US Army Medical R 
and D Command. In October 1969 the project was funded to test the hypothesis that 
silicate-based glasses and glass-ceramics containing critical amounts of Ca and P ions 
would not be rejected by bone. In November 1969 Hench made small rectangles of 
what he called 45S5 glass (44.5 weight % SiO2), and Ted Greenlee, Assistant 
Professor of Orthopaedic Surgery at the University of Florida, implanted them in rat 
femurs at the VA Hospital in Gainesville. Six weeks later Greenlee called: “Larry, 
what are those samples you gave me? They will not come out of the bone. I have 
pulled on them, I have pushed on them, I have cracked the bone and they are still 
bonded in place.” Bioglass was born, and with the first composition studied! Later 
studies by Hench using surface analysis equipment showed that the surface of 
the bioglass, in biological fluids, transformed from a silicate rich composition to a 
phosphate rich structure, possibly hydroxyapatite … 
The concept proposed by Professor Larry Hench completely revolutionized the field 
of biomaterials. Indeed, the general trend in bone repair shifted from the development 
of non-toxic inert biomaterials to the obtainment of materials that once implanted, 
directly bond with host tissues and, most importantly, stimulate body's own 
regenerative capabilities. The mechanism for bone bonding between bioglass and 
host tissue was further attributed to the formation of hydroxycarbonate apatite (HCA) 
layer on the surface of the glass, following the initial glass dissolution. HCA is close 
compositionally to bone mineral and is thought to interact with collagen fibrils to 
integrate (bond) with the host tissue [179]. Paragraph 3.5 describes in details the 
bioactivity mechanism and HCA formation. 
Other valuable features of bioactive glasses include their ability to enhance 
revascularization, osteoblast adhesion, enzyme activity, and differentiation of 
mesenchymal stem cells [179].  
The original glass invented by Prof. Hench, that further was trademarked as 45S5, 
had the following composition (wt.%): 45% silica (SiO2), 24.5% calcium oxide 
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(CaO), 24.5% sodium oxide (Na2O), and 6% phosphorous pentoxide (P2O5) in weight 
percentage [180]. 
It is worth to mention that, depending on the chemical composition of bioactive glass, 
its biological behavior (in particular, the ability to bond with bone) can vary 
significantly. In this regard, Figure 3.4 shows Na2O-CaO-P2O5-SiO2 glass 
composition (constant 6 wt% of P2O5) dependence for hard and soft-tissue bonding.  
Region I is the bioactive-bone bonding zone, and glasses with composition inside it 
are able to bond with the bone.  
Region II (e.g. composition of those silica glasses have applications including 
window, bottle or slides of microscope) behaves almost as inert materials and forms 
fibrous morphology at the implant-tissue interface.  
 
Figure 3.4: Compositional diagram for bone-bonding [181]. 
The compositional boundary between bonding to bone and non-bonding was 
found to be in the range of 60 wt% silica [182].  
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Region III compositions correspond to resorbable glasses, which disappears within a 
day once implanted.  
Region IV is not practical technically and not tested in vivo.  
Region V and * represents a bioactive region and 45S5 composition, respectively. 
Afterwards, in order to improve the characteristics of original Bioglass®, systems 
with various compositions were proposed and investigated [179,183]; some of them 
are reported in Table 3.4.  
Composition (wt%) 45S5 13-93 58S 70S30C 77S 13-93B1 
SiO2 45 53 58.2 71.4 80 34.4 
K2O 0 12 0 0 0 11.7 
Na2O 24.5 6 0 0 0 5.8 
MgO 0 5 0 0 0 4.9 
P2O5 6 4 9.2 0 4 3.8 
B2O3 0 0 0 0 0 19.9 
CaO 24.5 20 32.6 28.6 16 19.5 
Table 3.4: Composition of different bioactive glasses [183]. 
The SiO2-Na2O-CaO-P2O5 system and, particularly, its ancestor (45S5 Bioglass®), is 
still used as a template to develop new silica-based formulations [184]. Recently, also 
borate [185,186] and phosphate formulations have been investigated [187,188]. 
However, according to review of Jones [179] even after a 40‐year span of research on 
bioactive glasses, no other composition has been found to be more bioactive than 
45S5 Bioglass®.  
As far as the glass production techniques is concerned, various methods have been 
developed so far, such as the conventional melt quenching (for the first time 
introduced by Prof. Hench) [180] and the sol–gel [189–191].  
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It has been established that in vivo Bioglass® degrades more rapidly, and favors more 
rapid bone regeneration, unlike the synthetic hydroxyapatite [186]. Indeed, bioglass 
dissolution products (cations such as Na+, K+, Ca2+, etc.) stimulate osteoprogenitor 
cells at the genetic level. After 1 week, there was 17 times more bone in defects filled 
with Bioglass, and twice as much bone after 24 weeks, compared to defects filled 
with HA [192].  
Since 1985, several devices made from 45S5 Bioglass® have been used in clinical 
applications [180], for instance: 
- “Bioglass® Ossicular Reconstruction Prosthesis” (tradename MEP®).  
It represents a device used to treat conductive hearing loss by replacing the 
bones of the middle ear.  
- “Endosseous Ridge Maintainence Implant” (tradename ERMI®).  
This device was designed to support labial and lingual plates in natural tooth 
roots and to provide a more stable ridge for denture construction following 
tooth extraction. 
- PerioGlas®. 
The initial indication for this product was to restore bone loss resulting from 
periodontal disease in infrabony defects. In 1996, PerioGlas® was approved to 
be used in tooth extraction sites and for alveolar ridge augmentation.  
More recently, Bioglass® has been also employed for the treatment of dentinal 
hypersensitivity. It is used as an active repair agent in toothpaste, under the name 
NovaMin (GlaxoSmithKline, UK). Clinical studies show that the dentifrice can 
mineralize tiny holes in dentine, reducing tooth sensitivity (Fig. 3.5) [193]. 
Bioglass® is also used in different orthopedics, cranial-facial and dental-
maxillofacial clinical applications [194].  
Despite evident advantages demonstrated by bioactive glasses, in general they all 
suffer from several common drawbacks. First of all, due to the limited mechanical 
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strength, particularly low fracture toughness, bioactive glasses are suitable only for 
low-load bearing application areas in the human body.  
 
Figure 3.5: (a) Photograph of Sensodyne® Repair and Protect toothpaste, which 
contains NovaMin®; (b) SEM image of NovaMin® particles. (c-f) SEM micrograph 
of human dentine: (c) untreated, (d) immediately  after application of Novamin® in 
artificial saliva (AS); (e) 24 h after application of NovaMin® in AS; (f) 5 days after 
application [179]. 
Another challenging issue is related to the processing of bioactive glasses, since 
alterations in glass amorphous structure arise during the sintering into bulk bodies or 
3D porous scaffolds. 
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Indeed, the temperature and pressure levels, which typically need to be applied to 
densify BG powder, induce transitions from its original amorphous nature and 
modifications in its composition. Structural and compositional transformations in the 
45S5 bioglass which occur, depending on the temperature, are reported in Figure 3.6. 
 
Figure 3.6: Summary of 45S5 structural transformation [195]. 
The devitrification process (crystallization) of 45S5 starts at approximately 610oC. 
The formation of different crystalline phases occurs correspondingly. As a result, 
crystallisation was reported to produce the deterioration in bioglass bioactivity 
performance, in particular, the reduction of the HCA precipitation rate was observed 
[196]. However, the effect of crystallization on the bioactivity is still controversial, 
since it was found that certain crystallization degree might be beneficial in terms of 
bioactivity [197,198]. In general, the limited sintering ability of glass leads to bulk 
materials with low densification level; thus weaker and less interconnected structures, 
accompanied by the formation of micro-cracks and poor mechanical strength, are 
obtained [199]. 
Recently, based on the understanding how the glass composition can be tailored to 
delay crystallization, new formulations have been proposed (a more detailed 
description can be found in Chapter 5). 
As mentioned previously, the sintering step is fundamental to accurately control the 
structural and compositional changes of the powders during consolidation. In the 
Chapter 4, sintering phenomena and techniques will be discussed in details. 
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3.5 In vitro bioactivity of bioceramics  
According to their definition, bioactive ceramics are the ceramics that possess “the 
ability to bond with host bone tissue” [13]. The concept of bioactivity attracted much 
attention since Hench introduced it at the beginning of 70’s, by the describing of the 
bonding process between 45S5 and host bone. The core concept of bioactivity lays in 
partial dissolution of the glass and the corresponding release of ions, followed by an 
increase of local concentrations of calcium and phosphate ions and the final 
precipitation of biological apatite (also known as carbonated hydroxyapatite layer) on 
the surface of ceramics in vivo. The sequence of reaction events involved during the 
bond formation between bone and a bioactive glass, initially proposed by Hench and 
subsequently modified by Gerhardt and Boccaccini [200], is reported in the Figure 
3.7. 
In order to avoid high costs of in vivo tests, the following in vitro assays were 
proposed: 
1. A first approach, to estimate the HCA-formation ability of bioceramics soaked 
in an acellular simulated body fluid (SBF) [201].  
2. A second one, to study in vitro bone cell response on bioceramics [202,203].  
Regarding the first in vitro method,  at least when considering bioactive glasses or 
apatite-wollastonite ceramics, in 1991 Kokubo stated that “the essential requirement 
for an artificial material to bond to living bone is the formation of bone-like apatite 
on its surface when implanted in the living body, and that this in vivo apatite 
formation can be reproduced in a simulated body fluid” [204].  
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Figure 3.7: Sequence of reactions on the surface of a bioactive implant [205]. 
The key idea proposed by Kokubo comprises the use of an acellular SBF solution 
with an ionic concentration close to human blood plasma (Table 3.5). Since Kokubo 
protocol was proposed, the in vitro apatite formation on the surface of a material, 
when immersed in SBF, has been considered a useful method for assessing the 
potential in vivo bioactivity of new glasses or glass-ceramics.  
 Na+ K+ Mg2+ Ca+ Cl- HCO3- HPO42- SO42- 
Human blood 
plasma 142.0 5.0 1.5 2.5 103.0 27.0 1.0 0.5 
SBF 142.0 5.0 1.5 2.5 148.8 4.2 1.0 0 
Table 3.5: Ion concentration (mM) of human blood plasma and SBF solution [71].  
However, Bohner and colleagues recently pointed that there is not enough scientific 
data to support Kokubo’s statement [150]. Indeed, the reliability of this method 
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depends on the category of bioceramics tested and results of SBF assay need to be 
interpreted very carefully.    
In case of silicate-based bioceramics, excellent apatite forming abilities in SBF have 
been observed. Correspondingly, excellent in vivo bioactivity was observed, which 
indicates that SBF testing is an efficient method to evaluate in vitro bioactivity. 
However, in case of phosphate-based bioceramics (HA for instance), and sulfate-
based materials (CaSO4), behavior in vitro and in vivo differs significantly. Indeed, 
while these materials exhibit good bone formation abilities during in vivo test, SBF 
experiments did not the reveal same good formation of HCA layer. As a result, test in 
SBF alone cannot be considered sufficient to predict the bioactivity.  
A most likely explanation of this discrepancy can be related to the fact that “the 
biochemistry of in vivo bone formation of these bioceramics is significantly different” 
[206]. Briefly, the mechanism of the bonding with host bone of silicate-based 
bioceramics lies in the formation of bone-like apatite layers after the initial glass 
dissolution and ions release. On the other hand, the apatite-formation ability of 
phosphate-based ceramics depends on their crystallinity, porosity and material 
properties. For instance, it was found that fully sintered HA bulk ceramics are 
difficult to induce bone-apatite formation. 
The second in vitro method implies using of cells. In particular, these biological tests 
are aimed to study the material ability to support bone cell attachment, proliferation 
and differentiation. However, on their own, also cell based experiments cannot be 
completely reliable. For instance, highly resorbable ceramics such as CaSiO3 are 
destructive to the in vitro growth of human osteoblasts, due to their high dissolution 
rate followed by an abrupt local change of pH environment  [207]. On the other hand, 
it has been recently shown that CaSiO3 ceramics possess excellent in vivo bone-
formation ability [208].  
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In this regard, the combination of SBF and cell experiments may represent 
compromising solution to evaluate the in vitro bioactivity of ceramics. 
Implementation and optimization of these two methods is then important to provide a 
first bioactivity assessment of novel biocecamics or composites, prior to their in vivo 
implantation.  
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Chapter 4. Materials processing  
 
This chapter provides a general overview about materials processing routes, and, in 
particular, it focuses on the sintering method adopted in the present PhD thesis. 
4.1 Sintering techniques  
Biomaterials processing is an important step that involves mechanical and/or thermal 
treatments of the source material to obtain the final designed product. The selection 
of the processing technique to be adopted predominantly depends on the required 
application and type of biomaterial.   
Among the different processing techniques, sintering is a process consisting in 
compacting and forming initial powder of certain material by heat and/or 
pressure application. It allows bonding particles together into a coherent, 
predominantly solid structure via mass transport phenomena, that occur largely at the 
atomic level [209]. The possible action of a mechanical load promotes powder 
consolidation. Briefly, when solids are heated to high temperatures, constituent ions 
or atoms are driven to move to compensate the surface energy differences among 
their convex and concave surfaces. Bottlenecks are formed and grow among powders 
at the initial stage (Fig. 4.1). As a result, strong chemical bonds are formed among 
powders, and loosely compacted green bodies are hardened to compact materials. 
 
Figure 4.1: Schematic representation of the sintering mechanism: a) particles free 
flowing, b) neck formations and c) voids shrinkage [210].
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The general mechanism of sintering can be divided in three main stages [211]: 
 Initial stage of sintering (“powder rearrangement”); 
During this step, densification level of initial powder increases modestly up to about 
10 vol%. For instance, if the initial green density of the powder compact was 60%, 
after this step it could reach at most about 70% of the theoretical density (TD). This 
initial step is relatively quick (seconds or minutes) and occurs right after exposing the 
powder to high temperature, due to the large surface area and the high driving force 
for sintering under such conditions.  
 Intermediate stage of sintering; 
This stage results in an additional increasing of powder consolidation up to about 25 
vol%, resulting in powder compact density of about 93-95% of TD value. The sample 
shrinkage enhances due to the different diffusion mechanism such as neck growth; 
formation of pore interconnected cylindrical channels, etc. In some cases, during the 
intermediate step of sintering the shrinkage doesn’t occur via described phenomena.  
For instance, shrinkage is characterized by low level, if matter is transported from the 
particle surface, and proceeds through either gas, solid or along interface, as surface 
diffusion.  
 Final stage; 
This final sintering step starts when the powder compact reaches about 93-95 vol% of 
its TD. In an ideal case, this stage results in the elimination of all residual porosity. 
However, the elimination of residual porosity can be achieved if all pores are mainly 
located nearby the grain boundaries. In fact, the defective character of the grain 
interfaces allow easier path for diffusion that, eventually, promotes densification.  
The graph given in Fig. 4.2 summarizes how the relative density of the compact 
increases in each stage as a function of sintering time. As said before, the initial stage 
is relatively fast and leads to low density increase, while the intermediate and final 
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stages take longer time to reach high consolidation levels, possibly near to the 
theoretical value.   
It worth to mention that, for further characterization/application of bioceramic 
powders, obtained after the synthesis, it is necessary to produce bulk specimens. In 
this regard, the sintering represents effective technique that uses thermal energy to 
form chemical bonds between bioceramic particles, resulting in strong, coherent, 
solid structures. Sintering has been successfully adopted to consolidate various 
bioceramics and bioactive glasses [212,213].  
 
Figure 4.2: Influence of the sintering time on the relative density of powder compacts 
[214]. 
It should be noted that, the bioceramics densification behavior depends, in general, on 
the following factors: the applied temperature (thermal profile), particle size, 
specimen dimensions, heating rate, phase transformations, liquid phase formation and 
porosity [210,215,216].  
50 
 
In turn, mechanical and biological properties of post-sintered specimens mainly 
depend on the final microstructure, which is also strictly affected by the selected 
sintering technique.   
The most frequently adopted conventional and innovative sintering methods will be 
described in the following sections. 
Pressureless Sintering (PLS) 
This processing route represents the simplest sintering approach based on heating the 
powder compact without application of an external pressure.  
Three different heating schedules can be performed with pressureless sintering: 
constant-rate heating (CRH), rate-controlled sintering (RCS), and two-step sintering 
(TSS). During TSS, the sample is first heated to T1, then cooled to T2 and held at the 
latter temperature until densification is completed. The microstructure and grain size 
of the ceramics may vary depending on the material and schedule used [217]. 
Generally, in order to reach high densification levels by PLS, it is necessary to 
operate at high temperatures and long processing times. However, the resulting 
samples usually display residual porosity.   
Pressure-Assisted Sintering 
Differently from PLS, these techniques involve the application of a pressure during 
powder heating. Pressure or hydrostatic stress influences particle sliding, as well as 
pore shrinkage and densification rate. Shear induces particle rearrangement by 
sliding, collapsing large pores, while disrupting particle surface films [218]. Since 
pressure increases the driving force for densification, the temperature needed for 
sintering can be reduced to a level as low as half of the melting point of the ceramic. 
Additionally, shape forming and densification can be accomplished in a single step.  
There are two main pressure-assisted sintering methods known as hot pressing (HP) 
and hot isostatic pressing (HIP).  
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In conventional HP approach, the pressure is applied uniaxially at high temperatures 
during powder heating. In traditional HP, external heating elements are used as an 
energy source (Fig. 4.3).  
It should be stressed that it is difficult to obtain complex shape samples by hot 
pressing. Moreover, HP is slow (processing times on the order of hours) and high 
energy consuming process, since heating rates which can be typically achieved are 
relatively low.  
 
Figure 4.3: Schematic representation of Hot Pressing technique [219]. 
Hot isostatic pressing (HIP) involves the simultaneous application of an isostatic 
pressure and elevated temperature to a workpiece [220,221] (Fig. 4.4). The main 
features of this method are: 
- powders are consolidated to higher densities at low temperatures;  
- highly complex shapes with homogeneous density can be obtained;  
- brittle materials, such as ceramics, can be processed, because of the more 
uniform heating. 
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However, the related equipment and tooling are relatively complex and the process 
overall is more expensive than the sequential approach of compaction followed by 
conventional sintering [222]. 
 
Figure 4.4: Schematic representation of the Hot Isostatic Pressing process [223]. 
Spark Plasma Sintering 
The previously described conventional sintering techniques leave a room for their 
improvements, particularly because of the use of external energy sources, which 
make powders heating relatively slow and energy consuming. Furthermore, the 
microstructure of the resulting products is typically quite coarse, since grain growth is 
promoted by either an increase in the sintering temperature or the processing time. To 
overcome such drawbacks, some innovative, more efficient, sintering methods were 
proposed in the last decades.    
These include the Selective Laser Sintering (SLS), the Capacitor Discharge Sintering 
(CDS) and the Spark Plasma Sintering (SPS).  The last technique, which is widely 
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exploited in the present thesis for the fabrication of various bioceramics, will be 
described in details further. 
SPS, also known as plasma-activated sintering, pulse electric current sintering, and 
pulse discharge pressure sintering [224,225], is an advanced technique that uses 
pressure-driven powder consolidation in which a pulsed high DC direct electric 
current passes through a sample placed inside a graphite conductive mould (Fig. 4.5)  
[226]. This technique represents a more energy-saving technology due to its short 
processing times (on the order of minutes) and few steps.  
 
Figure 4.5: Schematic representation of the SPS process [227]. 
During this process, powders are placed inside a die (typically made of graphite) and 
exposed to a pulsed DC current, which flows through the die and the sample (if the 
latter is conducting). Heating of the powders occurs mainly by means of Joule effect 
generation, while a pressure is applied on the powder. The presence of other effects 
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(electromigration, sparks formation, etc.) also postulated to promote powder 
consolidation by SPS [225]. 
In any case, the simultaneous application of low-voltage/high current power along 
with a mechanical axial load generally leads to high densification levels at lower 
temperatures and, above all, shorter times with respect to conventional PLS and HP 
methods. Moreover, SPS can significantly limit the unwanted reactions in highly 
reactive systems, therefore the formation of undesirable product phases can be 
avoided or hindered. 
During SPS runs, the most important operating parameters such as temperature, 
current, and voltage between the machine electrodes, mechanical load and vertical 
sample displacement, can be monitored and recorded in real time. In particular, the 
displacement output provides a real-time indication of the evolution of the powders 
densification. However, the thermal expansion of sample, electrodes, graphite blocks, 
spacers and plungers is also responsible for the measured value [228].  
As summarized in a comprehensive review by Munir and coworkers [227], the use of 
SPS for the powder consolidation allows to obtain cleaner grain boundaries in 
sintered materials, a remarkable increase in superplasticity of ceramics, higher 
permittivity in ferroelectrics, improved magnetic and thermoelectric properties, 
bonding quality, as well as reduced impurity segregation at the grain boundaries.  
Indeed, SPS technology has been successfully applied to produce various advanced 
material both monolithic and composite ones [225]. More recently, the latter 
technique has been exploited also for the fabrication of Functional Graded Materials 
(FGMs) discussed in Paragraph 4.2 [229,230].  
In the present thesis, SPS is extensively applied to obtain monolithic and composite 
bioceramics based on calcium phosphates and bioactive glasses.  
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4.2 Functionally Graded Materials (FGMs) 
FGMs represent a special class of composite materials and can be defined as 
“inhomogeneous materials, consisting of two (or more) different materials, 
engineered to have a continuously varying spatial composition profile” [231].  
The idea of FGMs was firstly proposed in the 1984 in Japan to potentially solve the 
issues related to the design and production of heat-resistant materials for the 
aerospace applications. Indeed, it is known that when a space shuttle enters to and 
from the atmosphere, it undergoes harsh external conditions, to which the traditional 
homogeneous single-phase materials are unable to withstand. To meet this demand, 
FGMs represent an intriguing concept, since by the gradual variation in composition 
and structure over the volume, it is possible to create multi-phase composite materials 
with advanced properties.  
Conceptionally, two different types of FGMs have been proposed so far. The first 
type possesses a continuous structure, as shown in Fig. 4.6 (a); differently, the second 
type, illustrated in Fig. 4.6 (b) corresponds to a stepwise structure. The second type of 
FGMs, represents a multilayered structure with the presence of interfaces between 
discrete layers.  
Additionally, FGMs can be also divided according to the type of gradient, i.e. 
compositional, microstructural and porosity gradient FGMs, etc. 
 
 Figure 4.6: Schematic diagram of concept of gradation in FGMs [231]. 
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Processing 
The fabrication process is one of the most crucial aspect to deal with in FGM 
research [232,233]. Among the processing technique adopted so far to obtain 
synthetic FGMs, two main types can be distinguished: 
1. Densification/sintering methods based on powder metallurgy techniques. 
2. Coating methods: electro-deposition, plasma spray, laser cladding, 
vapor/chemical deposition et al.  
As far as the first approach is considered, it should be noted that, Spark Plasma 
Sintering technique [225], which was discussed more in details in Chapter 4 
(Paragraph 4.1), represents an advanced method compared to other densification 
routes, since it permits to produce high quality materials in relatively short periods of 
time, due to the combined simultaneous application of electrical energy and high 
pressures.  
Materials which can be used to produce FGMs can vary from metals (and their 
alloys), to ceramics and plastics. The current areas of applications of FGMs include 
aerospace, automobile, biomedical, defence, electrical/electronic, energy, marine, 
opto-electronics, and thermoelectronics [234]. 
FGMs in the human body 
It is worth to mention that FGMs are widespread in nature since functional gradation 
is one of the characteristic features of living tissues. Moreover, in a human body the 
majority of tissues and organs are made up of naturally occurring functionally graded 
materials. Skin and mineralized tissues like bones and teeth are among them.  
For instance, long bones change from a dense, stiff external structure (the cortical 
bone) to a porous internal core (the cancellous bone). In this case, functional 
gradation is essential biological adaptation to perform the required functions.  
Moreover, the surface of human teeth is made up of hard enamel, while the inner core 
appears in a form of soft dentine. The transition from the enamel to dentine is 
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provided by intermediate FGM layers, where the composition gradually changes from 
one material to another. Therefore, the production of implants which mimic the 
structure and composition of natural human tissues, i.e. using a biologically inspired 
approach, represents one of the current challenges in biomaterials research.  
Biomedical application of FGMs 
It is known, that an ideal biomaterial has to fulfill several needs, such as 
biocompatibility, corrosion resistance, thermal conductivity, suitable mechanical 
characteristics, and many other properties  (See Chapter 3, Paragraph 3.2) [235]. 
Natural biomaterials (for example, allografts) have the structure of Functionally 
Graded Materials (FGMs) which allow them to satisfy these requirements. However, 
synthetic biomaterials with single composition and uniform structure can barely 
fulfill all these requirements simultaneously.  Composites and, preferably, FGMs may 
represent a possible solution. In this regard, the latter class of materials have been 
extensively investigated in last decades for biomedical applications, such as in dental 
restorations and orthopaedic implants [236–238].  
In case of dental implants, it is worth to mention that specific biomechanical features 
are required; namely, implant should first provide an improved integration with the 
host living tissue (i.e. the cortical and cancellous bones) for better matching the 
mechanical properties; on the other hand, the region connected to crown should also 
be more stable and enduring against daily loads. Therefore, ideal dental implants 
should adapt to the different loading regions to provide stable support in the entire 
restoration. 
Different attempts to produce compositional FGMs which can meet these 
requirements have been proposed so far. FGMs based on Ti/HA, titanium/cobalt 
(Ti/Co), Ti/ZrO2, titanium/ silica (Ti/SiO2), and TiN/HA composition, as well as 
hydroxyapatite/collagen (HA/Col) mixtures, have been studied [239,240]. HA in 
these cases is used to improve bone/implant osseointegration. However, the crucial 
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issue related to the clinical use of titanium implants coated with HA is related to the 
fact that HA can be possibly biologically absorb with time, evoking defects and 
debonding in the coated layer.  
Regarding the use of FGMs in orthopaedic implants, different advanced compositions 
have been proposed and studied so far, including some which involve the use of ultra-
high molecular weight polyethylene (UHMWPE) fibers [241] for total hip, shoulder 
and knee joint replacements. UHMWPE is utilized because of superior mechanical 
properties and biocompatibility. On the other hand, the fabrication of FGM systems 
based on the combination of metal oxides and stainless steel has been also 
considered [230,242,243]. Specifically, in these studies, zirconia partially stabilized 
with 3 mol% yttria (3Y-PSZ)  or Al2O3 were combined with stainless steel, mainly 
316L or 410L [229]. Additionally, other advanced compositions which are currently 
under investigation were reviewed by Sola and co-workers [238]. 
Moreover, porous gradient functional materials also appear to be attractive as 
materials for hard tissue engineering, since they can mimic more closely the structure 
at the site of implantation. For example, permanent skeletal replacement implants 
made of titanium with graded porosity were proposed to improve structural 
compatibility and minimize the stress shielding [244]. Furthermore, it was found that 
titanium with gradient porosity can favor implant osseo-integration properties [245]. 
In addition, graded porous hydroxyapatite (HA) is suitable to mimic the bimodal 
structure of the human bone (cortical and cancellous), which helps to promote the 
new tissue growth, and also satisfy the desired mechanical properties [246,247]. 
 
 
The results obtained in the various research topics considered in the framework of 
this PhD will be described and discussed in detail in the following Chapters. 
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Chapter 5. Novel CaO-rich bioglass-derived glass-
ceramic: crystallization and effect on the in vitro 
bioactivity  
5.1 Introduction 
As previously mentioned in Paragraph 3.4.3, due to their ability to elicit favorable 
host response during interaction with biological tissues, bioactive glasses have 
become one of the most important and investigated classes of materials for 
biomedical application [179,205].  
Several in vivo studies demonstrated that bioglass stimulates bone growth away from 
the bone-implant interface and, in particular, bonds to bone more rapidly than other 
bioactive ceramics. In spite of this, calcium phosphates, such as tricalcium phosphate 
and hydroxyapatite, are currently still more widely used in clinical practice. This is 
mostly due to the fact that standard bioactive glasses display some critical aspects.  
For instance, a crucial issue concerning the use of original 45S5 Bioglass®  is related 
to its high tendency to crystallize: in fact, this system starts to devitrify approximately 
at 600oC and a crystallization peak is shown between 650°C and 690°C 
[197,213,248,249]. This aspect represents the primary limitation of such bioactive 
glass. Crystallization, which occurs during the sintering step, significantly alters 
mechanical and biological properties of 45S5 Bioglass® and hinders the densification 
process itself.  Thus, when the corresponding powders are exposed to the thermal 
levels required by pressureless sintering to obtain bulk materials, fully crystallized 
ceramics or glass-ceramic composites are produced [195,213]. In contrast, highly 
porous samples characterized by poor mechanical properties can be obtained when 
operating below the crystallization temperature. 
Although the lack of mechanical strength in amorphous 45S5 is improved after 
crystallization takes place, this feature could also lead to negative consequences 
[179,196,213]. Specifically, a precocious crystallization can retard the sintering 
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process [250,251]. In addition, it has been reported that the newly formed crystalline 
phases are scarcely bioactive or, at least, less bioactive than the “parent” amorphous 
phase. Nonetheless, in vitro tests recently carried out with acellular SBF solution and 
involving 45S5-based dense samples produced by Spark Plasma Sintering (SPS) 
evidenced that the enhanced apatite formation was promoted in crystallized samples 
as compared to the mainly amorphous material [198,252].  In any case, partial 
crystallization can lead to implant instability [253], since the residual glassy areas are 
degraded preferentially by physiological ﬂuids, as reported when investigating a 
glass-ceramic material called Ceravital®, which failed due to long-term instability, 
although it results bonded to bone [179]. 
For these reasons, in the last years, several investigations have been performed to 
understand how the glass composition can be modiﬁed to properly control or prevent 
crystallization during thermal treatments. It should be noted that, the crystallization of 
bioglass depends on the composition, i. e. relative amounts of oxide constituents. 
New formulations with relatively higher CaO/Na2O ratio with respect to 45S5 
Bioglass® were recently considered [254,255]. The introduction of suitable amounts 
of K2O in these CaO rich bioglass materials was also examined [256]. A novel CaO-
rich low alkaline bioglass was recently developed to be used whenever a thermal 
treatment is necessary, by virtue of its high bioactivity combined to a low tendency to 
crystallize [249,256]. The composition of this bioglass, so-called CaMix, is presented 
in Table 5.1.  
Bioglass type CaO SiO2 Na2O K2O P2O5 
Bioglass®45S5 [13] 26.9 46.1 24.4 - 2.6 
CaMix [256] 45.6 47.2 2.3 2.3 2.6 
Table 5.1: Composition (oxide mol%) of Bioglass® 45S5 and CaMix bioglass 
powders. 
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It was found that the amorphous nature of CaMix bioglass is preserved when the 
starting powders are processed at 800°C for 3h by pressureless sintering.   
In recent years, CaMix has been also successfully employed to obtain 
hydroxyapatite-based composites, produced either by means of pressureless [257] or 
Spark Plasma Sintering [258]. Although the results obtained so far are quite 
promising for the possible use of the CaMix-based glass-ceramic system in 
biomedicine, additional investigations are still needed to gain further insights on the 
behavior of this novel class of materials when exposed to biological environments.  
5.2 Aim 
In this regard, it is particularly useful to provide for the ﬁrst time a quantitative 
analysis of the amounts of apatite produced on the CaMix bioglass surface during in-
vitro experiments in SBF, when using glass-ceramic samples with diﬀerent 
compositional and structural properties.  
To this aim, in this part of thesis, three groups of fully dense specimens with diﬀerent 
composition, crystallization degree and crystallites size were produced by SPS from 
lab-made CaMix powders. The obtained sintered samples were subsequently 
immersed in SBF for various time periods in the range 0–14 days and the 
corresponding temporal changes of their mass, composition and microstructure were 
monitored. The concomitant modiﬁcations in the SBF solution (pH and the 
concentration of the more signiﬁcant species) were also determined and discussed. 
5.3 Experimental  
5.3.1 Materials and Methods 
Bioglass 
Powder of CaMix Bioglass was produced and provided by the Department of 
Engineering “Enzo Ferrari”, Università degli studi di Modena e Reggio Emilia 
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(Italy). The bioglass was obtained by a classical melt-quenching route reported 
elsewhere [256], with the following composition: 47.3% SiO2, 45.6% CaO, 2.3% 
Na2O, 2.3% K2O, and 2.6 P2O5 (mol. %). Briefly, the commercial raw powder 
reagents – all reagent grade – (SiO2, Na2CO3, CaCO3, K2CO3, Ca3(PO4)2 by Carlo 
Erba Reagenti, Rodano Milano, Italy) were mixed in a laboratory shaker for 2 h and 
then melted at 1450oC for 1 h. The molten CaMix was then quenched in water to 
obtain a frit which was dried at 110oC for 12 hours. The resulting glass powder 
showed an average particles size value of about 20μm, as revealed by laser light 
scattering analysis (CILAS 1180, France). 
Consolidation 
Dense cylindrical disks with 14.7 mm diameter and 3mm thickness were prepared by 
Spark Plasma Sintering (SPS 515S model, Fuji Electronic Industrial Co., Ltd., 
Kanagawa, Japan) (Fig. 5.1) starting from CaMix powder. SPS runs were conducted 
under vacuum conditions (20Pa) and temperature controlled mode using a K-type 
thermocouple (Omega Engineering Inc., USA) inserted inside a small hole drilled at 
the centre of the external surface of a cylindrical graphite die containing the CaMix 
powders to be consolidated.  
The die and the plungers shown in Figure 5.2 (a) and (b), respectively, were both 
made of AT101 graphite (Atal s.r.l., Italy). The powder to be sintered (1.40 g) was 
placed inside a cylindrical die with outside diameter of 30 mm, inside diameter of 15 
mm, and 30 mm high. In order to facilitate release of the bulk samples after sintering, 
the green compact was covered with a 0.13 mm thick graphite foil (cf.  Figure 5.2 (c)) 
(Alfa Aesar Karlsruhe, Germany). Additionally, a graphite felt (3 mm thick, Atal 
s.r.l., Italy) was used to isolate the die and limit thermal losses (cf. Figure 5.2 (d)). 
The most important SPS parameters, i.e. temperature, current, voltage between the 
machine electrodes, applied load, vertical sample displacement and displacement-
rate, were monitored and recorded during each experiment. The final consolidation 
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level was evaluated by measuring the density of the samples obtained after the 
sintering process by Archimedes method, using distilled water. 
During each SPS experiment, the temperature was increased from the room value to a 
maximum level (TD) according the following steps order: 
1. From the room temperature up to (TD -100oC) with the rate of 50oC/min. 
2. From (TD -100oC) to TD with the rate of 10oC/min.  
Then, the TD value was maintained for a prescribed duration (tD). Cooling process 
was also controlled; the rate of cooling was 50oC/min.  
  
Figure 5.1:  Spark Plasma Sintering 
Equipment (model 515S) used in this 
work. 
 Figure 5.2: (a) graphite die, (b) 
plungers, (c) foil and (d) felt used 
during the SPS experiments 
For in-vitro tests in SBF, three series of sintered samples have been prepared under 
diﬀerent TD and tD conditions (Table 5.2) in order to induce the generation of 
diﬀerent crystallization levels, phases and crystallite size in the sintered products. All 
experiments were conducted under a mechanical pressure of 16MPa. Before SBF 
tests, the sintered disks were ﬁrst accurately sanded using abrasive paper, to remove 
any residual graphite contamination, and then ﬁnely polished. The thickness of 
polished samples was approximately 2.6 mm.  
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Sample ID TD(oC) tD(min) 
S1 730 2 
S2 850 2 
S3 1000 20 
 
Table 5.2: Designation of CaMix bioglass samples and related SPS conditions 
(P=16MPa). 
5.3.2 In-vitro tests 
The a-cellular SBF solution for in-vitro tests was prepared according to the Kokubo 
protocol [204]. Speciﬁcally, NaCl (8.035g), NaHCO3 (0.355g), KCl (0.225g), 
K2HPO4·3H2O (0.231g), MgCl2·6H2O (0.311g), 1M HCl (39ml), CaCl2 (0.292g), 
Na2SO4 (0.072g) and (CH2OH)3CNH2 (6.118g) were added one by one to distilled 
water at 37°C to obtain 1000 mL of solution. The pH of the solution was adjusted at 
7.4 using 1M HCl.  
Each sample was immersed for diﬀerent time intervals (6h, 1, 3, 7 and 14 days) in 
about 46 mL of solution (Vs), that was determined according to the Kokubo 
procedure without refreshing, i.e.  
Vs (mL) = Sa (mm2)/10 (eq. 5.1) 
where Sa, approximately 460 mm2 in the present work, is the apparent surface area of 
the sample. For the sake of reproducibility, each SBF test was repeated at least three 
times.  
After the prescribed storage period, glass samples were rinsed with distilled water, 
dried and weighted using an analytical balance (KERN mod. ABS 120-4, Balingen, 
Germany).  
Structural characterization of the surface of glass-ceramic samples before and after 
their immersion in SBF was carried out by X-ray diffraction analysis (Philips PW 
1830, Netherlands) using a Ni ﬁltered Cu Kα radiation (λ =1.5405Å) (Fig. 5.3). 
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The relative content of the diﬀerent phases and the corresponding average crystallite 
size were determined taking advantage of a Rietveld analytical procedure [259,260].  
In addition, the compositional and microstructural changes of the samples' surface 
were also examined by high resolution scanning electron microscopy (HRSEM) 
(mod. S4000, Hitachi, Tokyo, Japan) equipped with a UltraDry Energy-dispersive X-
ray (EDS) Detector (Thermo Fisher Scientiﬁc, Waltham, MA, USA) (Fig. 5.4).  
  
Figure 5.3: X-Ray Diffractometer  (model 
Philips PW 1830). 
Figure 5.4: High –resolution Scanning 
Electron microscope (model Hitachi 
S4000). 
The most signiﬁcant compositional changes induced in the SBF solution by the 
interaction with the three classes of glass-ceramics were also examined. To this 
regard, it should be noted that the solution was not refreshed during the test, to 
emphasize, with respect to the initial condition, the changes produced in the SBF by 
the contact of the various samples with the ﬂuid. In particular, Ca, P, and Si 
concentrations as well as pH were measured at the prescribed immersion time ends. 
The content of the species above was determined by Inductively Coupled Plasma 
Optical Emission Spectroscopy (ICP-OES CCD Simultaneous, Vista – MPX Varian, 
Mulgrave, Australia). 
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5.4 Results 
5.4.1 Powder consolidation 
The sintering parameters adopted in this study (Table 5.2) have been selected based 
on the results obtained in a previous investigation, aimed to identify the optimal SPS 
conditions for achieving the full densiﬁcation of CaMix powders while preserving 
their original amorphous nature [249]. It resulted that completely dense and still 
amorphous materials can be obtained under the milder conditions of TD=730°C, 
tD=2min and P=16MPa. Therefore, such parameters have been chosen for the 
fabrication of the ﬁrst class of specimens, indicated as S1 in Table 5.2, for SBF tests. 
Moreover, to investigate the possible eﬀects of crystallization from the parent glass 
on the material bioactivity, the processing time and/or sintering temperature were 
increased to produce the two additional series of CaMix-derived glass-ceramics, 
listed as S2 and S3 in Table 5.2. 
5.4.2 In-vitro experiments 
5.4.2.1 XRD analysis  
The CaMix samples were examined in detail by XRD analysis to evidence the 
compositional and structural changes taking place on their surface during SBF 
experiments. The estimation of the relative amount of the diﬀerent phases present, as 
well as the corresponding crystallite size, was performed according to the Rietveld 
procedure.  
The experimental patterns (red rhombohedral) and the corresponding best-ﬁt (dark 
line) for the S1 samples are reported in Fig. 5.5. The ﬁrst pattern, named “original 
powders”, corresponds to an amorphous CaMix glass powder. This phase has been 
computed using a pseudo-crystalline structure factor (Ca1.5Na2.64Si9O3, crystallite 
size: 20Å, microstrain: 0.03) according to the LeBail approach [259–261]. In the 
pattern of bulk materials obtained when the initial powders were consolidated by SPS 
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at 730°C for 2 min (indicated in Fig. 5.5 as t=0d), the amorphous component is 
completely preserved. The subsequent pattern, named t=6h, is referred to the sample 
soaked in SBF for 6h. With respect to the previous pattern, a tangible diﬀerence can 
be observed only when focusing on the background at lower (23°) and middle (45°) 
2θ angle. This eﬀect can be also visualized in the sample stored in the solution for 1 
day. After 3 days, the peaks of the nanoapatite phase (around 9 wt.%) can be clearly 
detected in the corresponding pattern (t=3d). Speciﬁc data, concerning microstructure 
features and phases abundance are summarized in Table 5.3.  
Sample Phases Crystallite sizes (Å) Wt. % 
Original powders Amorphous CaMix - 100 
t = 0d   Amorphous CaMix - 100 
t = 6h   Amorphous CaMix/apatite - >95/trace 
t = 1d   Amorphous CaMix/apatite - >95/trace 
t = 3d   Amorphous CaMix/apatite /435 91/9 
t = 7d   Amorphous CaMix/apatite /421 74/26 
t = 14d   Amorphous CaMix/apatite /421 73/27 
Table 5.3: Phases and quantitive phase analysis results relatively to S1 samples 
immersed for different time intervals in the SBF. 
Nanocrystallites of around 44 nm have been estimated for the apatite phase. 
Therefore, it could be assumed that a thin layer of apatite is growing on the 
amorphous matrix of glass, presumably covered by a silica gel layer. 
Nanocrystalline CaMix, together with the apatite and amorphous glass phases, has 
been also detected when the sample was aged for 3 days. However, its quantity was 
below 6 wt.% in all the patterns, so it is not considered. In the samples immersed for 
7 and 14 days, the amount of nanoapatite increases up to 27 wt.%. In addition, the 
formed apatite presents a texture with a preferred orientation situated on the reﬂection 
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002 (25.84°). A similar outcome was obtained in a previous study focused on the 
conventional 45S5 Bioglass® [198]. Thus, it is possible to state that the apatite 
crystallites formed onto amorphous glass nucleated or grew with (002) orientation. 
The experimental patterns and the best-ﬁtted proﬁles of the S2 group of CaMix 
samples are reported in Fig. 5.6. As evinced in the pattern corresponding to t=0d, the 
more severe sintering conditions adopted in this case (TD=850°C) lead to drastic 
changes in the microstructure of the CaMix-derived product. Crystalline peaks of 
both CaSiO3 polymorphous are detected (α-pseudowollastonite and β-wollastonite 
phases) accompanied by an amorphous component ascribable to the glass (46, 28 and 
21 wt.%, respectively - see Table 5.4).  
In addition, the Rietveld analysis provided similar crystallite sizes for α- and β-
CaSiO3, i.e. about 95 and 90 nm, respectively (Table 5.4). Interestingly, traces of 
Kilchoanite (Ca3Si2O7) and Combeite (Ca1.5Na2.64O9Si3), 2 and 3 wt.%, respectively, 
have been also found in the SPS sample. This feature is visualized in detail in Fig. 
5.7, where the deconvolution proﬁles of the pattern at t=0d are shown. No signiﬁcant 
changes can be detected by XRD for the S2 system immersed in SBF for 6h, whereas, 
after 1 day, the samples undergo a partial amorphization with a decrease of the α and 
β-CaSiO3 phases. However, the presence of apatite (3 wt.%) can be detected after 3 
days in the related pattern. Correspondingly, the amorphous component was found to 
increase up to 76 wt.%, with lower amounts of α- and β-CaSiO3 phases. Other 
silicates were not detected under these conditions. In the sample soaked for 7 days, 
the content of nanoapatite further increases up to 20 wt.%, while the amorphous 
component remained the dominant phase. No signiﬁcant changes could be revealed 
by XRD when the storage period was extended to 14 days. In particular, a slightly 
larger amount of apatite (21wt. %) was formed under such conditions. 
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 `  
Figure 5.5: XRD patterns and related Rietveld refinements of 
S1 samples as function of the storage time in the SBF 
solution. 
Figure 5.6: XRD patterns and related Rietveld refinements of 
S2 samples as a function of the storage time in the SBF 
solution. 
 
Data relative to the original bioglass powders are also shown for the sake of comparison. Label CaMix refers to the 
Ca1.5Na2.64Si9O3 phase. 
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Table 5.4: Phases and quantitive phase analysis results relatively to S2 samples 
immersed for different time intervals in the SBF. 
 
Figure 5.7: Deconvolution of the XRD pattern relative to the S2 product before being 
immersed in the SBF solution. 
Regarding the behavior of the S3 group of the glass-ceramic specimens resulting 
when the sintering temperature and the dwell time were increased to 1000°C and 20 
Sample Phases Crystallite sizes (Å) Wt. % 
Original 
powders Amorphous CaMix - 100 
t = 0d   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
Kilchoanite/Combeite 
/950/900/ 21/46/28/2/3 
t = 6h   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
Kilchoanite/Combeite 
/950/900/ 20/45/30/3/2 
t = 1d   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
Kilchoanite/Combeite 
/970/950/ 43/31/22/4/0 
t = 3d   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
apatite 
/1000/920/180 76/7/14/3 
t = 7d   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
apatite 
/1290/1010/233 64/5/10/20 
t = 14d   Amorphous CaMix/α-CaSiO3/β-CaSiO3/ 
apatite 
/1300/1040/274 65/5/8/21 
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min, respectively (pattern t=0d in Fig. 5.8), the XRD analysis evidenced that, under 
such heat treatment conditions, the amorphous glass crystallizes to form β-CaSiO3 
(main one) and Kilchoanite (Ca3Si2O7) phases, whereas no traces of the other 
polymorphous, α-CaSiO3, could be found. 
The Rietveld analysis evidenced an increased size of β-CaSiO3 crystallites (about 
110nm), as compared to that one obtained for the S2 class of glass-ceramic products. 
When the material was exposed to the SBF solution for 6h, the only relevant change 
is represented by the relative increase of the kilchoanite phase (see Table 5.5). A 
rather similar situation was encountered after 1-day contact. 
On the other hand, appreciable changes are observed in the XRD pattern after 3 days, 
when the occurrence of an amorphization process can be readily deduced. As the 
storage time is prolonged to 7 days, the amorphous component increases signiﬁcantly 
(from to 18–56 wt.%), although a relevant amount of crystalline CaSiO3 (34wt.%) is 
still present on the sample surface. More important, the presence (5 wt.%) of the 
apatite phase is clearly identiﬁed for the ﬁrst time when considering the S3 system. 
Finally, when the contact time was extended to 14 days, the amount of apatite on the 
sample surface rises to 10 wt.%.  
To better compare the bioactivity of the three classes of CaMix-based sintered 
materials, the temporal proﬁles of the relative content of apatite produced during the 
in-vitro test, as determined by the Rietveld method, are plotted in Fig. 5.9. From these 
data, it appears that the amount of apatite on the samples surface follows the 
hierarchical order at each time point: S1 > S2 > S3. In addition, when considering the 
S1 and S2 systems, the presence of apatite can be unequivocally detected and 
quantitatively evaluated for immersion times equal to 3 days. 
In contrast, when the S3 counterpart is examined, the incipient formation of apatite is 
observed only after 7 days contact with the SBF solution.  
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Sample Phases Crystallite sizes (Å) Wt. % 
Original 
powders Amorphous CaMix - 100 
t = 0d   Amorphous CaMix/β-CaSiO3/ Kilchoanite /1103/984 12/85/4 
t = 6h   Amorphous CaMix/β-CaSiO3/ Kilchoanite /1100/926 12/72/16 
t = 1d   Amorphous CaMix/β-CaSiO3/ Kilchoanite /1119/925 12/70/18 
t = 3d   Amorphous CaMix/α-CaSiO3/β-CaSiO3 /1135/923 18/64/18 
t = 7d   Amorphous CaMix/β-CaSiO3/ Kilchoanite/ 
apatite 
/850/923/450 56/34/5/5 
t = 14d   Amorphous CaMix/β-CaSiO3/ Kilchoanite/ 
apatite 
/846/922/450 54/29/7/10 
Table 5.5: Phases and quantitive phase analysis results relatively to S3 samples 
immersed for different time intervals in the SBF. 
4.4.2.2 SEM/EDS  
Compositional and structural modiﬁcations promoted on the surface of the three 
classes of CaMix samples by the contact with the SBF solution were also examined 
by SEM/EDS. The obtained results are reported in Fig. 5.10. Several fractures, 
particularly on S1 samples, are observable on the samples’ surface after 6h (Fig. 
5.10b) and 1 day (Fig. 5.10c) immersion in SBF, whereas other degradation and 
apparently minor eﬀects are correspondingly observed on S3 specimens. An 
intermediate behavior is shown by S2 products. Such cracks are due to the drying of 
the micro-porous hydrated silica ﬁlm, which covers the samples surface – in 
particular if the starting sample was amorphous – after the extraction of the sample 
from the SBF; the degradation of the silica ﬁlm is further enhanced by the SEM 
vacuum [256,262]. 
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Figure 5.8: XRD patterns and related Rietveld refinements of 
S3 samples as function of the storage time in the SBF 
solution. 
Figure 5.9: Time evolution of the apatite content on the 
surface of the three series of CaMix samples during in-vitro 
test, as determined by the Rietveld analysis. 
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SEM observation does not evidence the presence after 6h of new phases on the 
surface of the three types of samples. This holds also true when examining the 
materials exposed for t=1d to the solution (Fig. 5.10c).  
However, the EDS analysis evidenced signiﬁcant and sudden changes in the 
composition of the surface of S1 and S2 groups of specimens during such storage 
period (Fig. 5.11). Speciﬁcally, the decrease of the relative content of Si and O, 
particularly when considering S1 sample, is accompanied by a rapid increase of Ca 
and P, due to the deposition of calcium phosphate precipitates on the top of the silica 
gel ﬁlm. In contrast, only modest variations are observed when S3 products were 
immersed. Fig. 5.11 also shows that the Ca/P atomic ratio drops to lower values 
during the ﬁrst 6h immersion for all the systems. However, this ratio becomes less 
than 2 for S1 and S2 in 1 d, whereas it takes quite longer time intervals (t=7d) to 
reach the same achievement when considering the S3 system.  
The SEM micrographs shown in Fig. 5.10d evidenced that after 3d storage, the 
surface of the S1 sample is almost fully covered by a layer of a new phase, i.e. 
globular shaped agglomerates with the typical morphology of the apatite which forms 
in vitro in SBF. Such phase is also clearly formed, although at a lower level, also 
when examining the micrograph of the S2 sample. On the other hand, this feature can 
be observed on S3 products only when the soaking time was prolonged to 7 days 
(Fig. 5.10e). 
Independently from the CaMix system, the new phase produced on the materials 
surface exhibits a lamellar structure, as seen in the detailed micrographs shown in 
Fig. 5.12 for the cases of S1 and S3 samples contacted with the SBF solution for 7 
days. The corresponding EDS spectra, also reported in Fig. 5.12, are consistent with 
the presence at this stage of the phases identiﬁed by XRD analysis. As the storage 
time was further increased, Fig. 5.11 shows that, when considering S1 and S2, the 
relative amounts of Ca and P achieved a maximum value and then slightly decreased, 
whereas an opposite trend was correspondingly found for O. Diﬀerently, Ca and P 
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slightly increase while O content displays only modest changes when S3 samples 
were taken into account. Nonetheless, very close values in the Ca/P atomic ratio, i.e. 
about 1.8 (Ca/P ∼ 1.67 for the stoichiometric hydroxyapatite [263]), were ﬁnally 
reached for the three classes of glass-ceramic products. 
 
Figure 5.10: SEM micrographs of the three series of CaMix specimens at diﬀerent 
storage times in the SBF solution: (a) 0h, (b) 6h, (c) 1 d, (d) 3 d, (e) 7 d and (f) 14 d. 
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Figure 5.11: Compositional changes (EDS analysis) on the surface of the three series 
of CaMix products during their storage in the SBF solution. 
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Figure 5.12: High magnification micrographs and related EDS spectra of (a) S1 and 
(b) S3 samples after 7 days immersion in the SBF solution. 
5.4.2.3 Sample mass changes  
The behavior of the three types of samples in term of weight variation, as a 
consequence of their contact with the SBF solution, is compared in Fig. 5.13. During 
the ﬁrst day immersion, S1 and S2 reduce signiﬁcantly (and similarly) their mass; on 
the contrary, the mass of S3 decreases only slightly. As the test proceeds, also S1 and 
S2 behave diﬀerently. Indeed, while a further mass loss was observed for S2, 
although with a progressively lower rate, S1 specimens displayed a certain weight 
gain during the immersion period from 1d to 3d. As the soaking time was further 
prolonged, sample weight remained approximately unchanged for the latter system, 
whereas the mass of S2 reached a minimum value for t=7d and then increases. As for 
the S3 class of samples, a progressive and slow weight loss takes place for the entire 
storage period investigated. Based on the obtained results, it is possible to state that 
S1 dissolution prevailed up to 1d with respect to the corresponding weight gain 
caused by the apatite formation on the materials surface. However, the opposite 
situation occurs when the contact time is augmented to 3d. A similar qualitative 
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behavior is also manifested by the S2 system, but in this case mass gain overcomes 
dissolution eﬀects only after 7 d. Finally, the latter phenomena are always 
predominant in S3 specimens, as they lose their weight in a monotonic manner for the 
complete test duration.  
 
Figure 5.13: Weight changes of the three series of CaMix samples as a function of 
storage time in the SBF solution. 
5.4.2.4 Compositional changes in SBF  
Fig. 5.14 provides the immersion time dependence of pH and the concentration of 
certain relevant species in the SBF solution during the in-vitro test. As far as pH is 
concerned, a very similar behaviour is observed when comparing S1 and S2 systems. 
In particular, a very rapid pH increase from the initial value to about 7.8 is observed 
during the ﬁrst day storage. As the test proceeds, this parameter still increases, albeit 
at a much lower rate, to approach a value of about 8 after 14 days contact. On the 
other hand, markedly minor changes are ascertained in the solution during the 
interaction with S3 samples, as proved by the relatively small increase in pH reached 
at the end of the test, i.e. 7.75 at most. Similar outcomes are found when the species 
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concentration plots for the three systems are compared. Indeed, Si and Ca release 
from samples to the solution occurred relatively faster for S1 and S2 systems with 
respect to S3. In particular, during the ﬁrst day immersion Si released was relatively 
higher for the S1 system, as compared to S2, whereas comparable values are obtained 
during the progress of the test. Moreover, the P content in the solution decreased 
rapidly and very similarly as soon as the S1 and S2 groups of specimens were soaked 
in SBF. In contrast, when the solution was in contact with the S3 system, the most 
marked depletion of this species is observed to take place during the immersion 
period from 3 to 7 days. 
 
Figure 5.14: Time evolution in pH, Si, Ca and P species content in the SBF solution 
where the three series of CaMix samples were stored. 
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5.5 Discussion  
The present part of PhD represents a follow-up of a recent study where a similar 
approach was considered to investigate the behavior of three groups of glass-
ceramics, produced under diﬀerent SPS conditions from standard 45S5 Bioglass® 
powders, when soaked in SBF [198]. The most important ﬁnding was that 
crystallized 45S5 samples, consisting of Ca1.5Na2.64Si9O3 with 20 nm sized crystallites 
were able to generate a larger amount of apatite, as compared to mainly amorphous 
materials obtained at relatively lower TD values, i.e. 600°C and 550°C, respectively. 
Furthermore, the use of ceramic products resulting when the temperature was further 
increased (700°C) and the dwell time prolonged (from 2 to 20 min) determined the 
formation of the highest apatite content, when the SBF experiment was extended at 
relatively long immersion time intervals (7–14 days). The latter feature was ascribed 
to the beneﬁcial presence of the rhenanite phase formed under more severe SPS 
conditions.  
Based on the outcomes described in the previous section, it is possible to state that a 
quite diﬀerent situation is encountered when the SBF test was conducted on the three 
series of CaMix-derived samples produced as reported in Table 5.2. Such groups of 
samples are all completely dense, while they diﬀer from the structural and 
compositional points of view, as evidenced by the Rietveld analysis used to simulate 
the related XRD patterns. In particular, as reported in Tables 5.3-5.5 (t=0d), 
specimens S1 obtained when the initial powders were sintered for 2 min at 730°C 
resulted completely amorphous. In contrast, the about 80wt. % crystallized S2 
products, with α-CaSiO3 as a dominant phase, was obtained when the dwell 
temperature was raised to 850°C. Finally, as the TD and tD were both increased to 
1000°C and 20 min, the S3 class of glass-ceramics, mostly constituted by β-CaSiO3, 
with no α-CaSiO3 and containing a residual 12 wt.% amorphous phase, was 
generated. The presence of such crystalline phases, which are not expected to be 
detrimental for the in vitro apatite-forming ability [264,265], is consistent with the 
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results obtained in previous investigations [249,257]. The more severe sintering 
conditions correspondingly adopted were also accompanied by a moderate crystallites 
growth, i.e. from 90 to 95 (S2) to 110 nm (S3). Minor amounts (2–4wt.%) of other 
silicate phases, namely Kilchoanite and Combeite, were also formed in the latter two 
systems.  
With regard to the in vitro test results, it is generally seen that the formation of the 
apatite phase is always preceded by the amorphization of the material. This fact could 
be likely ascribable to partial nucleation and growth of apatite (micro- and 
nanocrystallites), together with the formation of an underlying silica gel ﬁlm. In fact, 
as reported in the literature [262,266], the apatite precipitates formed on bioactive 
glasses in SBF are very defective and microcrystalline, therefore their XRD spectra 
are characterized by relatively weak and broad peaks. The latter ones become more 
intense with increasing soaking times in the solution, due to a more complete 
conversion of the samples surface into apatite. Moreover, the additional presence, 
detected after short immersion times, of a broad signal at lower diﬀraction angles 
(typically at 2θ values between 20° and 25°) than those correlated to the halo of the 
as-prepared glass was already explained in previous works [267,268]. Speciﬁcally, 
such signal can be ascribed to the development of a silica gel ﬁlm on the glass 
surface, i.e. a Si-rich layer with a lower content of alkaline and alkaline earth ions as 
compared to the original glass, whose formation is reported among the initial steps 
which lead to the apatite precipitation on the glass surface [13]. The presence of 
signals ascribable to micro and nanoapatite (i.e. a broad band at about 2θ ∼ 32°, 
where the most intense peak of apatite usually appears, an additional peak in the 25°-
27° 2θ range and a broad signal in the 45°-55° 2θ interval [268]) can be clearly 
detected (around 9 wt.%) in the corresponding pattern at t=3d.  
More important, a relevant discrepancy is evidenced between the three systems when 
examining the amount and the rate of formation of the apatite phase produced on 
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their surface. In particular, both these aspects follow the subsequent decreasing order 
S1>S2>>S3.  
Such a diﬀerent biological behavior has to be necessarily associated to the initial 
structural and compositional characteristics of these three classes of glass-ceramics, 
as discussed in what follows. The full amorphous character of S1 products makes 
them prone to display a high dissolution rate since during the ﬁrst stage immersion, as 
proved by the related weight loss as well as the corresponding increase in pH, Ca and 
Si contents. In addition, the slight weight gain recorded in the storage range from 1 to 
3 days could be readily explained by the fact that, during such time interval, sample 
dissolution is more than compensated by the formation of the apatite layer on its 
surface. Indeed, as mentioned above, the rate of formation and the amount of apatite 
generated are both higher for the S1 system with respect to the other two contenders.  
The relevant crystallization (up to 80wt.%) induced in the CaMix material when the 
sintering temperature was raised from 730°C (S1) to 850°C (S2) is observed to 
provide some, albeit not dramatic, depressing eﬀects in term of apatite production. In 
particular, the maximum content of apatite, as revealed by Rietveld analysis (Tables 
5.3 and 5.4), decreased from 27 to 21 wt.% after 14 d storage. Such diﬀerences, also 
evidenced for shorter immersion time intervals, are also likely responsible for the 
weight loss behavior observed in S2 samples up to 7 days, since at this stage the 
amount of apatite produced for this system is apparently not suﬃcient to compensate 
dissolution eﬀects. On the other hand, the opposite situation is established for 
relatively longer soaking times (Fig. 5.13).  
More relevant discrepancies, with respect to the previous systems, are observed when 
the test was conducted using the S3 group of samples. Indeed, the dominant presence 
of β-CaSiO3 in the resulting sintered material is found to determine, as compared to 
S1and S2 systems, not only a marked reduction in the amount of the apatite produced 
on the sample surface but also a delay in the generation of such phase (Fig. 5.9). This 
fact can be readily associated to the markedly slower dissolution rate (Fig. 5.13), the 
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minor pH increase and moderate change in the concentration of the species present in 
the SBF (Fig. 5.14) correspondingly manifested during the test involving S3 
specimens. Of particular importance is the very slow and modest P depletion from the 
SBF (Fig. 5.14), which represents the main source of this element for the formation 
of apatite. 
All these outcomes clearly indicate the rather modest interaction occurring among the 
last group of samples and the ﬂuid. Therefore, although diﬀerent studies in the 
literature have reported that both α- and β-CaSiO3 exhibit good bioactivity and 
biocompatibility [269–271], the results obtained in the present investigation clearly 
indicate that the presence of such phases, particularly the β-conﬁguration, could 
reduce, even strongly, the capability of the original glass to produce the apatite layer 
during SBF tests.  
In conclusion, some ﬁnal considerations should be made regarding the use of the SBF 
protocol in this work, as well as the utilization of fully dense samples, instead of 
porous scaﬀolds, for such tests. Regarding the ﬁrst issue, it was evidenced in the 
literature that the use of SBF for bioactivity testing might lead to some controversial 
results [150]. Therefore, the latter approach did not allow to unequivocally predict the 
in vivo behavior of the material. Despite these criticisms, the SBF testing is still 
broadly utilized by scientists, in particular, as for the present work, to compare the 
apatite forming ability of diﬀerent samples when dipped in the same solution.  
As far as the use of dense samples is concerned, it should be mentioned that, although 
bioglasses are commonly utilized as porous scaffolds, some applications of pore-free 
structures are also reported in the literature, for instance for the repair of orbital ﬂoors 
[179]. In any case, the fabrication of fully dense bioglass-derived products should not 
be necessarily addressed to their direct application, while it is considered more 
suitable for the primary purpose of the present study, i.e. to better compare their 
ability to form apatite when immersed in SBF. Therefore, the obtained results provide 
useful preliminarily indications of the material behavior, that could be subsequently 
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validated when considering porous bodies. In the latter regard, it is worth to mention 
that, although the primary use of the SPS technology is certainly the fabrication of 
dense materials, porous structures could be also produced through this technique by 
properly controlling the operating conditions (applied pressure/sintering temperature, 
initial powder, porogens addition, etc.) [272–274]. 
5.6 Concluding remarks 
There is no unequivocal answer relative to the eﬀects produced by devitriﬁcation 
phenomena which take  place during the consolidation of amorphous powder on the 
biological behavior of the resulting material. Indeed, although this event is often 
reported to negatively aﬀect the latter property, more recent studies highlighted that 
this aspect depends also on the crystallization degree achieved, the speciﬁc crystalline 
phases formed as well as the size of their crystallites. In turn, these features are 
speciﬁcally related to the sintering technique adopted. Therefore, the validation of 
novel glass compositions for biomedical applications has to be duly accompanied by 
an accurate experimental activity aimed to optimize their bioactivity characteristics.  
To this purpose, in this part of PhD work, the biological response during in vitro tests 
in SBF of three groups of dense samples, produced by SPS from a recently developed 
glass with high CaO content, was investigated in detail. Although all the examined 
specimens display apatite-forming ability when stored in SBF, noticeable 
discrepancies in their behaviour were clearly observed when the formation process 
dynamic and the new phase content are compared quantitatively. Speciﬁcally, the 
mildest sintering conditions adopted (730°C, 2min) corresponded to a completely 
dense and amorphous material, which exhibited superior capability to generate in 
shorter times (less than 3 days) amounts of the apatite phase up to 27 wt.% during in-
vitro tests in SBF. Such attitude was only moderately reduced when considering the 
79 wt.% crystallized specimens, obtained by SPS at 850°C and mainly consisting of 
about 95nm sized α-CaSiO3 crystallites, with smaller amounts of β-CaSiO3 and other 
85 
 
minor phases. On the other hand, the apatite formation process signiﬁcantly slowed 
down, when the SBF solution was interfaced with the third group of glass-ceramic 
samples produced at 1000°C and 20 min and mainly consisting of β-CaSiO3. Thus, 
the presence of the latter phase in CaMix derived products seems to play the major 
role, rather than the relatively modest increase of the crystallization degree (from 79 
to 88 wt.%), to determine the observed reduction in the generation of the apatite 
layer. This feature is readily associated to the correspondingly lower weight loss, pH 
increase and ions released, to indicate a scarce interaction of these materials with  the 
physiological ﬂuid. 
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Chapter 6. Study of cell biocompatibility of CaO-rich 
bioactive glass and bioceramic composites 
6.1 Introduction 
As discussed in Chapter 3 (Paragraph 3.4.3), bioceramics represent a broad class of 
materials that is employed in bone grafting and dentistry. Among them, calcium 
phosphate-based materials, and in particular hydroxyapatite (HA), are commonly 
used, in place of autografts and allografts, due to their biocompatibility and 
osteoconductivity [141,210]. Several investigations also demonstrated the 
osteoinductive character of HA, as the latter one is able to promote new bone 
formation [275,276]. HA is commonly used as bone grafts – in form of granules, 
powders, porous or dense bodies – and as coatings for metal implants with the aim to 
increase the biomimetic response of the prosthesis [157]. Nonetheless, this material is 
thermodynamically stable at body temperature and physiological pH, so that its 
reactivity in vivo is typically low and HA resorption occurs very slowly [277,278]. 
This fact represents the major clinical drawback, since bone grafts should degrade at 
the same rate as the new tissue forms, thereby resulting in the complete substitution 
by functional bone tissue. Another crucial aspect is associated to the realization of 
bulk HA products, which typically involves pressureless or classical pressure-assisted 
sintering methods to consolidate the starting powders, so that high temperature 
conditions are required (between 1150oC and 1350oC [279]). Consequently, possible 
HA decomposition [280] and, correspondingly, negative effects on the biological and 
mechanical performance of the final materials could arise.  
The production of HA-based composites with bioactive glasses as second phase is an 
intriguing alternative to go beyond these limitations [280,281]. In fact bioactive 
glasses, and in particular the 45S5 Bioglass® [13] – bond to bone more rapidly than 
HA. It is known that 45S5is osteoinductive, seems to induce neovascularization and it 
exerts an antibacterial effect on a range of oral bacteria [282,283]. For these reasons, 
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the fabrication of HA/bioactive glass composites could lead to innovative systems 
with tunable bioactivity, tailored to specific clinical applications [281]. In fact, by 
modifying the volume fractions of the constituents, it is possible to control the 
biological performance of the final system. At the same time, bioactive glasses can be 
used to incorporate important ions from a biological point of view (i.e. strontium, 
magnesium, silicon, etc. [284]) within the HA lattice, in order to closely mimic the 
composition of the biological apatite, i.e. the mineral phase of bone. 
As for the case of dense HA, also HA/bioglass composites are usually fabricated by 
means of pressureless or conventional hot-pressing sintering techniques. 
Unfortunately, such methods require high temperatures (up to 1200oC–1300oC, 
depending both on the HA to glass ratio and the glass composition [280]), which 
exceed the crystallization point of the glass. For example, as described in a Chapter 3 
(Paragraph 3.4.3.2, see Fig. 3.5), 45S5 Bioglass® starts to crystallize at about 600oC 
and it has a crystallization temperature between 650oC and 690oC, depending on the 
heating rate and particle size [197,213,249]. Such high temperature treatments not 
only induce the devetrification of the bioglass in the composite, with possible 
negative effects on the resulting bioactivity [179], but may also cause HA 
decomposition and reactions between the ceramic and the glassy phase. For these 
reasons, the production of more suitable HA/bioglass composites requires: 
(1) novel bioactive glass compositions with high bioactivity and lower tendency to 
crystallize than 45S5;  
(2) the exploitation of more efficient densification techniques to obtain fully dense 
ceramic products under milder sintering conditions, as an alternative to classical 
sintering.  
In this context, a novel CaO-rich, K2O-containing bioglass (CaMix) with the 
composition described in details in Chapter 5 (See a Table 5.1) was specifically 
designed to be employed whenever a thermal treatment is required, thanks to its 
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lower tendency to crystallize, higher devetrification temperature of about 880∘C [256] 
and higher sinterability than 45S5  [285,286]. The feasibility of CaMix/HA-based 
composites with different ratio of constituents has been recently investigated [257]. 
Unfortunately, even though it was possible to fabricate such composites by means of 
pressureless sintering, the samples with lower bioglass amounts were characterized 
by some residual porosity after the heat treatment, which negatively affected their 
mechanical properties. 
On the other hand, HA/CaMix composites with lower porosity, higher compactness 
and hardness, than the counterparts obtained by conventional sintering techniques 
were successfully produced by means of Spark Plasma Sintering (SPS) [287]. As 
described more in details in a Paragraph 4.1 SPS represents an efficient and powerful 
consolidation method with respect to conventional ones, in terms of both temperature 
and processing time [225].  
Most important, the bioactivity of the HA/CaMix composite samples produced by 
SPS has been  successfully tested in vitro using a SBF solution; in particular, it was 
demonstrated that the relative amount of hydroxycarbonate apatite (HCA) which 
formed on the samples’ surface during the immersion in SBF increased when the 
amount of CaMix is augmented [287].  
6.2 Aim  
In this light, the scope of the present part of PhD is to investigate the in vitro 
biocompatibility towards cells of different HA/CaMix composites as well as to study 
the possible influence of the relative amount of CaMix on cells viability and 
proliferation.  
For this purpose, the biocompatibility of a set of pure HA, pure CaMix and 
HA/CaMix composites with different HA/CaMix proportions (i.e. from 20 wt.% to 
70 wt.% HA) produced by SPS will be tested with murine long bone osteocytes 
(MLO-Y4) by means of a multi-parametric approach. Tetrazolium salt XTT and 
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Neutral Red (NR) uptake assays will be used to investigate cell viability, while 
Bromodeoxyuridine (BrdU) assay will be employed to evaluate the effects of the 
produced materials on cell proliferation. Possible cytotoxic effects of the samples’ 
extracts will be also considered. The findings arising from the SBF tests previously 
cunducted on HA/CaMix composite samples prepared by SPS [287] will be 
compared with the results of the present biological investigation. 
6.3 Experimental  
6.3.1 Materials and Methods 
6.3.1.1 Glass and Composites preparation 
The CaMix glass (composition: 47.3 mol% SiO2, 45.6 mol% CaO, 2.3 mol% K2O, 
2.3 mol% Na2O, and 2.6 mol%  P2O5) was prepared by a melt-quenching route 
[256,288,289] at the Department of Engineering “Enzo Ferrari”, Università degli 
studi di Modena e Reggio Emilia (Italy). Briefly, the commercial raw powder 
reagents – all reagent grade – (SiO2, Na2CO3, CaCO3, K2CO3, Ca3(PO4)2 by Carlo 
Erba Reagenti, Rodano Milano, Italy) were mixed in a laboratory shaker for 2 h and 
then melted at 1450oC for 1 h. The molten CaMix was then quenched in water to 
obtain a frit which was dried at 110oC for 12 hours. Subsequently, the frit was ground 
for 40 min in dry conditions to produce a powder (grain size< 67µm).  
Proper amounts of commercial HA powders (CAPTAL® Hydroxylapatite, Plasma 
Biotal Ltd, UK) were mixed for 6 hours with CaMix powders in order to prepare the 
following set of composites [287]:  
 80 wt.% CaMix and 20 wt.% HA powders (“80BG_20HA”);  
 50 wt.% CaMix and 50 wt.% HA powders (“50BG_50HA”); 
 30 wt.% CaMix and 70 wt.% HA powders (“30BG_70HA”). 
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6.3.1.2 Spark Plasma Sintering of glass, HA and composite powders 
The SPS 515S apparatus (described in the previous Chapter, Paragraph 5.3.1) was 
used for the consolidation of CaMix, 80BG_20HA, 50BG_50HA, 30BG_70HA, and 
HA powders. The amount of powders used for the obtainment of the various dense 
specimens is reported in Table 6.1 along with the adopted SPS conditions. It should 
be noted that the latter ones have been defined based on the systematic investigation 
conducted in previous works on the effect of the SPS parameters on powder 
densification [228,249,287].  
System Powder amount (g) 
Dwell 
temperature, TD 
(oC) 
Dwell time, tD 
Mechanical 
pressure, P (MPa) 
CaMix 1.4 730 2 min 16 
80BG_20HA 1.49 800 3s 30 
50BG_50HA 1.53 1000 3s 30 
30BG_70HA 1.56 1150 3s 30 
HA 1.6 1200 5 min 30 
Table 6.1: Experimental conditions adopted to produce bulk CaMix, HA, HA/CaMix 
composites by SPS. 
Five series of sintered disks with 14.7 mm diameter and about 3 mm thickness were 
correspondingly obtained. For each composition 10 samples were prepared.  
The relative density (ρ) of each polished specimen was measured by Archimedes 
method using distilled water. Weighting of the specimen was carried out taking 
advantage of a Ohaus Explorer Pro (Ohaus Corporation, NJ, USA) analytical balance 
(± 0.0005 g precision). The theoretical densities of the composite systems, i.e., 2.915 
(80BG_20HA), 3.015 (50BG_50HA) and 3.074 g/cm3 (30BG_70HA), were 
determined using a rule of mixture (Eq. 6.1) [290] and by considering the values of 
3.16 and 2.86 g/cm3 for HA and CaMix, respectively [287].  
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where ρc, ρHA, ρBG, represent the density of the composite, HA and CaMix, 
respectively; wHA, wBG the weight fraction of HA and CaMix respectively, in the 
composite.  
In this regard, it should be noted that the amount of powder used for the preparation 
of about 3 mm thick nearly fully dense products was varied as reported in Table 6.1, 
according to the relative content of the two constituents in each series of bioceramics 
taken into account. 
6.3.2 Biocompatibility tests 
In this work, MLO-Y4 (murine long bone osteocyte-like immortalized cell line) cells 
were selected to investigate the ability of the prepared samples (CaMix, HA, 
80BG_20HA, 50BG_50HA and 30BG_70HA) to support cell growth.  
The cytotoxicity of the materials was evaluated both through indirect contact, with 
the aim to test the possible negative effects of the materials’ eluates, and direct 
contact, where the cells are seeded on to the sample and subsequently incubated 
under proper conditions.  
Cell survival, viability and proliferation were studied by means of Neutral Red (NR) 
uptake, tetrazolium salt XTT (2,3bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino) carbonyl]-2H-tetrazoliumhydroxide) and Bromodeoxyuridine (BrdU) 
assays. 
6.3.2.1 Cell culturing and preparation of materials’ extracts 
MLO-Y4 cells were cultured, as indicated by the supplier, in Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen, Karlsruhe, Germany), supplemented with 
10% fetal bovine serum (Invitrogen), sodium pyruvate 1 mM (Invitrogen), D-
Glutamine 2mM and 100 µg/ml penstreptomycin (Invitrogen). The cells were seeded 
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in 6 well plates with the materials for the direct contact tests and the NR assay (see 
next paragraphs) was performed. The plates were incubated at 37±1∘C in 5%±1% 
CO2 humidified air (90%± 5% humidity) and subcultured every about 72 h to 
maintain the cell populations at less than 70% confluent.  
The materials’ eluates for the indirect contact test were obtained by treating them in 
centrifuge tubes (6 cm2/ml area) containing DMEM. DMEM only and DMEM with 
0.45% of phenol solution were used as negative (CTRL-) and positive (CTRL+) 
controls, respectively. The vials were maintained at 37oC for 5 days and every eluate 
was filtered by means of a 0.22 µm filter, according to ISO 10993–5 [291] and ISO 
10993–12 [292] standard procedures. pH measurements were periodically carried on 
to control the physiological conditions of the culture medium.  
6.3.2.2 NR test 
The NR cytotoxicity (Neutral Red solution N6264 Sigma, Germany) assay is a 
widely used procedure to investigate cell survival/viability. It is based on the ability 
of healthy viable cells to incorporate and bind neutral red, a supravital dye. MLOY4 
cells were cultured in direct contact with the materials for 24 h and 72 h at 
37∘C±1∘C, 90%±5% humidity, and 5.0%±1% CO2/air. After the removal of the 
samples and the culture medium, 250 µL of NR solution (Neutral Red solution 
N6264 Sigma, Germany) were added to all wells including the CTRL+ and the 
CTRL- and left to incubate for 3h. Subsequently, the NR solution was removed, the 
cells were rinsed with 250 µL D-PBS and 100 µL NR Desorb (ETOH/acetic acid) 
solution, which is used to extract the NR from the cells, was added to all wells. After 
incubation (20 min), the amount of dye which has been incorporated by the cells was 
measured employing a spectrophotometer (Multiscan RC by Thermolab system, 
Finland) at 540 nm. CTRL+ and the CTRL- were used as references.  
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6.3.2.3 Morphological evaluations 
The cells morphology after 24 h and 72 h direct/indirect contact with the materials 
was observed using optical microscopy (Nikon TMF, Japan). 
6.3.2.4 XTT test 
The XTT test was used to evaluate the cell viability after exposure to the samples’ 
eluates. Such colorimetric assay is widely used to study the mechanisms of cell 
activation and damage via cellular metabolic activity. XTT protocol evaluates the cell 
viability based on the activity of mitochondrial enzymes in metabolic active cells that 
reduce the yellow tetrazolium salt XTT to a water-soluble orange coloured product, 
whose amount is proportional to the number of living cells. Such newly synthesized 
orange formazan dye can be quantified by measuring absorbance at wavelength of 
490 nm [293,294]. Cells were grown in 96 well culture plates and incubated with the 
materials’ eluates for 24 h and 72h. Subsequently, the incubation XTT labeling 
solution (Cell Proliferation KitII (XTT) Roche diagnostics, USA) was added (final 
concentration 0.3 mg/ml) and left to incubate for 4h. The amount of the orange 
formazan dye generated from XTT was then measured by spectrophotometry 
(Multiscan RC by Thermolab system, Finland), using CTRL+ and the CTRL- as 
references. 
6.3.2.5 Bromodeoxyuridine (BrdU) test 
BrdU cell proliferation test is a commonly used assay to quantify the incorporation of 
5-bromo-2-deoxyuridine in replicating DNA of proliferating cells, with the aim to 
evaluate cell proliferation. Cells were grown in 96 well culture plates and exposed to 
the materials’ extracts for 24h. Subsequently, 50µl/well of BrdU labeling solution 
(Cell Proliferation ELISA, BrdU, Roche) was added and left to incubate. The 
incubation time (90 min) is long enough as BrdU is incorporated in place of 
thymidine into the newly synthesized DNA of the cycling cells. Subsequently the 
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labeling culture medium was removed and FixDenat solution (Cell Proliferation 
ELISA, BrdU, Roche) was added, with the aim to fix cells and denature DNA in one 
step. Such solution was then removed and the samples were further incubated with an 
antibody conjugated to peroxidase (anti-BrdU-POD), which is able to bind to the 
BrdU incorporated into the newly synthesized cellular DNA; in this way, it is 
possible to detect the immune complexes through the subsequent substrate reaction. 
The amount of the reaction product can be quantified by measuring absorbance at 
wavelength of 370 nm by means of a spectrophotometer (Multiscan RC by 
Thermolab system, Finland). The signal intensity is correlated to the amount of the 
newly synthesized DNA, and, therefore, to the number of proliferating cells. 
6.3.2.6 Statistical analyses 
One-way variance analysis (ANOVA) was used to statistically treat the obtained 
results, which are expressed as the mean ± standard deviation; t-test analysis by a two 
populations comparison was employed to establish differences among groups. 
Statistical significance was considered at a probability p < 0.05.  
6.4 Results and Discussion  
Prior considering the results obtained in the present study, some findings related to 
the evaluation of different properties of HA/CaMix composites obtained in previous 
works should be discussed [228,249,287]. In particular, the microstructure and 
mechanical behavior of the five series of sintered products, obtained under the SPS 
conditions summarized in Table 6.1, as well as phase composition and in vitro 
bioactivity in SBF. The main outcomes can be summarized as follows: 
1. The obtained bioglass, HA and composite samples are characterized by higher 
compactness and density with respect to the counterparts obtained with classical 
sintering methods. In particular, it was possible to produce for the first time by SPS a 
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set of HA/CaMix composites with high HA content (≥ 50wt.%) with a density close 
to the theoretical value.  
2. Thanks to both aspects, the low tendency to crystallize of CaMix and the 
milder sintering conditions required by SPS, it was possible to reduce the 
crystallization of the glassy phase in the samples, with positive effects on their 
bioactivity. The XRD spectra acquired on the samples are compared in Fig. 6.1. It is 
seen that the bioglass specimens maintained their original amorphous character after 
sintering. This holds also partially true when considering the composite system richer 
in the bioglass constituent. Indeed, the initial occurrence of the glass crystallization 
during SPS was evidenced by the presence of minor amounts of α-CaSiO3, as 
detected by the XRD analysis. Moreover, the content of CaSiO3 in both the α- and β- 
configurations was found to increase as the holding temperature was progressively 
augmented to achieve the nearly full densification in the other two HA-richer 
composites systems. Finally, the glass-free HA product is only composed of apatite, 
with no evidence of secondary phases.  
3. The samples’ bioactivity in SBF improved when the amount of CaMix in the 
sample is augmented.  
4. Finally, the biocompatibility of CaMix and of HA/CaMix composites with 
different HA to glass ratio, produced by conventional sintering, has been successfully 
tested with respect to murine osteocytes and/or fibroblasts [257,295]. 
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Figure 6.1: XRD patterns of bulk BG, HA, and BG-HA composite samples produced 
by SPS. A detailed description of the XRD analysis performed on the samples 
discussed in the present work has been previously reported in [228,249,257]. 
As outlined in Chapter 3 (Paragraph 3.5), the SBF assay aims to qualitatively 
evaluate the bone bonding ability of a material (typically bioactive glass,  
bioceramics or bioactive coatings) by examining the ability of apatite to form on its 
surface once in contact with SBF, which is a solution with ions concentration similar 
to that of human blood plasma [204]. In this light, the study performed by Bellucci et 
al. [287] on pure HA and various HA/CaMix sintered composite samples immersed 
in SBF revealed that the HCA precipitation, which should reflect the samples 
bioactivity and their bone bonding ability, increased when the CaMix content in the 
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sample was increased. Indeed, Figure 6.2 shows the surface of the HA and the 
80BG_20HA samples (images observed by Scanning Electron Microscopy) after 
soaking in SBF for 3 days [287]. It can be clearly observed that the relative content of 
the apatite precipitates is much higher in the sample with the higher content of CaMix 
bioglass.  
 
Figure 6.2: Scanning Electron Microscope images of the HA and the 80BG_20HA 
surfaces after immersion in SBF for 3 days. A detailed description of the SBF tests 
performed on the samples discussed in the present work has been previously reported 
in [228,249,287]. 
In this regard, the present work aims not only to test the biocompatibility towards 
cells of bioceramics samples obtained by SPS, but also to further demonstrate that 
SBF assays should be considered as a preliminary screening test. Indeed, the latter 
one is not able to mimic in a reliable way the complexity of a real physiological 
environment, which contains cells, proteins, specific trace elements, etc. [150]. 
Cytotoxicity tests, based on in vitro cell culture assays, are therefore crucial to 
confirm the findings from the bioactivity evaluation with SBF, which has been 
reported in the literature to lead both to false negative and false positive results [296–
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298]. In this context, probably the most striking case is that represented by β-
Tricalcium Phosphate: despite its high bone-bonding ability in vivo, this ceramic does 
not always induce the formation of apatite in SBF [150]. Moreover, in vitro cell 
culture assays provide an estimate of cell viability, differentiation, proliferation and 
they can be employed to determine if a material has potential to be cytotoxic (i.e. 
through the so-called direct contact tests) or to release agents or degradation products 
that may be cytotoxic (the so-called indirect contact tests). In this work, the biological 
performance of HA, CaMix and HA/CaMix composites produced by SPS was studied 
by means of both direct and indirect contact approaches. Since the materials here 
proposed have been developed to be used in bone repair and regeneration, the 
samples were tested with respect to MLO-Y4, which is an osteocite-like 
immortalized cell line isolated from murine long bones [299,300]. 
Figure 6.3 shows the results of the viability test with NR uptake, a colorimetric assay 
which is commonly used to investigate the toxic effects of chemicals and 
biomaterials on a variety of cell lines from different origin [301,302].  
 
Figure 6.3: NR uptake after 24h (a) and 72h (b) in the different samples. 
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It shows that healthy cells are able to incorporate the supravital dye neutral red, 
which is accumulated within their lysosomes. Therefore, a potential loss of integrity 
and function of the cell (for example, alterations of the cell or the lysosomal 
membrane), due to exposure to cytotoxic xenobiotics, is expected to result in a 
decreased uptake and binding of NR [303].  
In this way, it is possible to distinguish between injured (or dead) and viable cells. 
The NR uptake test has been adopted as a recommended assay for qualitative 
evaluation of biomaterials’ safety by several agencies for testing and normalization 
[304]. The NR uptake and the cell cultures have been here evaluated after 24h (Fig. 
6.3(a)) and 72 h (Fig. 6.3(b)) of exposure to the materials. It should be noted that, 
based on the results of the SBF tests performed on these materials [287] and Fig. 6.2, 
an enhanced biological performance of the samples with higher CaMix content, 
which lead higher formation of hydroxyapatite on their surface, could be expected.  
On the contrary, the results obtained in this work indicated that, after 24h (Fig. 
6.3(a)), the exposure to CaMix induces a slightly lower cell viability, although the 
decreasing in the lysosomal activity is not so significant to be considered a cytotoxic 
effect. Such effect is more pronounced after 72h (Fig. 6.3(b)), where the samples with 
higher CaMix content (i.e. CaMix itself and 80BG_20HA) correspond to a lower cell 
viability. However, also in this case, the produced materials remained not cytotoxic. 
This fact was detectable only by considering the results from the NR uptake assay 
(see the next paragraphs), which is a direct contact test, and it could be ascribed to the 
high release of ions and particulate from the glassy phase.  
It is known that bioactive glasses have a typically higher reactivity than apatite. On 
the other hand, it is also reported in the literature that the presence of particles and 
crystals in the culture medium may affect the accuracy of the absorbance readings 
employed to detect the dye neutral red [305,306]. Therefore, it is crucial to integrate 
such test with the results from additional cytotoxicity assays, in particular based on 
an indirect approach. In such an indirect test it is typically evaluated if a solution, 
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which contains the extractable compounds of a given material, has potential to cause 
changes cells’ morphology and/or lysis. The NR uptake after 24 h and 72 h of direct 
contact to 50BG_50HA, 30BG_70HA and HA was analogous or even higher than 
CTRL- (Fig.  6.3), therefore also these materials did not show a cytotoxic response. 
A morphological evaluation of MLO-Y4 cells after 24h indirect contact with the 
samples is reported in Fig. 6.4. Despite the CaMix content is different in these 
samples, no relevant effects were here observable in the cells’ behaviour. In fact, 
MLO-Y4 grew very well in all the materials’ extracts and showed a morphology 
similar to that of the cells in the CTRL-: no significant cell morphology changes were 
observed, including lysed or rounded cells.  
Fig. 6.5 (a, b) shows the results of the viability test performed by means of XTT 
colorimetric assay [294,307]. After 24h and 72h of culture in the samples’ eluates, 
the mitochondrial activity of the cells is higher than CTRL- for all the materials, 
including the samples with higher CaMix content, thus indicating that MLO-Y4 grew 
and proliferated normally. However, also in this case, the pronounced in vitro 
bioactivity in SBF of CaMix and 80BG_20HA ([287] and Fig. 6.2) did not result in 
an enhanced biological performance with respect to pure HA.  
Finally, Bromodeoxyuridine test (BrdU) was used to evaluate the proliferation of 
MLO-Y4 cells cultured in extracts from the developed materials. BrdU is 
incorporated into the newly synthesized DNA in place of thymidine, therefore it acts 
as a marker of the cycling cells, which can be detected by immunohistochemistry 
[308]. According to the results reported in Fig. 6.5(c), the produced materials did not 
affect negatively the cells. Specifically, it is possible to observe that CaMix, 
80BG_20HA and 50BG_50HA samples preferably stimulate the cell proliferation. 
While this fact has been previously observed and discussed in several works (see, for 
example, [284,309]) when dealing with the “gold” standard 45S5  in powder or bulk 
form, analogous investigations carried out using sintered bioglasses and, in particular, 
bioglass-based composites sintered by SPS are lacking in the literature. Based on 
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these findings, SPS seems to be a promising tool to produce sintered bioglasses and 
bioglass-based composites, without negatively affecting the biocompatibility of the 
powder undergoing consolidation. 
 
Figure 6.4: Morphological evaluation of MLO-Y4 cells after 24h indirect contact 
with the samples using optical microscopy (Nikon TMF, Japan). 
102 
 
 
Figure 6.5: XTT test of MLO-Y4 cells cultured in eluate from the samples after 24h 
(a) and 72h (b); BrdU test after 24h (c). 
6.5 Conclusions  
Some recent investigations were addressed to the fabrication by SPS of bulk 
bioglasses, HA and HA/bioglass composites. In this context, a novel lab made CaO-
rich, K2O containing glass, named CaMix was also considered. It should be recalled 
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that CaMix was specifically designed to be employed whenever a thermal treatment 
is required, thanks to its lower tendency to crystallize with respect to the widely used 
45S5 . According to SBF tests, the in vitro bioactivity of the samples, which should, 
in principle, reflect the bone bonding ability of the material, is progressively 
improved with the increasing amount of CaMix in the sample itself. In this work, for 
the first time, the biocompatibility of a set of pure HA, pure CaMix and HA/CaMix 
composites produced by SPS was evaluated with respect to murine long bone 
osteocytes by means of both direct (NR uptake) and indirect test (XTT and BrdU). It 
should be noted that, although previous works [257,295] confirmed the 
biocompatibility of both CaMix and HA/CaMix composites produced by 
conventional sintering, analogous investigations involving bioglasses and bioglass-
based composites sintered by SPS are lacking in the literature.  
Despite none of the samples here considered was cytotoxic, the findings of the 
biological evaluation did not confirm the outcomes arising from the SBF assay. In 
particular, the results of direct tests did not show an enhanced “biological 
performance” in the samples with increasing glass content. This fact may be ascribed 
to the high release of ions and particulate from the glass phase, which could affect the 
cell viability. Nonetheless, it should be noted that it is also reported in the literature 
that the presence of particulate in the culture medium may affect the accuracy of the 
absorbance readings employed in the colorimetric assay. In general it is found that, 
the samples with a higher glass content (CaMix, 80BG_20HA and 50BG_50HA) 
slightly stimulate the cell proliferation. It is possible to conclude that SPS is a 
convenient technique for the preparation of sintered bioglasses and bioglass-based 
composites, under less severe conditions, so that the suitable biological properties of 
initial powders are highly preserved.   
Moreover, the present work demonstrates once more that the results of the SBF 
assays should be interpreted with great care, making sure that the results arising from 
direct contact tests are integrated with those deriving from the indirect ones. 
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Chapter 7. Advanced Functionally Graded Materials in 
Calcium Phosphate/Bioactive glass system  
 
7.1 Introduction 
A significant challenge in orthopaedic and dentistry clinical practice is currently 
addressed to long-term stability of implants usually made from metals and their 
alloys. Indeed, in this context, mismatch of mechanical properties, i.e. Young’s 
modulus, between host tissue and implant can cause a stress shielding; additionally, 
the release of metallic ions, which can occur due to the implant corrosion in contact 
with the physiological fluids, may give rise to inflammatory reaction in the body. In 
order to improve implant surface properties coatings with more 
biocompatible/bioactive materials such as hydroxyapatite on the metal substrates 
were proposed so far [310,311].  However, still nowadays coating failure due to the 
poor adhesion with substrate remains unsolved issue. In this regard, functionally 
graded materials (FGMs) may represent an intriguing alternative.  
According to a definition of Udupa and co-workers (see Chapter 4, Paragraph 4.2), 
functionally graded materials (FGMs) are “inhomogeneous materials, consisting of 
two (or more) different materials, engineered to have a continuously varying spatial 
composition profile” [231].  
The concept of FGMs is relatively new, firstly proposed in the middle of 80s to solve 
the challenges related to the design and production of heat-resistant materials for the 
aerospace industry. Further, the interest in FGMs was extended to automobile, 
defence, electrical/electronic, energy and biomedical fields.  
The idea behind the possible explotation of functional gradient in biomaterials (either 
compositional and/or porosity gradient) is that properties of such materials can be 
tailored in accordance with the specific needs at the site of implantation.  
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Indeed, implants made of FGM can adapt to the different regions of hosting tissues, 
therefore creating an improved overall integration and stability in the entire 
restoration.  
As stated in Chapter 4 (Paragraph 4.2), there are two main types FGMs: the first one 
characterized by a continuous gradient; while the second one with a stepwise 
structure. Generally, when considering stepwise FGMs, it is intended to obtain two 
different single-phase materials on the opposite sides of the sample (for example, HA 
and bioactive glass), while the material in between usually consist of composites 
based on the two constituents and functional change through space occurs in a 
discontinuous way. 
For example, it is possible to couple a more stable osteoconductive material, on one 
side of a device, and a more bioactive and bioresorbable one on the other side, thus 
avoiding any abrupt interface that can negatively affect the system’s reliability.  
Among the different calcium phosphates studied for bone substitutes, hydroxyapatite 
(HA), a highly crystalline form of synthetic calcium phosphate Ca10(PO4)6(OH)2 (see 
the Chapter 3, Paragraph 3.4.3.1.1), is known to posseses osteoconductive properties, 
and also to promote new bone formation in vivo [276,312]. However, bioactive 
properties of HA are limited, meaning that it shows scarce stimulation of osteogenic 
differentiation and comparably low surface reactivity, i.e. once implanted HA is 
thermodynamically stable at physiological pH and body temperature. 
On the other hand, bioactive glasses (BG), for instance, 45S5 Bioglass® (see the 
Chapter 3, Paragraph 3.4.3.2), display osteostimulative functions. Therefore, through 
the formation of a carbonate-substituted hydroxyapatite-like (HCA) layer on their 
surfaces, both in vitro and in vivo, this material can provide faster and stronger 
bonding to bone and surrounding tissues rather that HA [179,188]. Furthermore, 
according to various studies, certain bioactive glasses were found to stimulate 
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angiogenic and osteogenic differentiation of stem cells by releasing some bioactive 
ions [313,314].  
However, it is also well recognized that bioglasses suffer from poor mechanical 
properties, and it is a matter of fact that properties of initially amorphous bioactive 
glasses can be altered because of the crystallization which can occur during the 
processing into a final product (i.e. bulk or 3D scaffold).  
Moreover, it also should be stressed that the 45S5, especially when used in vitro 
(“static”) experimental conditions, can cause a strong local pH-increase because of 
significant release of sodium in physiological ﬂuids. This alkaline media might be 
harmful to cells [315,316], in particular, osteoclasts function was found to decrease 
[317]. 
In order to overcome the mentioned above limitations of 45S5, a novel CaO-rich, 
K2O-containing bioglass (CaMix), with the composition described in details in the 
Chapter 4 (See a Table 4.1), can represent a promising alternative. Thanks to its low 
tendency to crystallize, it is possible to obtain fully dense amorphous bulk samples at 
higher temperature in contrast to 45S5 Bioglass®.  
It is known that the fabrication process is one of the most crucial fields in FGM 
research. Therefore, an appropriate technique which can allow to fabricate samples 
without altering their initial properties is required. Spark Plasma Sintering was found 
to be effective for the consolidation of HA [228], CaMix bioglass powders [249] (See 
Chapter 4) and their composites (See Chapter 5)  [287] and permitted to obtain  the 
samples with lower porosity, higher compactness and hardness in comparison to the 
counterparts produced by conventional sintering techniques. Due to the relatively 
milder conditions generally required, with respect to conventional consolidation 
methods to achieve high density levels, several beneficial effects, such as avoiding or 
limiting decomposition and crystallization phenomena, as well as retaining grain 
growth, are associated with the use of SPS.  
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As mentioned above, the use of composites materials in stepwise FGMs, allows to 
smoothly vary their composition along a given direction of the sample. In this regard, 
it should be mentioned that the composites made from calcium phosphates and 
bioactive glasses have been extensively investigated so far, specifically for the bone 
tissue engineering. As pointed in a comprehensive review by Bellucci and coworkers 
[280], there are two main motivations for the fabrication and application of CaP/BG 
composites: 
- The first one is related to the biological behavior: in particular, by combining 
two materials, it is possible to tailor the dissolution and the resorption rate of 
the final product in order to achieve improved biological properties.  
- The second justification concerns the mechanical properties: the addition of 
BGs to CaPs as a sintering aid make the obtainment of improved mechanical 
properties, compared to either BGs or CaPs sintered alone possible. 
Indeed, according to another extensive review by Karadjian et al. [281], which 
summarizes the results obtained so far when investigating both in vitro and in vivo 
biological properties of different calcium phosphate bioactive glass composites, it can 
be concluded that, in general, the BG-addition has positive effects on cell adhesion, 
viability, and proliferation, as compared to pure CaP materials. As far as in vivo 
behavior is concerned, the presence of BG is found to support integration of the 
material into bone and enhances bone formation. 
7.2 Aim 
In this light, taking advantage of findings resulting from previous studies where HA, 
CaMix and HA/CaMix composites were investigated [228,249,287], the main aim of 
this part of PhD is to fabricate crack-free samples based on advanced stepwise 
functionally graded HA/CaMix system, where the bioactive glass content varies 
according to the axial direction.  
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7.3 Experimental 
7.3.1 Materials  
Commercial HA powders (CAPTAL® Hydroxylapatite, Plasma Biotal Ltd, UK) with 
average particle size of 45.7 μm were utilized.  
Powder of CaMix bioactive glass was produced and provided by the Department of 
Engineering “Enzo Ferrari”, Università degli studi di Modena e Reggio Emilia 
(Italy). Glass was obtained by a classical melt-quenching route reported elsewhere 
[256], with the following composition: 47.3% SiO2, 45.6% CaO, 2.3% Na2O, 2.3% 
K2O, and 2.6 P2O5 (mol. %). The resulting bioactive glass powder showed an average 
particles size value of about 20μm, as revealed by laser light scattering analysis 
(CILAS 1180, France). 
7.3.2 Preparation of FGMs 
FGMs with two different compositional profiles were studied; for the sake of brevity 
they were assigned as FGM-S1 and FGM-S2 (Table 7.1). HA and CaMix powders 
relative to each intermediate composite layer were mixed for 1 hours in specified 
amounts according to Table 7.1. 
Layer FGM-S1 FGM-S2 
(1) 100 wt.% HA 70 wt.%HA-30 wt.% CaMix 
(2) 70 wt.%HA-30 wt.% CaMix 50 wt.%HA-50 wt.% CaMix 
(3) 50 wt.%HA-50 wt.% CaMix 20 wt.%HA-80 wt.% CaMix 
(4) 20 wt.%HA-80 wt.% CaMix 10 wt.%HA-90 wt.% CaMix 
(5) 100 wt.% CaMix 100 wt.% CaMix 
Table 7.1: FGM-S1 and FGM-S2 layers compositions. 
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A schematic representation of the FGM-S1 and FGM-S2 to be prepared is reported in 
Fig. 7.1. Both FGMs were prepared by loading, layer by layer of 5 different mixtures 
with prescribed composition (Table 7.1).  
Layers 
 
1 
2 
3 
4 
5 
Figure 7.1: Schematic representation of FGM systems based on the combination of 
HA and CaMix. 
The amount of powders utilized for the obtainment of the various dense specimens is 
reported in Table 7.2 It should be noted that the latter ones have been defined based 
on the systematic investigation conducted in previous works on the effect of the SPS 
parameters on powder densification [228,249,287]. It should be noted that the 
amounts indicated in Table 7.2 correspond to fully dense layers of the following 
prescribed thickness: layer (1) and (5) of approximately 1.5 mm; layers (2)-(4) of 
about 1 mm. The larger thickness of the layers located on the opposite sample ends is 
because an accurate grinding/polishing is required with consequent reduction of the 
high of the disks, before the characterization 
7.3.3 Spark Plasma Sintering 
The SPS 515S apparatus (described in previous Chapters) was used for the 
consolidation of both FGM-S1 and FGM-S2 samples. 
The configuration of the die which was designed to sinter FGM samples in this work 
is reported in a Fig. 7.2. The aim of changing the cross section of the die along the 
axial direction, in principle, is to correspondingly modify the current density and to 
generate a temperature gradient.  
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Layer FGM-S1 Powder amount (g) 
FGM-S1 
Powder amount (g) 
(1) 0.7 0.7 
(2) 0.5 0.5 
(3) 0.5 0.5 
(4) 0.5 0.5 
(5) 0.8 0.8 
Table 7.2: Amount of powders used to prepare each layer of FGM-S1 and FGM-S2.  
This is necessary to satisfy the following needs: 
- Sufficiently high temperatures for layer 1 (located on the top in Fig. 7.2) to 
guarantee that powder mixtures rich in HA will be highly consolidated. 
- Not too high thermal levels for level 5 (bottom part in Fig. 7.2), to avoid or 
limit devetrification phenomenon from glass phase.  
This aspect will be discussed in detail in the following sections.  
The die was fabricated from AT101 graphite (Atal s.r.l., Italy). A protective graphite 
foil (0.13 mm thick, Alfa Aesar, Karlsruhe, Germany) between the compact and inner 
walls of die/plungers was used to facilitate sample release after SPS. During the 
process, the die was covered by the graphite felt (3 mm thick, Atal s.r.l., Italy) for the 
thermal insulation purpose. 
  
Figure 7.2: Design of the die used to sinter FGM specimens in this work.  
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SPS experiments were carried out under temperature controlled mode using a 
thermocouple (Omega Engineering Inc., USA), placed inside in the upper part of the 
graphite die (see TD Fig. 7.2). A digital pyrometer (CHINO, mod. IR-AHS2, Japan) 
focused on the lateral surface of the graphite die was used to monitor the temperature 
in bottom part of the die.  
7.3.4 Characterization of powders and sintered samples 
Structural characterization of the initial powders and the opposite surfaces of sintered 
FGM samples was carried out by X-ray diffraction analysis (Philips PW 1830, 
Netherlands) using a Ni ﬁltered Cu Kα radiation (λ =1.5405Å).  
7.4 Results and discussion 
7.4.1 Sample’s densification 
It is known that, in order to convert hydroxyapatite powder into fully dense bulk 
specimen temperature conditions generally between 1150oC and 1350oC [279] are 
required. On the other hand, the densification of bioactive glasses typically implies 
much lower temperature values.  For instance, it was reported that, to obtain fully 
dense, still amorphous, bulk samples from CaMix the temperature of 880oC [256] is 
needed. Therefore, it is not possible, when processing FGMs to obtain fully dense 
hydroxyapatite layer on the one side and keep the amorphous state of bioactive glass 
layer on the other side of the sample if using the conventional die setup where the 
temperature is distributed uniformly. In order to generate a suitable temperature 
gradient along a chosen direction, during SPS a modified die configuration is indeed 
required. In this context, Jajarmi and co-workers [229] reported the successful 
densification of FGM samples based on 3mol% Y2O3-partially stabilized ZrO2 (3Y-
PSZ) and 316L stainless steel (3Y-PSZ/316L) using a specifically engineered  die 
where the upper cross-section diameter was 28 mm, while the bottom part was 30 
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mm diameter. A similar approach was also utilized in the present study, to provide a 
temperature gradient across the axial direction (Fig. 7.2).   
A systematic investigation to identify the optimal dwell temperature, pressure and 
holding time conditions which allow to obtain crack-free FGM-S1 samples, where 
the pure hydroxyapatite layer is placed on one side of the sample while CaMix 
bioactive glass layer is placed on a opposite site, was first conducted. The identified 
optimal parameters are reported in Table 7.3. It is seen that slightly lower temperature 
(950oC) was required when operating at 50MPa instead of 16MPa. 
 
Table 7.3: Optimal SPS parameters which allowed to obtain crack-free FGM-S1 
samples.   
However, despite the different temperatures, pressures and dwell periods tested, it 
was not possible to preserve the initial amorphous nature of the bioactive glass layer. 
Indeed, the XRD analysis carried out on the surface of the BG layer revealed the 
occurrence of glass devetrification (Fig. 7.3a).  
In both cases, the crystallization of initially amorphous BG powder produced α- and 
β-CaSiO3.  
A different behavior was observed, when considering the FGM-S2 system processed 
under conditions listed in Table 7.4, amorphous BG was preserved on the bottom side 
of the sample. The initial occurrence of glass devetrification on the top side of the 
specimen was evidenced by XRD analysis (Fig. 7.4a). Indeed, the presence of β-
CaSiO3 was detected in all 70wt.%HA-30wt.%BG prepared by SPS at 800oC under 
different processing conditions. 
Temperature, oC Pressure, MPa Dwell time, min 
950 50 2 
1000 16 2 
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1) 2) 
Figure 7.3: XRD patterns of (a) pure BG and (b) pure HA sides of the FGM-S1 
samples corresponding to the SPS condition applied: (1) 950oC, 50MPa, 2 min; (2) 
1000oC, 16MPa, 2 min. 
Nonetheless, these results seem to be promising for the future development of HA-
BG based FGMs.  
 
 
 
 Table 7.4: Optimal SPS parameters which allowed to obtain crack-free FGM-
S2 samples.   
Some representative images of FGMs samples obtained in this work for the two 
systems taken into account are shown in Fig. 7.5.   
Temperature, oC Pressure, MPa Dwell time, min 
800 16; 30; 50 2 
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(1)  (2) 
 
(3) 
 
Figure 7.4: XRD patterns of (a) pure BG and (b) 70wt.%HA/30wt.%BG sides of the FGM-S2 samples corresponding to the 
following SPS conditions: (1) 800oC, 16MPa, 2 min; (2) 800oC, 30MPa, 2 min;  (3) 800oC, 50MPa, 2 min. 
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The produced samples are currently under characterization from mechanical and 
biological points of view (sample diameter 14.7±0.1 mm, thickness 6.0±0.2 mm).  
FGM-S1 
950oC/50MPa/2 min 
FGM-S2 
800oC/30MPa/2 min 
  
 
 
Figure 7.5: Photos of the FGM-S1 and FGM-S2 samples obtained in this work.  
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Chapter 8. Development of novel bioresorbable 
ceramics from Carbonated/Magnesium doped 
Amorphous Calcium Phosphates   
8.1 Introduction 
In the past decades, the development of synthetic calcium-phosphate-based 
bioceramics as alternative approach for allograft and autograft tissue replacement has 
been a major subject of research [210,318,319]. As already pointed in previous 
Chapters, hydroxyapatite (HA), (Ca10(PO4)6(OH)2), due to its good biocompatibility 
and structural similarity to the mineral part of calcified tissues, is one of the most 
commonly used  bioactive ceramics as of today [141]. However, it is 
thermodynamically stable under physiological conditions and thus exhibits a low 
resorption rate in vivo. Additionally, due to limited surface reactivity, HA bioactivity 
is hindered after implantation [277,278]. Such differences with respect to bone 
mineral, also called biological apatite, are ascribed to the fact that the latter consists 
of nanocrystalline, non-stoichiometric polysubstituted apatite[162]. Besides 
carbonate (CO32-), which is the main substituting ionic group in biological apatite (5-
9 wt.%) [54–56], other ions such as HPO42, Mg2+, Sr2+, Na+ and F- are also 
encountered [62,320]. According to Legros et al. [49], the composition of bone 
mineral is characterized by significant vacancy contents in Ca and OH sites, and it 
can be described (omitting trace elements) by the general formula 
Ca8.3(PO4)4.3(CO3,HPO4)1.7(CO3,OH)0.3. A recent report, when a fresh bone specimen 
was analyzed by NMR and vibrational spectroscopies, evidenced in particular a high 
amount of HPO42- ions besides carbonates [321]. In apatites, whether biological or 
synthetic, hydroxide (OH-) and phosphate (PO43- or HPO42-) ionic groups can indeed 
be replaced by carbonate ions, leading respectively to A and B-type carbonated 
apatites. Additionally, AB mixed-type apatites are also often reported [322]. One 
important feature of nanocrystalline apatites, whether in bone or dentine or their 
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synthetic biomimetic analogs, is the presence of a hydrated non-apatitic ionic layer 
covering the surface of the nanocrystals, and conferring very reactive properties 
[73,75]. In bone, this layer is used for maintaining ion homeostasis in body fluids. 
Thus, in synthetic analogs, these characteristics can be tailored and exploited to 
modulate the reactivity/bioactivity of the nanocrystals, in view of a variety of 
biomedical applications, like bone regeneration but also nanomedicine [323,324]. 
This may also imply ionic substitutions, to modulate the bioactivity of the 
nanocrystals, which may be achieved either for impacting the stability/ degree of 
crystallinity/ thermodynamic properties of the apatitic phase [323], or for tuning 
biological properties, or for both. For example, doping with Mg2+ ions can activate 
osteoblast cells, and Mg-doped apatites also exhibit a less pronounced crystallinity 
(lower maturation state) than Mg-free ones, thus leading to a higher reactivity. Like 
magnesium, carbonate ions are also growth inhibitors for the apatite structure, having 
also an impact on apatite nanocrystals reactivity/solubility [325]. 
These substitutions and subsequent structural disorder provide thus a way to prepare 
biomaterials with a higher solubility, as compared to stoichiometric hydroxyapatite, 
which may be particularly appealing to rapidly confer constitutive building blocks of 
mineral in view of activated bone regrowth. 
In fact, in bones, not only apatite nanocrystals but also transient metastable calcium 
phosphate (CaP) precursors are considered to be naturally present and actively serve 
as a basis for bone neoformation. Although the mechanisms of bone mineralization 
have not yet been fully clarified, it was suggested that the formation of new bone may 
involve amorphous calcium phosphate (ACP) reactive precursors [326–328]. The 
latter are not crystallized but possess short-range order in the form of small organized 
units with average size of about 0.9 nm, known as Posner’s clusters of chemical 
formula Ca9(PO4)6.nH2O [172]. Despite the relevance of ACP in the field of bone 
regeneration, these amorphous compounds have not yet found the development they 
deserve – except as ingredient in bone cement formulation [329,330]. This can 
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probably be linked to the difficulty to process ACP to make granules or 3D pieces, 
while avoiding their crystallization into apatite. Two main techniques have been 
proposed so far to obtain synthetic ACP, i.e. a wet route, in aqueous medium 
[177,331], and a dry method, carried out at high temperatures [332]. The 
consolidation of ACP represents a difficult goal to achieve, due to the thermal 
instability of this amorphous precursor. Therefore, relatively mild conditions are 
required to consolidate it, while preserving its metastable character. Solving of this 
issue could then provide a new family of CaP compounds with even greater reactivity 
and bioresorbability (resorbability in vivo being directly related to solubility [319]). 
Along these lines, the use of Spark Plasma Sintering (SPS) at very low temperature 
(150°C) was reported to be effective for the consolidation of biomimetic 
nanocrystalline apatite powders [163,333,334], thus opening the way to so-called 
“cold sintering” approaches. It should be noted that, these initial experiments were 
performed on non-carbonated apatites. More recently, the possibility to adjoin natural 
polymers, such as cellulose fibers, to obtain reinforced biomimetic apatite/polymer 
composites, has also been demonstrated [335]. Very recently, the exploration of low 
temperature SPS has been extended to the obtainment of carbonated apatites [336]. 
Despite SPS has been used extensively for the fabrication of a variety of advanced 
materials, very few reports have been focused on cold sintering. On the other hand, 
sintering at very low temperature (<300°C) is of relevant importance, especially for 
consolidating biomimetic apatites, to preserve their nanocrystalline, hydrated and 
thermodynamically metastable features [334].  
8.2 Aim 
In this light, the goal of this study was to investigate the ability of SPS to consolidate 
at low temperature amorphous CaP compounds, with the general aim of producing 
ACP-based highly reactive and resorbable biomaterials, as a novel family of bone 
substitutes. It should be noted that all previous attempts to stabilize ACP after 
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sintering, including by SPS at low temperature [336], have failed since the 
crystallization into apatite was systematically observed. This may be related to 
several factors such as inadapted synthesis protocols or too low carbonate contents, 
thus they cannot fully play their crystallization inhibition role. 
In the present work, alternative synthesis routes to prepare very highly carbonated 
ACP powder precursors, eventually also containing magnesium ions, were 
investigated. This approach was utilized for stabilizing/retaining the powder 
amorphous character even after SPS consolidation. Indeed, carbonate and magnesium 
ions are two crystallization inhibitors for the apatitic structure [325], but their effect 
on low temperature sintering had not been investigated so far. Thus, for the first time, 
the possibility to obtain still-amorphous calcium phosphates, after the SPS treatment, 
was studied. As a main scope it is intended to prepare highly resorbable CaP ceramics 
for fast release of bioactive building blocks relevant to bone tissue regeneration. The 
most important physicochemical characteristics of the obtained samples are also 
investigated, by taking advantage of complementary techniques.  
8.3  Experimental  
8.3.1 Materials and methods 
8.3.1.1 Synthesis of amorphous powders  
The synthesis of five types of ACP-based powders was carried out by double 
decomposition method [166,337], with and without carbonate and eventually 
magnesium ions.  
The starting materials used to this aim are listed in Table 8.1, along with the selected 
relative amounts. 
Two different solutions, indicated as A and B, respectively, were prepared 
individually by dissolving the precursors in deionized water. The pH of both 
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solutions was adjusted to ~10 (experimental value of 9.9). To this purpose, either 
ammonium hydroxide (NH4OH 20%, Fisher Chemical) (method 1) or potassium 
hydroxide solution (KOH, Fisher Chemical) (method 2) were utilized. As explained 
in the Result and Discussion section, the Mg30-cACP powders were prepared 
according to both methods. In this regard, di-ammonium hydrogen phosphate 
(NH4)2HPO4 was also replaced in the initial solution B by di-potassium phosphate 
(K2HPO4), in the same proportion. To reach pH 9.9, KOH solutions with pH = 13 or 
15 were added to solutions A and B, respectively. Solution B containing HPO42- ions 
exhibited buffer properties, so that a stronger initial alkaline solution was required to 
increase its pH. The rest of the synthesis procedure was the same for both methods. In 
each case, solution A was added to solution B at room temperature (~22°C). The 
resulting mixture was stirred for few minutes and then immediately filtered on a 
Buchner funnel, washed with alkalinized deionized water (pH 9.9) and, finally, 
freeze-dried. Pure ACP powder was prepared, as a reference, using the method 
described by Heughebaert [177]. 
Name of the 
sample/ 
Method 
Composition 
Solution A Solution B 
Ca(NO3)2.4H2O, 
wt.% 
Mg(NO3)2.6H2O, 
wt.% 
(NH4)2HPO4, 
wt.% 
NaHCO3, 
wt.% 
ACP [177](1) 100 0 100 0 
cACP (1) 100 0 50 50 
Mg5-cACP (1) 95 5 50 50 
Mg15-cACP (1) 85 15 50 50 
Mg30-cACP (1,2) 70 30 50 50 
Table 8.1: Starting composition used to synthesize amorphous calcium phosphates.  
8.3.2 Spark Plasma Sintering (SPS)  
SPS experiments for the consolidation of amorphous precursors were carried out by 
means of a 2080 Sumitomo Coal Mining equipment under argon atmosphere. This 
equipment provides uniaxial pressing and simultaneous heating via DC pulsed 
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current (maximum 8000 A and 10 V). During the experiments, current was limited to 
4000 A, and the sequencing of pulses was 12:2 (12 pulses of 3.3 ms followed by two 
time intervals without current). Powder samples (0.35 g) were placed in a graphite die 
with internal diameter equal to 8 mm covered with Papyex® graphite foil, to facilitate 
sample release after SPS.  
Sintering runs were performed following temperature and pressure programmed 
sequences shown in Fig. 8.1, similar to those used in previous studies aimed to the 
consolidation of biomimetic apatites and derived composites [334,335].  
 
Figure 8.1: SPS conditions (temperature and pressure programs) adopted for the 
consolidation of ACP-based powders. 
8.3.3 Physicochemical Characterization  
Initial powders and sintered samples obtained after SPS were first characterized by 
X-ray diffraction, using a BRUKER D8 Advanced diffractometer with a CuKα 
radiation. XRD spectra were recorded in the range 10-90o, with a step size 0.02 and 
dwell time 1s. In addition, vibrational spectrometry analysis was conducted on a 
Nicolet 5700 Fourier transform infrared (FTIR) spectrometer. Spectra were recorded 
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in transmission mode in the 400–4000 cm-1 range with 64 scans and 4 cm-1 
resolution, the KBr pellet method was used. The obtained FTIR spectra were 
analyzed using the OMNIC software (Thermo Fisher Scientific). 
8.4 Results and discussion  
8.4.1 Powder synthesis and characterisation  
The first systems considered in this study were synthesized using ammonium 
hydroxide solution as alkalinization medium. The XRD patterns of the corresponding 
powders are shown in Fig. 8.2. Standard ACP is shown on Fig. 8.2a. All the other 
CaP-compounds were precipitated in presence of carbonate ions, hence the 
denomination cACP, and with increasing magnesium concentrations (Fig. 8.2b-e). 
For magnesium contents in the starting powder mixture system equal or less than 15 
wt.% (Fig. 8.2b-d) our results indicated that no defined peaks could be detected in the 
XRD patterns. This finding indicates the full amorphous character of these 
carbonated or non-carbonated “ACP” samples. On the other hand, the XRD pattern of  
Mg30-cACP powder (Fig. 8.2e) showed, in addition to the broad halo with maximum 
2θ value at around 30°, several other prominent peaks, which are attributed to the 
presence of a secondary crystalline phase NH4MgPO4.6H2O, Struvite (ICDD-PDF 
01-077-2303). 
The formation of undesired struvite beyond a limit Mg content may be related to the 
use of ammonium hydroxide in the synthesis protocol, thus providing the necessary 
NH4+ ions. Therefore, this biphasic Mg30-cACP sample was not further considered 
for the rest of the study.  
FTIR analyses were also carried out for complementary characterization, and the 
related spectra are presented in Fig. 8.3.  All the spectra reveal broad bands, which 
are similar to those reported in previous works related to ACP obtained by 
precipitation in an alkaline medium [336,338]. The broad band between 3700 and 
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2800 cm-1 and the one at ~1640 cm-1 can be attributed to the presence of water 
(respectively O-H stretching and H-O-H bending modes) associated to Posner 
clusters [339].  
 
Figure 8.2: Diffraction patterns of powders synthesized when using the ammonium 
hydroxide solution: (a) ACP; (b) cACP; (c) Mg5-cACP; (d) Mg15-cACP; (e) Mg30-
cACP. 
 
Figure 8.3: FTIR spectra of the synthesized powders: (a) ACP; (b) cACP; (c) Mg5-
cACP; (d) Mg15-cACP. 
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The amorphous character of the samples leads to poorly defined phosphate vibration 
bands, especially associated to the 3(PO4) and 4(PO4) modes, as opposed to the 
observations with other CaP compounds like apatites [340], and also to a position of 
the 1(PO4) band close to 959 cm-1 (instead of ~ 961-962 cm-1 for apatites) [341]. For 
carbonated compounds, additional bands, assignable to the CO32- ionic group, are also 
detected (Fig. 8.3). In particular, typical regions of the spectra, where signals of 
carbonate ions can be observed, are 850-900 cm-1 and 1350-1550 cm-1, related to the 
2(CO3) and 3(CO3) vibration modes, respectively. Details of these regions are given 
in Fig. 8.4(I), for the case of cACP synthesized powder. For comparative purposes, 
the characteristic features of A and B-type carbonate environments in carbonated 
apatite, which correspond to carbonate ions replacing some hydroxyl and phosphate 
groups in the apatite structure, have also been pointed out in this figure. The 
wavenumbers corresponding to CO32- ionic groups in nanocrystalline apatites are 
summarized in Table 8.2. In addition, the estimated position of IR bands 
corresponding to surface carbonates (i.e. CO32- ions located on the hydrated layer on 
apatite nanocrystals) [342,343], also known as “labile” has also been indicated in Fig. 
8.4 and Table 8.2. 
 Vibrational 
band 
A-type 
substitution 
B-type 
substitution Labile CO3
2- References 
ν2 882 cm-1  872 cm-1 866 cm-1  [58,344] 
ν3 
1465 cm-1 
1542 cm-1 
1412 cm-1 
1462 cm-1 
1417 cm-1 
1480 cm-1 
[342] 
Table 8.2: Characteristic wavenumbers of ν2 and ν3 vibration modes of CO32-. 
Such labile carbonates are indeed characteristic of metastable chemical environments 
that may be found in hydrated amorphous domains, not embedded into the 
crystallographic apatitic structure. It is interesting to note that, in the case of this 
cACP amorphous precursor, carbonate species seem to mostly correspond to such 
labile CO3 (see Fig. 8.4), to confirm their similarity to the labile surface carbonates 
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found in the amorphous hydrated layer on nanocrystalline apatites. The same 
behavior was also observed in the cases of Mg5 and Mg15-cACP initial powders. 
The overall content of CO32- ions was estimated for all samples by exploiting the 
FTIR features in a quantitative way, according to Grunenwald et al.’s updated 
methodology [343] (Table 8.3). In particular, the ratio rc/p between the integrated 
intensity of 3(CO3) (1550-1350 cm-1 domain) and ν4(PO4) band (1230-912 cm-1) was 
measured and compared to the calibration curve. For the carbonated ACP (cACP), 
the total amount of CO3 was found to be around 17 wt.%, while it reached a value of 
18.3 wt.% for Mg15-cACP. To the best of our knowledge, such highly carbonated 
amorphous calcium phosphate powders have been synthesized in the present work for 
the first time.  
By comparison, it should be noted that amorphous powders with carbonate content 
reaching around 3.1 wt.% was reported by Ortali et al., and such level was found 
insufficient to allow the preservation of the amorphous character after SPS 
consolidation [336]. The obtained improvement of the carbonation level can be 
explained on the basis of the several modifications in the synthesis procedure 
employed in the present work as compared to literature reports: unheated synthesis 
(room temperature ~22°C), high alkaline pH, raised close to 10, high starting C/P 
ratio ~1.6 (as opposed to a maximum of 0.5 in ref. [336]), low starting Ca/P ratio, 
close to 1.1, and the absence of precipitate maturation.  
These conditions thus favor the carbonation process by providing not only fewer 
cations and more carbonate ions per unit volume, but also by ensuring of a more 
stable chemical environment for limiting CO2 release (high pH, absence of 
maturation). 
In order to avoid the precipitation of Struvite during the synthesis of Mg30-cACP, the 
preparation of the latter system was attempted by substituting NH4OH with KOH, as 
described in the Materials and Methods section. FTIR spectra of the synthesized 
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powder and the corresponding sample consolidated by SPS are given in Fig. 8.5a and 
8.5b, respectively.  
 
Figure 8.4: FTIR spectra of the cACP powders: 4a(I) initial powder; 4a(II) sample 
after SPS; 4b zoom on the ν3 CO32- band; 4c zoom on the ν2 CO32- band. 
The carbonation level of raw Mg30-cACP powder was found to be around 13.8 wt.%, 
while its amorphous character was confirmed by XRD analysis (Fig. 8.6a). 
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Figure 8.5: FTIR spectra of Mg30-cACP synthesized with KOH solution: (a) initial 
powder; (b) after SPS. 
 
Figure 8.6: XRD patterns of Mg30-cACP synthesized with KOH solution: (a) initial 
powder; (b) after SPS. 
The above data clearly confirm that we were able to prepare single-phase, highly 
carbonated ACP powders, with or without co-incorporation of Mg2+ ions.  
The next step therefore consisted of checking their consolidation at low temperature 
by SPS, and the characterization of the obtained bioceramic pellets. This is the object 
of the following section. 
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8.4.2 Characterisation of Spark Plasma Sintered bioceramics 
SPS consolidation was then carried out on each of the carbonated/magnesium ACP 
compositions prepared (see Fig. 8.1). The XRD pattern of the ceramic obtained from 
pure ACP (Figure 8.7a) revealed, as anticipated, that crystallization into an apatite 
phase (ICDD-PDF 00-009-0432) occurred during SPS. Attempts to avoid this 
crystallization were then made by investigating the effect of the carbonation and 
magnesium contents of the amorphous precursor powder. The apatite formation was 
also noticed for the cases of cACP exempt of magnesium (Fig. 8.7b) as well as for 
low amounts of Mg, namely for samples Mg5-cACP (Fig. 8.7c) and Mg15-cACP 
(Fig. 8.7d). However, it may be noted that samples with high Mg content display 
patterns with relatively low resolution of their peaks to evidence their low 
crystallinity character (similarly to bone mineral [345]), in contrast to pure ACP. This 
tendency toward lower apatite crystallinity is progressively more obvious as the Mg 
content increases (Fig. 8.7). 
Therefore, it can be stated that, in these conditions, carbonate and magnesium ions 
limit, but do not block the progression of apatite crystallization during SPS. This 
conclusion agrees with previous results reported in the literature [325,346]; however 
such findings thus indicate that these starting CO3/Mg compositions were not 
sufficient to stabilize amorphous CaP after SPS. 
FTIR spectra also revealed the occurrence of the transformation of amorphous 
powders into low-crystallinity apatite after SPS treatment for these samples (Fig.  
8.4a-II). Carbonate ions can then enter the apatite lattice, leading to the formation 
either A or B-types of substitution. In particular, based on the FTIR spectral analysis, 
partial transformation mostly into B-type apatite can be noted after SPS of these 
samples, when examing 1462 cm-1  (Fig. 8.4b-II) and 872 cm-1 (Fig. 8.4c-II) domains. 
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Figure 8.7: Diffraction patterns of the SPS samples obtained from the amorphous 
powders in presence of ammonium hydroxide solution: (a) ACP; (b) cACP; (c) Mg5-
cACP; (d) Mg15-cACP. 
FTIR spectra relative to the specimens consolidated by SPS also evidenced a 
decrease in the carbonation level (Table 8.3), albeit samples still remained highly 
carbonated. This diminution can be linked to the partial decomposition of carbonate 
ions, followed by expulsion of CO2 gas, during SPS.  
Name of the 
sample 
CO3 wt.% 
Initial powders 
CO3 wt.% 
Samples after 
SPS 
ACP 0 0 
cACP 17.0 14.0 
Mg5-cACP 15.9 11.3 
Mg15-cACP 18.3 14.1 
 Table 8.3: Chemical composition of the powders before and after SPS. 
In order to stabilize ACP even after SPS, larger levels of Mg were then tested. SPS 
treatment at 150oC was again found to be effective in the consolidation of the sample 
Mg30-cACP synthesized using the KOH solution. As main difference, in this case, 
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the initial amorphous character of calcium phosphate powder could be successfully 
maintained even after SPS, as confirmed by XRD analysis (Fig.  8.6b). To the best of 
our knowledge, this outcome is obtained for the first time in the literature, thus 
opening the way for identifying new families of bioceramic/composite materials with 
high metastability/surface reactivity/resorption abilities The preservation of this 
amorphous state even after SPS is thought to be related to the strong inhibiting effect 
of Mg2+ ions which, in combination with that of carbonates prevent apatite 
crystallization. The carbonation level on this sample after SPS was found to be kept 
around 9 wt.%. 
8.5 Conclusions  
Carbonated and magnesium co-doped amorphous calcium phosphate powders with 
different compositions were first synthesized in present work using modified 
precipitation method. The resulting powders then were consolidated at low 
temperature by Spark Plasma Sintering (150oC) in view of cold sintering. The content 
of carbonate ions in initial powders and sintered samples was evaluated. In particular, 
maximum carbonate content of about 18.3 wt.%. was achieved for Mg15-cACP 
initial powder. Cold-sintering at 150oC by SPS was found to be effective to 
consolidate all types of powders. The influence of the introduction of carbonate and 
magnesium ions in ACP on the consolidation process was also investigated. After 
SPS, both undoped ACP, carbonated ACP (cACP) and 5/15 wt.% Mg-doped cACP 
transformed into low crystallinity apatites. However, high carbonation (mostly B-
type) was preserved even after SPS; it is expected that they could lead to high 
resorption rates in vivo and concomitant fast release of bioactive ions. Indeed, an 
increased amount of carbonate ions in the apatite lattice alters its thermodynamic and 
biological characteristics, carbonated apatite being more soluble than HA [347]. 
Thus, the highly carbonated low crystalline apatite-based ceramics obtained in this 
work will likely to exhibit enhanced biological behavior in terms of reactivity and 
resorbability. However, the main finding of the present work is the identification of 
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suitable experimental conditions allowing, for the first time, to retain the amorphous 
nature of ACP compounds system even after SPS. We show that suitable mild SPS 
conditions associated to adequate Mg and CO32- substitutions in ACP are needed to 
obtain this original result. These findings open the way to the development of 
consolidated ACP-based bioceramics with high (bio)reactivity. 
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Chapter 9. Electrospun PCL/PGS composite fibers 
incorporating bioactive glass particles for soft tissue 
engineering applications    
9.1 Introduction 
The fabrication of synthetic, degradable scaffolds able to mimic native features of 
extracellular matrix (ECM) represents a significant challenge for soft and hard tissue 
engineering (TE) [348]. Among the different scaffold fabrication techniques, 
electrospinning (ES) has emerged as a promising approach for different biomedical 
applications, since it provides a simple and versatile tool to produce interconnected 
porous nano- and microfibrous structures from various synthetic and natural 
polymers [349,350].  Briefly, the principle of ES is based on the application of a high 
intensity electrical potential between two electrodes of opposite polarity, a metallic 
needle containing the polymeric solution and a grounded target. ES process is 
strongly affected by different factors, which can be generally grouped in three main 
categories, i.e. solution features (e.g. concentration, viscosity, rheological properties, 
etc.), process parameters (e.g. electrical field, flow rate, distance between the tip of 
the syringe and the type of collector), and, external environmental conditions (e.g. 
relative humidity and temperature). The effects of these factors on ES have been 
already extensively investigated in the literature [349,351,352].  
Poly(glycerol-sebacate) (PGS), a biocompatible and biodegradable soft elastomer 
firstly introduced by Wang and co-workers [353], has recently attracted much 
attention since its properties appeared to be particularly interesting for regenerative 
medicine [354]. Indeed, PGS was studied for a broad range of applications including 
cardiovascular patches [355–358], heart valves [359], cartilage [360,361] and nerve 
[362,363] tissue engineering, retina [364,365] and tympanic membrane healing 
[366,367]. Synthesis of PGS consists of a two steps procedure: first, PGS pre-
polymer (PGSp) is synthesized from pre-polycondensation of glycerol and sebacic 
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acid, then the cross-linked polymer can be obtained by an additional vacuum heat 
treatment of the PGSp precursor. The PGS mechanical properties and degradation 
kinetics, which are relevant features for tissue engineering applications, can be 
tailored during the synthesis process by altering the molar ratio of glycerol and 
sebacic acid constituents, curing time and temperature. For example, Chen and co-
workers studied the effect of the curing temperature on the mechanical properties of 
PGS patches for the myocardial tissue healing [355]. It is also worth to mention that, 
electrospinning of neat PGS represents a challenging task due to the low solution 
viscosity caused by the low molecular weight of the polymer [353,354]. To increase 
the solution viscosity, PGS can be blended with other biodegradable polymers, 
synthetic or natural [368,369].  
In this context, poly(ε-caprolactone) (PCL) is a semi-crystalline biocompatible, non-
toxic, degradable, suitable to be processed by ES, polymer, which has been already 
approved by the US Food and Drug Administration (FDA) for certain biomedical 
applications [370,371]. Generally, PCL is used in the field of hard TE, where longer 
healing periods are required [372,373], since this polymer is relatively stable in vivo 
and possesses lower degradation rate compared to PGS [374,375]. Therefore, 
PCL/PGS fibrous blend scaffolds appear to be particularly interesting for TE, since 
PCL can ensure structural support at the site of implantation, while faster degrading 
PGS can provide essential space for the new ECM deposition. Indeed, elastic blended 
PCL/PGS electrospun fiber mats with various constituent ratios have been already 
successfully tested as materials for the heart valve regeneration [368,376,377]. 
Advanced electrospun PCL/PGS fiber mats with patterned topographical features as 
well as PCL/PGS scaffolds functionalized with vascular endothelial growth factors 
for cardiac patch application, were then developed [358,378]. Moreover, Kalakonda 
and co-workers studied the antibacterial properties of PGS/PCL fibrous scaffolds 
coated with silver [379].  
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During the fabrication step of PCL/PGS electrospun scaffolds, harsh solvents, such as 
a mixture of anhydrous chloroform, dichloromethane or dimethyl carbonate with 
ethanol or methanol, are mainly used. It should be noted that an appropriate solvent 
selection plays a pivotal role for the obtainment of smooth, bead-free fibers. 
Recently, the substitution of the toxic solvents mentioned above with more 
environmental friendly benign solvents was attempted [380,381]. Acetic acid (AA), 
according to guideline established on the International Conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH), 
falls within the class 3 of solvents which are considered less toxic and harmful for 
humans [382]. Vogt et al. firstly reported on the possibility to obtain  PCL/PGS (1:1) 
fibrous mats using AA for cardiac patch applications [357].  
Recently, the scientific community has focused its attention on the use of bioactive 
glasses (BG) for soft tissue engineering applications [316,383].  Indeed, as already 
mentioned in Chapter 3, researches conducted so far have been mainly oriented on 
the investigation of osteogenic properties of bioactive glasses, thus addressed to bone 
regeneration. After demonstrating the ability of bioactive glasses to promote 
angiogenesis, as a consequence of the dissolution products arising from the contact 
between BG and body fluids, more attention was dedicated to all the applications 
related to healing of soft tissue wounds [384,385].   
9.2 Aim 
In this framework, the aim of the present research work is to fabricate electrospun 
PCL/PGS composite fibrous structures, where silicate 13-93 and borosilicate 13-
93BS bioactive glass particles are introduced as inorganic part, and acetic acid is 
utilized as a solvent. The biocompatibility of seven different compositions is 
examined, including cell metabolic activity, attachment and proliferation. The 
influence of fibers composition on the mechanical properties and degradation 
characteristics is also assessed.  
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9.3 Materials and method 
9.3.1 Solution preparation  
Electrospun fiber mats with 7 different compositions, as reported in Table 9.1, were 
fabricated starting from PCL (80 kDa, Sigma Aldrich®, Munich, Germany) solutions. 
Glacial acetic acid (AA, VWR, Darmstadt, Germany) was utilized as a solvent.  
Synthesis of the PGS polymer ((C13H22O5)n) was performed according to the protocol 
of Wang et al. [353]. Briefly, in order to obtain PGS prepolymer (PGSp), 0.1 M 
sebacic acid (99%, SigmaAldrich®, Munich, Germany) and 0.1 M polyol glycerol 
(BioXtra, 99%, SigmaAldrich®, Munich, Germany) were mixed and subsequently 
heated at 120°C under inert nitrogen atmosphere for 24h. A mildly cross-linked PGS 
polymer (PGSmxl) was further synthesized from PGS⁠p precursor by the additional 
treatment at 120°C in an oven under vacuum (1.3–2.5×10 ⁠−2 mTorr) for 24 h, as 
previously reported by Vogt et al. [357]. 
Silicate and borosilicate glasses (13-93 and 13-93BS, respectively) were synthesized 
by melt-quenching according to the procedure described by Schuhladen et al. [386]. 
Briefly, the starting reagents (all from Sigma-Aldrich®, Munich, Germany), namely, 
H3BO3, (CaHPO4)(2(H2O)), CaCO3, K2CO3,  Na2CO3, MgO, and Belgian quartz 
sand, were melted in a platinum crucible under the following conditions: 1100 °C for 
3 h (13-93BS) and 1360 °C for 3 h (13–93). Further, all compositions were cast and 
annealed at 520°C. To ensure homogeneity, melting was performed twice. The glass 
product was then crushed using a Jaw Crusher (Retsch, Germany) and grounded to 
fine powder with average particle size of 5–20 μm, using a zirconia planetary ball 
mill (Retsch, Germany). The composition of both glasses is reported in Table 9.2. 
The solution preparation was performed according to the following procedure: firstly, 
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Sample name Solution concentration 
[% w/v] / polymer-BG 
ratio PCL:PGS:BG 
Voltage [kV] Distance tip-
target [cm] 
Needle 
diameter  
Flow rate 
[mL/ h] 
Temperature 
[oC] 
Relative 
humidity 
[%] 
(S1) PCL/PGSp  20/1:0.5:0 15 11 21G 0.4 24±0.8 34±12 
(S2) PCL/PGSmxl  20/1:0.5:0 15 11 21G 0.4 24±0.8 34±12 
(S3) PCL/PGSmxl/ 
13-93  
20/1:0.5:0.3 15 11 18G 0.4 24±0.8 34±12 
(S4) PCL/PGSmxl/ 
13-93BS  
20/1:0.5:0.3 15 11 18G 0.4 24±0.8 34±12 
(S5) PCL  20/1:0:0 15 11 21G 0.4 24±0.8 34±12 
(S6) PCL/13-93  20/1:0:0.3 15 11 18G 0.4 24±0.8 34±12 
(S7) PCL/13-93BS  20/1:0.5:0.3 15 11 18G 0.4 24±0.8 34±12 
Table 9.1: Composition of PCL and PCL/PGS polymeric solutions and operating parameters for electrospinning of PCL and 
PCL/PGS fiber mats. 
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20% w/v solution of PCL in acetic acid was prepared, stirred overnight at room 
temperature and sonicated for 30 min prior to addition of PGS. PGSp or PGSmxl 
(Table 9.1) were further added to the solution, stirred and sonicated for additional 30 
min. The bioactive glass powders, 13-93 or 13-93BS, were homogeneously dispersed 
(Table 9.1) in the polymeric solution and stirred for 5 min. Electrospinning was 
performed immediately after in order to avoid possible alterations of bioactive glass 
particles in acetic acid.  
Bioactive glass 
denomination 
SiO2 B2O3 CaO K2O Na2O MgO P2O5 
13-93 56.6 - 18.5 11.1 5.5 4.6 3.7 
13-93BS 20 36.6 18.5 11.1 5.5 4.6 3.7 
Table 9.2: Composition (wt.%) of the synthesized bioactive glasses used for the 
preparation of the composite fibers. 
9.3.2 Electrospinning process  
Electrospun fiber mats were obtained using a commercially available setup (Starter 
Kit 40KV Web, Linari Engineering srl, Valpiana (GR), Italy). The utilized 
parameters for the electrospinning process, as well as temperature and relative 
humidity, are summarized in Table 9.1.  
9.3.3 Characterisation 
9.3.3.1 Microstructure and composition 
SEM analysis (FE-SEM-EDS, Auriga 0750, Carl-Zeiss, Jena, Germany) was 
conducted for examining the microstructure and morphology of the series of 
electrospun mats. Prior to this analysis, the samples were sputtered with gold using a 
sputter coater (Q150T, Quorum Technologies Ltd., Germany). Magnification was 
varied in a range of 1000 to 45,000x. The average fiber diameter was calculated using 
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a Fiji 1.51s analysis software (NIH, Bethesda, MD, USA). The measurement of the 
diameter of 30 randomly chosen fibers was performed for each sample [387]. 
FTIR analysis of the sample’s composition was carried out in attenuated total 
reﬂectance mode (ATR), using a FTIR spectrometer (IRAffinity-1S, Shimadzu, 
Japan). For the analysis, 40 spectral scans in absorbance mode were averaged across 
the wavenumber range of 4000 to 400 cm⁠−1 with a resolution of 4 cm⁠−1. 
9.3.3.2 Mechanical characterisation 
Mechanical properties of a set of fiber mats were investigated by uniaxial tensile 
strength tests (3366 Dual Column Tabletop Testing System, Instron®, Darmstadt, 
Germany). Measurements were performed at a crosshead speed of 10 mm/min using 
50 N load cell. To avoid any undesired stretching of fiber mats before the tensile test, 
specimens were cut into rectangular shape (3 mm x 20 mm) and arranged into paper 
frames (20 mm x 20 mm). Average values and standard deviations of Young’s 
modulus (E), ultimate tensile strength (UTS) and strain to failure (FS), were 
determined based on the five measurements for each composition.   
9.3.3.3 Wettability 
The measurements of static water contact angle of the fibrous specimens were 
conducted by the sessile drop method (DSA30, Krüss GmbH, Hamburg, Germany) in 
air. To this aim, drops of 3 μL deionized water were placed onto the fiber mats. At 
least five measurements at room temperature were performed for each blend. The 
data were collected and analysed using the DSA software (DSA4 2.0, Krüss GmbH, 
Hamburg, Germany). 
9.3.3.4 In vitro degradation   
The in vitro degradation study of the as-spun samples was carried out in phosphate 
buffered saline (PBS) (VWR Life Science AMRESCO®, USA).  
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For each composition, sample triplicates were immersed in 16 ml of PBS solution at 
37°C. Experiments were performed in a standard incubator (KS 4000 i Control, 
IKA®-Werke GmbH & Co. KG, Germany) with mild shaking (82 rpm). During the 
incubation period, pH was monitored and recorded at the following time points: 1h; 
2h; 4h; 1 day; 4 and 7 days. After 1 and 7 days, the samples were removed from the 
solution, rinsed with ultra-pure water, dried and examined by SEM and ATR-FTIR 
analysis, to evidance changes in morphology and chemical composition. A falcon 
tube containing solutions of PBS without any samples was also incubated for the 
entire period of the experiment, to ensure and control overtime solution stability. 
9.3.3.5 Cell culture 
The biological assay was performed using the bone marrow-derived stromal cells, 
ST-2, (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany). Before the seeding step, ST-2 cells were cultured in RPMI 
1640 medium (Thermo Fisher Scientiﬁc), supplemented with 10% fetal bovine serum 
(Lonza) as well as 1% penicillin/streptomycin (Lonza), and incubated at 37°C with 
5% CO2. Cell viability, proliferation and morphology after 1 and 7 days were 
evaluated according to the protocol developed by Liverani et al. [388].  Briefly, prior 
to the cell test, all the samples were cut and fixed on a holder for 24 well plates 
(Scaffdex, Sigma). To disinfect the specimens, treatment under UV light was carried 
out for 1 h. ST-2 cells were drop seeded onto fixed fiber samples with a density of 
2.5·105 cells/mL in a droplet of 100 µl of RPMI media per sample and incubated for 
15 min. Then, 1mL of RPMI medium was added to each well. 
After 1 and 7 days, cell proliferation and cytotoxicity were assessed using 
colorimetric Cell Counting Kit-8 (CCK-8) assay based on tetrazolium salt WST-8 (2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt). The reduction of WST-8 by cellular dehydrogenases to an orange 
formazan product was measured in absorbance mode at 450 nm by the plate reader 
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(PHOmo microplate reader, Autobio Labtec Instruments Co. Ltd., Zhengzhou City, 
China). 
Cell morphology was investigated after 1 and 7 days upon seeding. To this aim, 
samples were exposed to ﬂuorescence microscopy (Axio Scope A1, Zeiss). Prior to 
analysis, seeded samples were stained with rhodamine phalloidin and DAPI (Thermo 
Fisher Scientific, Massachusetts, USA), according to the protocol reported previously 
by Liverani et al. [389]. Brieﬂy, sample’s fixation was carried out using a solution 
containing 1,4-piperazinediethanesulfonic acid buﬀer, ethylene glycol tetraacetic 
acid, polyethylene glycol, paraformaldehyde, PBS, and sodium hydroxide (Sigma 
Aldrich®, Munich, Germany). Then, the specimens were rinsed three times with PBS 
and immersed in a permeabilization buﬀer containing Triton X-100, sucrose and PBS 
(Sigma Aldrich®, Munich, Germany). Prior to characterization, fixed samples were 
stained using Rhodamine phalloidin solution (8 µL/mL) and DAPI solution (1 
µL/mL).  
9.3.3.6 Statistics 
All experimental data are presented as average values ± standard deviation. One-way 
analysis of variance (ANOVA, Origin) was used to analyze the differences between 
groups with a probability deﬁned as (* p < 0.05). 
9.4 Results and discussion 
9.4.1 Fiber morphology 
SEM micrographs of the seven series of as-spun porous samples are reported in Figs. 
9.1(a)-(g). In the present work, the selection of the key parameters for the 
electrospinning process, namely, the solution concentration and applied voltage, was 
adapted from Liverani et al. [390]. Indeed, it was shown that homogeneous, bead-free 
neat PCL fiber mats can be obtained using 20 w/v% solution of PCL in acetic acid 
and 15kV applied voltage. These parameters, as well as distance tip-target and flow 
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rate (Table 9.1), were maintained constant in order to better clarify the influence of 
the composition, i.e. presence of PGS polymer and bioactive glass particles (BG), on 
the mechanical and biological performances of fiber mats. 
The average fiber diameter of the different series of blend electrospun mats is 
reported in Table 9.3. It can be seen that, the addition of PGS polymer leads to an 
increase of the average fiber diameter. This phenomenon can be ascribed to the 
increasing total amount of polymer content in the solution. The value (0.9±0.4 μm) of 
the average fiber diameter for the neat PCL mats falls within the range of 0.11-3.85 
μm reported in literature [389–391]. Moreover, the estimated values of average 
diameter for PCL/PGSp (1.5±0.5 μm) and PCL/PGSmxl (1.5±0.6 μm) are also in 
accordance with the literature, where the fiber diameter of PCL/PGS blends were 
reported to vary in a range between 0.55 and 4.7 μm  [368,377,392,393]. These 
features are important as they demonstrate that the use of benign solvents did not 
affect the morphology of the electrospun composite fibers, since the average fiber 
diameter is comparable with the fibers obtained with standard solvents for ES. 
The amount of bioactive glass added in the present work, to fabricate composite fiber 
mats, was fixed at 30 wt% and maintained constant for all composite blends, in 
particular for PCL/13-93, PCL/13-93BS, PCL/PGSmxl/13-93, and PCL/PGSmxl/13-
93BS. The incorporation of  glass microparticles into fiber scaffolds can be observed 
in Fig. 9.1 (d)-(g). The presence of BG particles inside the as-spun mats was also 
confirmed by the SEM/EDX analysis (Fig. 9.2). As reported in Table 9.3, the 
addition of glass did not alter significantly the average fiber diameter. However, the 
standard deviation in samples with the glass, i.e. PCL/13-93, PCL/13-93BS, 
PCL/PGSmxl/13-93, and PCL/PGSmxl/13-93BS, was found to increase. 
Correspondingly, the distributions of fibers diameter reported in Fig. 9.1 (l)-(p) show 
that maximum and minimum vary more noticeably. This effect can be caused by the 
increasing conductivity of the polymeric solution in presence of bioactive glass 
particles.   
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Figure 9.1: SEM images of electrospun fiber mats and corresponding fiber diameter 
distribution: (a), (h) neat PCL; (b), (i) PCL/PGSp; (c), (k) PCL/PGSmxl; (d), (l) 
PCL/PGSmxl/13-93; (e), (m) PCL/PGSmxl/13-93BS;  (f), (n) PCL/13-93 and (g),(p) 
PCL/13-93BS, respectively. 
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a) 
 
b) 
 
c) 
 
d) 
 
Figure 9.2: SEM/EDX images, confirming the presence of BG particles in (a) PCL/PGSmxl/13-93, (b) PCL/PGSmxl/13-
93BS, (c) PCL/13-93, (b) PCL/13-93BS, samples.  
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Sample name Average fiber 
diameter [μm] 
Young’s 
Modulus 
[MPa] 
Ultimate tensile strength 
[MPa] 
Failure 
strain  
[%] 
PCL  0.9±0.4 2.4±0.5 1.3±0.2 447±226 
PCL/PGSp 1.5±0.5 3.8±0.8 1.0±0.2 219±112 
PCL/PGSmxl 1.5±0.6 4.4±0.3 1.2±0.2 200±103 
PCL/PGSmxl/13-93 1.6±0.7 4.5±0.3 1.0±0.1 117±62 
PCL/PGSmxl/13-93BS 1.7±0.9 1.2±0.4 0.6±0.1 185±106 
PCL/13-93 1.1±0.7 2.2±0.4 1.1±0.2 228±139 
PCL/13-93BS 1.1±0.7 0.5±0.3 0.9±0.2 115±57 
Table 9.3: Average fiber diameter and mechanical properties of electrospun fiber mats.  
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9.4.2 Chemical characterization of as-spun mats 
FTIR analysis was performed to examine the chemical composition of prepared fiber 
mats. Fig. 9.3 illustrates the obtained spectra of neat PCL, PCL/PGSp, PCL/PGSmxl 
and polymer/BG fiber composites. No typical absorption bands of acetic acid were 
detected, confirming that this solvent totally evaporated during the electrospinning 
process.  
All spectra exhibit the characteristic PCL bands already reported in the literature 
[357,392,393]: 2942 cm-1, 2865 cm-1 and 1366 cm-1, relative to stretching of alkyl 
group (CH2); 1240 cm-1 and 1165 cm-1 peaks, attributed to symmetric and asymmetric 
C─O─C stretching, respectively; the peak centered around 1722 cm-1 of carbonyl 
stretching (C═O); finally, the additional peak around 1294 cm-1 is due to the 
backbone C─O and C─C stretching.   
PGS vibration bands, namely,  2929 cm-1, 2851 cm-1 and 1384 cm-1, are  attributed to 
alkyl groups, the peak around 1734 cm-1 is associated to carbonyl stretching (C═O); 
and C─O band stretching vibration at 1165 cm-1 [392], are overlapping with PCL 
absorption bands. Moreover, the broad band between 3300 cm-1 and 2500 cm-1, 
corresponding to the stretch vibration of hydroxyl bond, cannot also be distinguished, 
since a relatively small amount of PGS was used to fabricate PCL/PGS mats (50wt% 
with respect to PCL). Only a slight shift to lower wavenumbers, typical for PGS, can 
be noticed when spectra of PCL/PGS blends were analyzed.  
A similar situation can be observed in samples containing BG particles (PCL/13-93, 
PCL/13-93BS, PCL/PGSmxl/13-93, PCL/PGSmxl/13-93BS). Characteristic absorption 
bands of silicate glass 13-93 [386], namely, Si─O─Si and Si─O  stretching modes, 
which are located in the range between 900 and 1100 cm-1, along with that one of  
Si─O─Si bending mode at 470 cm-1, are relatively weak and cannot be detected. 
Peaks of borosilicate glass 13-93BS exhibit the same vibrations as silicate 13-93 
glass and the additional peaks are attributed to the B─O stretching mode of 
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tetrahedral BO4 groups located around 700 cm-1 and in the range between 900 
and1100 cm-1; finally, B─O stretching bands of BO3 group are situated in 1150-1300 
cm-1 and 1200-1500 cm-1 ranges.  
 
Figure 9.3: ATR-FTIR spectra of as-spun fiber mats. 
9.4.3 Wettability 
Surface wettability or hydrophilicity represents one of the key parameters for a 
biomaterial, which affect cell behavior via protein adsorption, platelet 
adhesion/activation, blood coagulation and cell bacterial adhesion [394,395].  It was 
found that either strongly hydrophobic or hydrophilic surfaces are not favorable for 
cell attachment. Indeed, the optimal water contact angle range, which allows effective 
cell adhesion should lay in the range between 40o and 70o [394,396]. 
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As mentioned in section 9.3.2.3, in the present study, the wettabilty of as-spun fiber 
mats was evaluated by contact angle measurements. Fiber mats containing only PCL 
polymer, i.e. PCL, PCL/13-93, PCL/13-93BS, were found to exhibit an hydrophobic 
behavior, with contact angles of 100 ± 5o, 100 ± 4o and 101 ± 4o, respectively. 
Therefore, the estimated values lay in the range between 98o and 133o previously 
reported in the literature for PCL electrospun mats [357,368,392]. Such outcome 
confirms that the presence of BG particles and the related roughness of the composite 
mats do not affect the wettability. 
On the contrary, blended fibers containing PGS polymer, namely, PCL/PGSp, 
PCL/PGSmxl, PCL/PGSmxl/13-93, and PCL/PGSmxl/13-93BS showed a highly 
hydrophilic behaviour. Indeed, the contact angle was not even detectable, since the 
water drop deposited on their surface rapidly penetrated and spread through all the 
tested compositions. Thus, being strongly hydrophilic, due to the hydroxyl groups 
attached to its backbone, PGS is found to markedly affect the wettability of PCL/PGS 
blend mats [368,392].  
9.4.4 Degradation 
It is known that when biomaterials exposed to biological environments undergo 
degradation, their initial physicochemical properties change. In particular, in case of 
polymers, degradation leads to the polymer chain scissions. 
PCL and PGS belong to aliphatic polyesters and are subjected to hydrolytic 
degradation through the cleavage of ester linkages, but with different rates. Total 
resorption of PGS in vivo was observed within few weeks after implantation 
[375,397]. On the other hand, PCL, being semi-crystalline at room temperature, is 
relatively stable in vivo and  possesses low resorption rate [374,398]. It was found 
that crystallinity and molecular weight of PCL strongly affect its degradation rate 
[374,399]. In this perspective, it is particularly interesting to study PGS/PCL blends, 
in order to obtain hybrid materials that exhibit modulated degradation.  
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To investigate degradation features, neat PCL, PCL/PGS and PCL/PGS/BG blends 
were subjected to in vitro immersion tests in PBS solution. Over the course of the 
tests, the change of pH was monitored. Measurements were performed after 1h, 2h, 
4h, 24h, 96h and 168h of incubation. The curves of pH change during  immersion (up 
to 5 and 168h) are shown in Fig. 9.4 (a) and (b), respectively. 
 
Figure 9.4: Change of pH during immersion of as-spun samples: (a) after 5h; (b) after 
168h. 
a) 
 
b) 
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It can be observed, that during the first 4 hours, pH values in PBS solutions in contact 
with PCL/PGSp and PCL/PGSmxl mats drop more significantly, indicating the 
acidification of the media; on the contrary, neat PCL samples determine only modest 
changes. In addition, after 168h of immersion, pH of the solutions containing 
PCL/PGSp and PCL/PGSmxl were found to be 7.22±0.3 and 7.24±0.15, respectively. 
Such acidification effect of PGS, which is ascribed to the leaching of non-reacted 
monomers, was already reported in literature [400,401].  In order to remove residual 
monomers and oligomers, which potentially can be harmful for cells, authors utilized 
either sample’s washing in a mixture of ethanol and water or pre-conditioning of PGS 
containing mats in the culture medium.  
Some representative SEM micrographs of PCL/PGSp and PCL/PGSmxl after 1 and 7 
days of immersion in PBS, are reported in Fig. 9.5 (b), (i) and (c), (k), respectively. 
They clearly indicate the fiber s degradation takes place already after 1 day of 
immersion. According to the literature, PGS degradation occurs via surface erosion 
[375,402]. The occurrence of this phenomenon, which is evidenced through the 
formation of porous structure and polymer leaching, can be observed in Fig. 9.5 (b), 
(c).  
A different situation was encountered with samples containing neat PCL (Fig. 9(a), 
(h)), which did not exhibit, even after 7 days of immersion, significant evidence of 
degradation, thus confirming the results arising from pH measurements.  
On the other hand, Fig. 9.4 shows that blends containing both PGS polymer and 
bioactive glass particles, i.e. PCL/PGSmxl/13-93 and PCL/PGSmxl/13-93BS, in contact 
with PBS did not promote media acidification. In contrast, the value of pH increased 
after 4 hours of immersion, reached a maximum value after 96 hours and slightly 
dropped after 168 hours. This effect could be ascribed to the ion release from the 
glass, which took place and compensated the acidification effect of PGS polymer. 
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Figure 9.5: SEM images of electrospun fiber mats after immersion in PBS solution: 
(a), (h) neat PCL; (b), (i) PCL/PGSp; (c), (k) PCL/PGSmxl; (d), (l) PCL/PGSmxl/13-93; 
(e), (m) PCL/PGSmxl/13-93BS;  (f), (n) PCL/13-93 and (g),(p) PCL/13-93BS, 
respectively. 
This holds also true in samples containing only PCL and bioactive glass, i.e. PCL/13-
93 and PCL/13-93BS, where pH increased due glass dissolution and ions release. 
Correspondingly, the SEM micrographs of PCL/PGSmxl/13-93, PCL/PGSmxl/13-93BS, 
PCL/13-93, and PCL/13-93BS, evidenced huge empty pores, as a consequence of the 
dissolution of bioactive glass particles (Fig. 9.5 (f), (n), (g), (p)).  
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9.4.5 Mechanical properties 
It is known that, to ensure structural integrity and provide a support to the cells, the 
mechanical properties of biodegradable fiber scaffolds should match those of the 
regenerating tissues. In the present study, uniaxial tensile testing was carried out to 
evaluate the mechanical properties of the as-spun fiber mats under external stress. 
Resulting stress-strain curves as well as the averaged values of Young’s modulus, 
ultimate tensile strength  and failure strain are reported in Fig. 9.6 (a), (b) and Table 
9.3, respectively. The stress-strain profiles of all tested fiber mats are consistent with 
the profiles typical of elastomeric materials.  
The obtained values of the Young’s modulus for PCL specimens (2.4±0.5 MPa) were 
found to be lower with respect to the previously published data [357,390]. On the 
other hand, values of E for PCL/PGS blends (3.8±0.8 MPa and 4.4±0.5 MPa for 
PCL/PGSp and PCL/PGSmxl, respectively) were close to those ones reported in the 
literature [377,393].  Therefore, Young’s modulus of PCL/PGSp and PCL/PGSmxl 
blends increased in comparison to neat PCL tested samples, thus indicating the 
improvement achieved in scaffold’s stiffness with PGS introduction (Fig. 9.6 (b)). 
However, as reported in Table 9.3, UTS values of PGS/PCL samples were found to 
be comparable, while failure strain decreased when PCL/PGS blends were 
considered.  
It should be noted that the mechanical properties of fiber scaffolds depend 
particularly on the microstructural parameters such as the fiber diameter and the 
average fiber diameter distribution. As seen in Fig. 9.6 (a), the mechanical properties 
of the samples containing BG particles were found, as expected, to be lower, due to 
the increased inhomogeneity in the distribution of the average fiber. As reported 
previously by Liverani et al. [390], the presence of the interface between organic-
inorganic phases likely contributes to the decreased mechanical properties. 
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a) b)
Figure 9.6: Mechanical properties of as spun samples: (a) all compositions; (b) 
compositions containing only polymers. 
9.4.6 Cell study 
Cellular tests using the stromal cell line ST-2 were performed to access cell viability, 
proliferation and adhesion in presence of as-spun mats. The results of the WST-8 
assay after 1 and 7 days of incubation are presented in Fig. 9.7. It can be noticed that 
cell viability is significantly lower in all samples containing the PGS polymer, i.e. 
PCL/PGSp, PCL/PGSmxl and PCL/PGSmxl/13-93, and PCL/PGSmxl/13-93BS, as 
compared to neat PCL control. However, different authors reported an improved cell 
adhesion and proliferation when PCL/PGS fiber mats were considered. In this regard, 
it is worth to mention that, according to the literature, an immersion in aqueous 
ethanol solution followed by UV light treatment is usually utilized for the sample’s 
disinfection before cellular tests. This two steps procedure aimed not only to disinfect 
the samples, but also to remove all unreacted monomers and oligomers from the PGS 
structure. The presence of residual monomers can strongly affect the pH of culture 
medium and be harmful for cells.  In this regard, Vogt and co-workers [357] studied 
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possible effects of the disinfection procedure (using of 70% v/v aqueous ethanol 
versus UV light treatment) on the chemical composition and morphology of as-spun 
PCL/PGS mats. Results arising from their study indicate that immersion in ethanol 
even for 1h leads to the complete removal of PGS from the blend. Authors also 
pointed that leaching of PGS is accompanied by the formation of pores on the fiber’s 
surface. In the present study, UV light was used for 1h to disinfect the samples. Then, 
samples pre-conditioning in culture medium was performed just for 1 min before cell 
seeding. 
 
Figure 9.7: WST-8 analysis: optical density at 450 nm for all samples 1 and 7 days 
after seeding. 
Results of the WST-8 assay for the blended and composite fiber mats presented in 
Fig. 9.7 show no statistically significant differences in cell viability with respect to 
neat PCL after 1 day from the seeding. The results are different after 7 days, since it 
is possible to evidence an increase of the measured optical density (OD) values for all 
samples.   
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Figure 9.8: Fluorescence images of ST-2 cells on as-spun mats after 1 and 7 days of 
incubation: (a), (h) neat PCL; (b), (i) PCL/PGSp; (c), (k) PCL/PGSmxl; (d), (l) 
PCL/PGSmxl/13-93; (e), (m) PCL/PGSmxl/13-93BS;  (f), (n) PCL/13-93 and (g),(p) 
PCL/13-93BS, respectively.  
The normalized ratio values, expressed as (d7-d1)/d1, are reported in Table 9.4. It is 
clear that the presence of PGS and its related fast degradation rate affect not only 
cells adhesion but also their proliferation. This aspect appears to be mitigated by the 
presence of bioactive glass particles 13-93, while the same effect is not detectable in 
the sample containing 13-93-BS. These differences, related to the bioactive glass 
composition, are not noticeable in the neat PCL composite samples. In fact, the 
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presence of bioactive glass particles seems not to be pivotal in the proliferation rate 
of samples which are not containing PGS. The fluorescence images of tested samples, 
presented in Fig. 9.8 confirmed findings arised from the WST-8 assay. Indeed, well 
spread cells can be detected at 7 day after seeding in samples without PGS polymer.  
Sample denomination S1 S2 S3 S4 S5 S6 S7 
Ratio ODd7/ODd1 4 1 10 2 14 13 12 
Table 9.4: WST-8 assay: measured OD values (at 450nm) expressed as ratio between 
the measured OD at 7 days after seeding respect to the OD value at 1 day. 
9.5 Conclusions 
Homogeneous bead-free fiber mats with different compositions were prepared using 
degradable polymers such as PCL, PGSp and PGSmxl. Bioglass particles of two 
different compositions, namely 13-93 and 13-93BS, were successfully incorporated 
within the structures of electrospun polymeric mats. A benign solvent (acetic acid) 
for electrospinning was utilized to fabricate blended and composite mats.  
Biocompatibility of the obtained mats was examined including cell metabolic 
activity, attachment and proliferation. Results indicated that the presence of PGS 
polymer can negatively influence the cell viability. Indeed, the acidification of the 
media observed in samples containing PGS is thought to be linked to the polymer fast 
degradation. In the present study, samples disinfection was performed using UV 
light. In this regard, the release of residual monomers, which can be removed only 
after immersion in ethanol solution, was found to have a negative effect on cells 
proliferation. However, such treatment could possibly alter the composition of fiber 
mats.  The effect of fibers composition on the mechanical properties and degradation 
characteristics was also assessed. In particular, samples containing the PGS polymer 
showed an improved scaffold’s stiffness. On the other hand, the incorporation of 
bioactive glass particles led to the overall decrease of mechanical properties, due to 
160 
 
the increased fibers inhomogeneity. Finally, the degradation study in PBS solution 
revealed that PGS polymer tends to dissolve the already after 1 day. Correspondingly, 
leaching accompanied be the pores formation on the surface of the fibers was 
observed.  
On the basis of the obtained results two crucial aspects have to be solved: 
 The identification of an alternative method for samples disinfection, 
since the presence of undesired residual monomers after UV treatment 
(with no ethanol) has negative consequences on cell proliferation. 
 Improvement of fibers homogeneity after the incorporation of BG 
particles: the use of smaller sized powders is expected to provide a 
beneficial effect in this regard.  
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Chapter 10. Concluding remarks 
 
Since in the present thesis are described and discussed the results of different research 
projects conducted during my PhD program, the conclusions, reported in the follows, 
are divided according the chapters order.  
The eﬀects produced by devitriﬁcation phenomena which takes place during the 
consolidation of amorphous powder on the biological behavior of the resulting 
material was considered in Chapter 5. Such effects remain highly controversial still 
nowadays, and, in general, thought to negatively affect biological properties of 
bioceramics. However, more recent studies highlighted that this aspect depends also 
on the type of bioglass, crystallization degree achieved, the speciﬁc crystalline phases 
formed as well as the size of their crystallites. In turn, these features are speciﬁcally 
related to the sintering technique adopted. 
In the present study, the biological response during in vitro tests in SBF of three 
groups of dense samples, produced by SPS from a recently developed glass with high 
CaO content, was investigated in detail. 
The main findings can summarized as following: 
- The mildest sintering conditions adopted (730°C – holding temperature, 2min 
dwell time) provided a completely dense and amorphous material, with 
superior capability to generate in shorter times (less than 3 days) amounts of 
the apatite phase (up to 27 wt.%) on the glass surface. 
- The  79 wt.% crystallized specimens obtained by SPS at 850°C and 2min, 
mainly consisting α-CaSiO3 crystallites with smaller amounts of β-CaSiO3 and 
other minor phases, exhibited only a slightly reduced ability in generating the 
HCA layer. 
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- In contrast, the apatite formation process signiﬁcantly slowed down when the 
SBF solution was interfaced with the third group of glass-ceramic samples 
produced at 1000°C and 20 min and mainly consisting of β-CaSiO3. 
Thus, the presence of the latter phase in CaMix derived products seems to play the 
major role, rather than the relatively modest increase of the crystallization degree 
(from 79 to 88 wt.%), to determine the observed reduction in the generation of the 
apatite layer. This feature is readily associated to the correspondingly lower weight 
loss, pH increase and ions released, to indicate a scarce interaction of these materials 
with the physiological ﬂuid. 
In Chapter 6, the biocompatibility of different HA/BG composites, as well as pure 
bioactive CaO-rich glass and HA samples, all sintered using the SPS technique, was 
systematically evaluated using murine long bone osteocytes, by means of both direct 
(NR uptake) and indirect test (XTT and BrdU).  The obtained results were compared 
to previous findings arised from the SBF test. 
The main findings are described below: 
- Even though none of the samples considered in the present study was found to 
be cytotoxic, the outcomes of cellular test did not confirm the ones arising 
from the SBF assay. In particular, the direct test results did not show an 
enhanced “biological performance” in samples with increasing glass content. 
This fact may be ascribed to the high release of ions and particulate from the 
glassy phase, which could negatively influence the cell viability; in this regard, 
it should be noted that, as reported in the literature the presence of particulate 
in the culture medium may affect the accuracy of the absorbance readings 
employed in the colorimetric assay.  
- The performance of the CaMix alone is, in general, better during the indirect 
test. In particular, the samples with the higher glass content (CaMix, 
80BG_20HA and 50BG_50HA) slightly stimulate the cell proliferation. 
163 
 
Regardless the specific glass-ceramic composition, it was confirmed in this 
study that SPS is a promising technique to produce sintered bioglasses and 
bioglass-based composites without negatively affecting the biocompatibility of 
the final system.  
Most importantly, the present work demonstrated once more that the results obtained 
using SBF assays should be interpreted with great care, and need to be confirmed 
with suitable cellular tests.  
Preliminary results obtained during the fabrication of Functionally Graded samples 
based on HA/CaO-rich bioactive glass using the SPS technique were described in 
Chapter 7. The main goal of this study was to identify the optimal SPS parameters 
which could allow to obtain crack-free stepwise FGM specimens, with the more 
reactive CaO-rich glass surface on the one side of the device and more stable HA 
phase on the another side. The optimized operating conditions for the two different 
systems studied were determined (FGM-S1 and FGM-S2, compositions are reported 
in Table 7.1), including the design of a modified die configuration able to provide the 
required temperature gradient across the sample.  
Mechanical and biological characterizations are still in progress. 
Chapter 8 was dedicated to the development of novel highly bioresorbable ceramics 
for bone tissue regeneration. In particular, carbonated and magnesium co-doped 
amorphous calcium phosphate (ACP) powders with different compositions were 
synthesized by a precipitation method and then consolidated by Spark Plasma 
Sintering at low temperature, according to cold sintering approach.  
The main findings of this investigation are listed in what follows: 
- ACP powders with high carbonate content (about 18.3 wt.%) were prepared.  
- Cold-sintering at 150oC by SPS was found to be effective to consolidate all 
types of powders. 
164 
 
- The influence of the introduction of carbonate and magnesium ions in ACP on 
the consolidation process was also investigated. After SPS, undoped ACP, 
carbonated ACP (cACP) and 5/15 wt.% Mg-doped cACP transformed into low 
crystallinity apatites. However, a high carbonation degree (mostly B-type) was 
preserved even after SPS; high resorption rates when operating in vivo and the 
concomitant fast release of bioactive ions are then expected. In conclusion, the 
highly carbonated low crystalline apatite-based ceramics obtained in this work 
will most likely exhibit enhanced biological behavior in terms of reactivity and 
resorbability.  
The most important finding of the present investigation is the identification of the 
experimental conditions allowing, for the first time, to retain the amorphous nature of 
ACP materials even after SPS. The suitable sintering conditions, associated to 
adequate Mg and CO32- substitutions, were determined. These findings open the way 
to the development of consolidated ACP-based bioceramics with high (bio)reactivity. 
Finally, in Chapter 9, electrospun PCL/PGS composite fibers incorporating bioactive 
glass particles were fabricated and characterized for possible soft tissue engineering 
applications. Indeed, only recently, the ability of bioactive glasses to promote 
angiogenesis, due to dissolution phenomena arising from the contact between BG and 
body fluids, was proved. In this light, the incorporation of bioactive glass particles 
within the structure of the polymeric mats was attempted. Homogeneous bead-free 
fiber mats with different compositions were prepared using degradable polymers such 
as PCL, PGSp and PGSmxl. Bioglass particles of two different compositions, namely 
13-93 and 13-93BS, were successfully introduced within the structures of electrospun 
polymeric mats. A benign solvent (acetic acid) for electrospinning was utilized to 
fabricate blended and composite mats. Biocompatibility of obtained samples was 
evaluated through cell metabolic activity, attachment and proliferation. It was found 
that the presence of PGS polymer can negatively influence cell viability. Indeed, the 
acidification of the media observed in the samples containing PGS is thought to be 
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linked to the polymer fast degradation. The release of residual monomers, which can 
be removed only by the immersion in ethanol solution, represents a crucial problem 
since it can have negative effects on cell proliferation. However, the treatment with 
ethanol could alter the composition of fiber mats.  Therefore, future research work 
should be focused on the identification of the suitable disinfection methods, with 
respect to those adopted so far in the literature. 
Regarding the mechanical properties, samples containing PGS polymer showed the 
improvement of scaffold’s stiffness. On the other hand, incorporation of bioactive 
glass particle led to the overall decrease of mechanical properties due to the increased 
inhomogeneity of fibers. The use of finer BG particles is expected to provide 
beneficial effects in this regard. 
As a general conclusion, it is possible to state that the results obtained in the 
framework of the present PhD thesis will provide a useful contribution to the 
scientific community involved in the identification of more suitable 
bioactive/bioresorbable materials with respect to the state of the art. Indeed, although, 
as mentioned above, several crucial aspects are still unsolved, some of the obtained 
findings are very promising in view of the development of novel advanced 
biomaterials with improved performances for tissue applications.  
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Appendix. Characterization techniques, software and 
equipment exploited in this thesis. 
 
 
Chapter Characterization technique/equipment/software Aim 
5 
X-ray diffraction analysis (XRD) 
(Philips PW 1830, Netherlands) using a Ni 
ﬁltered Cu Kα radiation (λ =1.5405Å). 
Phase identification of the glass-
ceramic samples before and after their 
immersion in the SBF solution. 
High resolution scanning electron 
microscopy (HRSEM) (mod. S4000, 
Hitachi, Tokyo, Japan) equipped with a 
UltraDry Energy-dispersive X-ray 
Detector (EDS) (Thermo Fisher Scientiﬁc, 
Waltham, MA, USA) 
Microstructural and compositional 
characterization of samples before 
and after their immersion in the SBF 
solution. 
Inductively Coupled Plasma Optical 
Emission Spectroscopy (ICP) 
(ICP-OES CCD Simultaneous, Vista – 
MPX Varian, Mulgrave, Australia). 
Assessment of compositional changes 
induced in the SBF solution  during 
immersion of the three classes of 
glass-ceramics. 
Rietveld technique (MAUD program) Determination of the relative content 
of the diﬀerent phases and the 
corresponding average crystallite size.  
6 
X-ray diffraction analysis (XRD) 
(Philips PW 1830, Netherlands) using a Ni 
ﬁltered Cu Kα radiation  
Phase identification in bulk bioactive 
glass, hydroxyapatite, and composite 
samples produced by SPS. 
Optical microscopy (OM)  
(Nikon TMF, Japan)  
Observation of cells morphology after 
direct/indirect contact with the 
glass/ceramic samples. 
Spectrophotometry (Multiscan RC by 
Thermolab system, Finland) 
Evaluation of cell viability after 
exposure to the samples’ eluates.  
7 
X-ray diffraction analysis (XRD) 
(Philips PW 1830, Netherlands) using a Ni 
ﬁltered Cu Kα radiation  
Compositional/structural character-
rization of the initial powders and the 
surfaces of bulk FGM samples. 
8 
X-ray diffraction analysis (XRD) 
(BRUKER D8 Advanced diffractometer 
with a Cu Kα) 
Phase identification of initial powders 
and bulk samples obtained after SPS. 
Fourier transform infrared vibrational 
spectrometry (FTIR) using KBr method 
(Nicolet 5700 spectrometer)  
 Evaluation of the composition of 
crystalline and amorphous samples, to 
assess, in particular, the incorporation 
of the carbonate ion group.  
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OMNIC software  
(Thermo Fisher Scientific). 
Analysis of FTIR spectra. 
9 
Scanning electron microscopy (SEM)  
(FE-SEM-EDS, Auriga 0750, Carl-Zeiss, 
Jena, Germany) 
Observation of the microstructure and 
morphology of the different series of 
electrospun mats. 
Fiji 1.51s analysis software (NIH, 
Bethesda, MD, USA) 
Evaluation of the average fiber 
diameter  
FTIR in attenuated total reﬂectance mode 
(FTIR-ATR) (IRAffinity-1S, Shimadzu, 
Japan) 
Analysis of the polymeric electrospun 
mat composition (before and after 
immersion in SBF and PBS 
solutions). 
Uniaxial tensile strength  (3366 Dual 
Column Tabletop Testing System, 
Instron®, Darmstadt, Germany). 
Evaluation of Young’s modulus, 
UTS, and failure strain of a set of 
fiber mats. 
Sessile drop method  
(DSA30, Krüss GmbH, Hamburg, 
Germany)  
Measurement of wettability properties 
of the fibrous specimens. 
Fuorescence microscopy (FLUO) 
(Axio Scope A1, Zeiss) 
Observation of cell morphology upon 
seeding. 
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